Patent Publication Number: US-2022211823-A1

Title: Clostridial Neurotoxins Comprising an Exogenous Activation Loop

Description:
The present invention relates to clostridial neurotoxins and methods for activating and using the same. 
     Bacteria in the genus Clostridia produce highly potent and specific protein toxins, which can poison neurons and other cells to which they are delivered. Examples of such clostridial neurotoxins include the neurotoxins produced by  C. tetani  (TeNT) and by  C. botulinum  (BoNT) serotypes A-G, and X (see WO 2018/009903 A2), as well as those produced by  C. baratii  and  C. butyricum.    
     Among the clostridial neurotoxins are some of the most potent toxins known. By way of example, botulinum neurotoxins have median lethal dose (LD 50 ) values for mice ranging from 0.5 to 5 ng/kg, depending on the serotype. Both tetanus and botulinum toxins act by inhibiting the function of affected neurons, specifically the release of neurotransmitters. While botulinum toxin acts at the neuromuscular junction and inhibits cholinergic transmission in the peripheral nervous system, tetanus toxin acts in the central nervous system. 
     Clostridial neurotoxins are expressed as single-chain polypeptides in  Clostridium . Each clostridial neurotoxin has a catalytic light chain separated from the heavy chain (encompassing the N-terminal translocation domain and the C-terminal receptor binding domain) by an exposed region called the activation loop. During protein maturation proteolytic cleavage of the activation loop separates the light and heavy chain of the clostridial neurotoxin, which are held together by a disulphide bridge, to create fully active di-chain toxin. This process must be reproduced during recombinant toxin production. 
     Exogenous proteases such as trypsin or Lys-C are used for proteolytically activating single-chain clostridial neurotoxins. However, for some clostridial neurotoxins, incubation with Lys-C or trypsin results in partial or improper cleavage of the single-chain polypeptide resulting in the production of contaminating single-chain and/or inactive cleavage/degradation products (e.g. in the case of BoNT/E), necessitating purification of the full-length di-chain polypeptide. Thus, at present there is no universal exogenous protease for activation of clostridial neurotoxins. This is particularly problematic upon identification of a new clostridial neurotoxin or production of a modified (e.g. chimeric or hybrid) neurotoxin, which requires screening of multiple proteases to determine correct activation. 
     Botulinum neurotoxin serotype X (BoNT/X) was recently identified (WO 2018/009903 A2). It has been found that BoNT/X is particularly problematic to activate, and cleavage with trypsin or Lys-C completely degrades the polypeptide. 
     The present invention overcomes one or more of the above-mentioned problems. 
     The protease enterokinase exhibits a much higher substrate specificity compared to conventionally used trypsin and Lys-C. This protease recognises and cleaves immediately C-terminal to a DDDDK peptide sequence (SEQ ID NO: 72). Notably, this sequence is absent from all of the clostridial neurotoxin activation loops (see  FIG. 1 ), thus enterokinase has previously been ruled out as a protease for use in activating clostridial neurotoxins. 
     The present inventors have surprisingly found that enterokinase recognises and cleaves immediately C-terminal to an IDGR sequence present in the BoNT/C1 activation loop (see  FIG. 1 ). Advantageously, this sequence can also be recognised and cleaved by factor Xa, another protease exhibiting high substrate specificity (e.g. compared to trypsin and Lys-C). Moreover, the BoNT/C1 activation loop also has lysine and arginine residues, allowing cleavage by either lysine or trypsin. Thus, the present inventors have surprisingly found that the BoNT/C1 loop constitutes a universal activation loop for clostridial neurotoxins, thus providing the flexibility to use four different proteases. 
     In one aspect the invention provides a method for proteolytically processing a single-chain clostridial neurotoxin (e.g. of an engineered clostridial neurotoxin described herein) into a corresponding di-chain clostridial neurotoxin, the method comprising:
         a. providing a single-chain clostridial neurotoxin; and   b. contacting the single-chain clostridial neurotoxin with enterokinase;   wherein the single-chain clostridial neurotoxin has an activation loop comprising the polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1); and   wherein enterokinase hydrolyses a peptide bond of the activation loop thereby producing a di-chain clostridial neurotoxin (e.g. an engineered di-chain clostridial neurotoxin described herein).       

     In a related aspect the invention provides a method for proteolytically processing a single-chain clostridial neurotoxin (e.g. of an engineered clostridial neurotoxin described herein) into a corresponding di-chain clostridial neurotoxin, the method comprising: 
     a. providing a single-chain clostridial neurotoxin; and 
     b. contacting the single-chain clostridial neurotoxin with factor Xa; 
     wherein the single-chain clostridial neurotoxin has an activation loop comprising the polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1); and 
     wherein factor Xa hydrolyses a peptide bond of the activation loop thereby producing a di-chain clostridial neurotoxin (e.g. an engineered di-chain clostridial neurotoxin described herein). 
     The single-chain clostridial neurotoxin is preferably an engineered single-chain clostridial neurotoxin of the present invention, wherein the activation loop is an exogenous activation loop. Advantageously, the present inventors have found that replacing an endogenous clostridial neurotoxin activation loop with an exogenous activation loop shown as SEQ ID NO: 1 (which contains a protease cleavage site in its natural context) overcomes problems associated with modifying an endogenous activation loop to insert a protease cleavage site (e.g. a factor Xa cleavage site, such as Ile-Asp-Gly-Arg [SEQ ID NO: 18] or Ile-Glu-Gly-Arg [SEQ ID NO: 19]). In particular, modifying an endogenous activation loop to insert a protease cleavage site can lead to conformational changes, which, in turn, can have a negative effect on cleavage efficiency (see Example 7 herein). 
     In a particularly preferred embodiment the methods of the present invention comprise the use of enterokinase. 
     In one aspect the present invention is directed to use of enterokinase for hydrolysing a peptide bond of a polypeptide (e.g. a clostridial neurotoxin) comprising a sequence shown as SEQ ID NO: 18 or SEQ ID NO: 19 (preferably SEQ ID NO: 18). Preferably enterokinase hydrolyses a peptide bond immediately C-terminal to SEQ ID NO: 18 or SEQ ID NO: 19 (more preferably SEQ ID NO: 18) comprised within the polypeptide sequence. In one embodiment a polypeptide comprises a polypeptide sequence shown as SEQ ID NO: 1 or a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 2 or SEQ ID NO: 3. 
     The present invention also provides a method for manufacturing an engineered clostridial neurotoxin, the method comprising:
         a. identifying an endogenous activation loop of a clostridial neurotoxin, wherein the clostridial neurotoxin is characterised in that a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is hydrolysed by trypsin or Lys-C; and   b. replacing the endogenous activation loop with an exogenous activation loop thereby providing an engineered clostridial neurotoxin, wherein the exogenous activation loop comprises the polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1).       

     The present invention also provides a method for manufacturing an engineered clostridial neurotoxin, the method comprising:
         a. identifying an endogenous activation loop of a clostridial neurotoxin, wherein the clostridial neurotoxin is characterised in that the endogenous activation loop is inefficiently proteolytically processed by trypsin or Lys-C; and   b. replacing the endogenous activation loop with an exogenous activation loop thereby providing an engineered clostridial neurotoxin, wherein the exogenous activation loop comprises the polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1).       

     In one embodiment the clostridial neurotoxin is characterised in that a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is hydrolysed by trypsin or Lys-C and the endogenous activation loop is inefficiently proteolytically processed by trypsin or Lys-C. 
     In embodiments where the endogenous activation loop is inefficiently proteolytically processed by trypsin (and preferably a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is not hydrolysed by trypsin), the method may further comprise contacting an engineered clostridial neurotoxin with trypsin, which is capable of hydrolysing a peptide bond in the exogenous activation loop of the engineered clostridial neurotoxin. Similarly, in embodiments where the endogenous activation loop is inefficiently proteolytically processed by Lys-C (and preferably a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is not hydrolysed by Lys-C), the method may further comprise contacting an engineered clostridial neurotoxin with Lys-C, which is capable of hydrolysing a peptide bond in the exogenous activation loop of the engineered clostridial neurotoxin. 
     In one embodiment a method comprises a step of screening a clostridial neurotoxin for its suitability for use in a method of the invention. The screening step may comprise determining whether a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is hydrolysed by trypsin or Lys-C. Alternatively or additionally, the screening step may comprise determining whether the endogenous activation loop of a clostridial neurotoxin is inefficiently proteolytically processed by trypsin or Lys-C. 
     In contrast to the clostridial neurotoxin (pre-engineering) in one embodiment an engineered clostridial neurotoxin of the invention is not inefficiently proteolytically processed by enterokinase or factor Xa and/or a peptide bond outside of the exogenous activation loop of the engineered clostridial neurotoxin is not hydrolysed by enterokinase or factor Xa. Thus, the clostridial neurotoxin (pre-engineering) is preferably resistant to proteolytic processing by enterokinase and/or factor Xa. 
     A clostridial neurotoxin may be identified as being suitable for engineering in a method of the invention by an assay comprising contacting 1 mg of clostridial neurotoxin with at least 0.25 μg of trypsin at ≥3350 units/mg or Lys-C at ≥200 units/mg in a 50 mM Tris-HCl pH 8.0, 50 mM NaCl reaction buffer for at least 5 hours at at least 4° C. 
     In one embodiment the assay comprises contacting 1 mg of clostridial neurotoxin with 0.25 μg of trypsin at ≥3350 units/mg (˜1:611 molar ratio of clostridial neurotoxin to trypsin) or Lys-C at ≥200 units/mg (˜1:734 molar ratio of clostridial neurotoxin to Lys-C) in a 50 mM Tris-HCl pH 8.0, 50 mM NaCl reaction buffer for 18 hours at 4° C. 
     In another embodiment the assay comprises contacting 1 mg of clostridial neurotoxin with 0.40 μg of trypsin at ≥3350 units/mg (˜1:978 molar ratio of clostridial neurotoxin to trypsin) or Lys-C at ≥200 units/mg (˜1:1174 molar ratio of clostridial neurotoxin to Lys-C) in a 50 mM Tris-HCl pH 8.0, 50 mM NaCl reaction buffer for 5 hours at 20° C. 
     The trypsin used is preferably commercially available TrypZean (Sigma #T3568). Trypsin may have a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 47. In one embodiment trypsin may have a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 47. Preferably trypsin may have a polypeptide sequence shown as SEQ ID NO: 47. One unit of said trypsin (Trypzean) is defined as the amount of enzyme that will produce a change of absorbance at 253 nm of 0.003 per min at pH 7.6 at 25° C. using 0.23 mM Na-Benzoyl-L-Arginine Ethyl Ester Solution (BAEE) as substrate in a reaction volume of 3.2 mL. 
     The Lys-C used is preferably commercially available Lys-C(Sigma #000000011047825001). Lys-C may have a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 48. In one embodiment Lys-C may have a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 48. Preferably Lys-C may have a polypeptide sequence shown as SEQ ID NO: 48. One unit of said Lys-C is defined as the amount of enzyme that will hydrolyze 1.0 μmol Tos-Gly-Pro-Lys-pNA per min at 25° C., pH 7. 
     If one or more cleavage products additional to those of the H-chain and L-chain of the clostridial neurotoxin are observed by SDS-PAGE (preferably when stained with Coomassie or a dye of equivalent sensitivity), then it is confirmed that a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is hydrolysed by trypsin or Lys-C. Preferably if at least 3, 4, 5, 6, 7, 8, 9 or 10 cleavage products additional to those of the chain and L-chain of the clostridial neurotoxin are observed by SDS-PAGE after carrying out an assay described above, then it is confirmed that a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is hydrolysed by trypsin or Lys-C. 
     Additionally or alternatively, if less than 70% of endogenous activation loop is proteolytically processed by trypsin or Lys-C to yield a di-chain clostridial neurotoxin (assessed by way of SDS-PAGE, preferably when stained with Coomassie or a dye of equivalent sensitivity, after carrying out an assay described above), then it is confirmed that the endogenous activation loop is inefficiently proteolytically cleaved by trypsin or Lys-C. Preferably if less than 60%, 50%, 40%, 30%, 10% or 5% of endogenous activation loop is proteolytically processed by trypsin or Lys-C (assessed by way of SDS-PAGE after carrying out an assay described above) then the clostridial neurotoxin can be characterised in that the endogenous activation loop is inefficiently proteolytically cleaved by trypsin or Lys-C. More preferably if less than 30% of endogenous activation loop is proteolytically processed by trypsin or Lys-C (assessed by way of SDS-PAGE after carrying out an assay described above) then the clostridial neurotoxin can be characterised in that the endogenous activation loop is inefficiently proteolytically cleaved by trypsin or Lys-C. 
     A clostridial neurotoxin (pre-engineering) is preferably one in which a peptide bond (either within or outside of the activation loop) is not, or is not substantially, hydrolysed by enterokinase or factor Xa. The term “not substantially hydrolysed” means that less than 10%, 5%, 4%, 3%, 2% or 1% of the clostridial neurotoxin present in a reaction contains a peptide bond that has been hydrolysed by enterokinase or factor Xa in a method of the invention. 
     In one embodiment a method of the invention further comprises contacting an engineered clostridial neurotoxin with enterokinase or factor Xa (more preferably enterokinase) thereby producing a corresponding di-chain engineered clostridial neurotoxin. 
     In one aspect the invention provides an engineered clostridial neurotoxin (e.g. obtainable by a method of the invention), wherein an endogenous activation loop of a clostridial neurotoxin has been replaced by an exogenous activation loop thereby providing an engineered clostridial neurotoxin,
         wherein the exogenous activation loop comprises the polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1).       

     In one embodiment the clostridial neurotoxin (pre-engineering) is characterised in that: a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is hydrolysed by trypsin or Lys-C. In one embodiment the clostridial neurotoxin (pre-engineering) is characterised in that: the endogenous activation loop is inefficiently proteolytically processed by trypsin or Lys-C. In another embodiment the clostridial neurotoxin (pre-engineering) is characterised in that: a peptide bond outside of the endogenous activation loop of the clostridial neurotoxin is hydrolysed by trypsin or Lys-C; and the endogenous activation loop is inefficiently proteolytically processed by trypsin or Lys-C. Confirmation of these features of the clostridial neurotoxin (pre-engineering) is preferably by way of an aforementioned assay. 
     The invention may comprise replacing an endogenous activation loop of any clostridial neurotoxin with an exogenous activation loop described herein. Preferably the clostridial neurotoxin is not BoNT/C1. The clostridial neurotoxin may be a botulinum neurotoxin or a tetanus neurotoxin. Preferably the clostridial neurotoxin is a botulinum neurotoxin (BoNT), such as BoNT/A, BoNT/B, BoNT/D, BoNT/E, BoNT/F, BoNT/G or BoNT/X. 
     In one embodiment a clostridial neurotoxin for use in the present invention is BoNT/X, BoNT/E or a BoNT/A1C1 hybrid. Preferably the clostridial neurotoxin is BoNT/X or BoNT/E, both of which have been characterised in that trypsin and/or Lys-C hydrolyses a peptide bond outside of the endogenous activation loop thereof, and/or in that both clostridial neurotoxins contain an endogenous activation loop that is inefficiently proteolytically processed by trypsin and/or Lys-C. Most preferably a clostridial neurotoxin for use in the present invention is BoNT/X. 
     The term “endogenous activation loop” as used herein means an activation loop present in a subject clostridial neurotoxin, e.g. a subject clostridial neurotoxin of the indicated serotype. For example, BoNT/A1 includes a BoNT/A1 heavy chain and light chain, thus the endogenous activation loop of BoNT/A1 is an A1 activation loop. For clostridial neurotoxin chimeras or hybrids, the person skilled in the art can identify the “endogenous activation loop”, for example by determining the serotype(s) from which the L-chain and H N  domain are derived. In some embodiments, a chimera or hybrid clostridial neurotoxin may have an endogenous activation loop that is a fusion of an activation loop from two different serotypes. By way of example, a chimeric clostridial neurotoxin such as BoNT/A1C1 has a BoNT/A1 light chain and translocation domain, thus the endogenous BoNT/A1C1 activation loop is an A1 activation loop. Examples of activation loops are provided in  FIG. 1 . 
     Preferably an “endogenous activation loop” is any activation loop that is not SEQ ID NO: 1. In one embodiment an “endogenous activation loop” is any activation loop that is not SEQ ID NO: 2 and/or SEQ ID NO: 3. 
     By contrast, an “exogenous activation loop” as used herein means an activation loop that is different to the endogenous activation loop present in a subject clostridial neurotoxin, e.g. a subject clostridial neurotoxin of the indicated serotype. For example, a BoNT/C1 activation loop has a different polypeptide sequence to a wild-type BoNT/A1 activation loop, therefore the BoNT/C1 activation loop is exogenous to BoNT/A1. For clostridial neurotoxin chimeras or hybrids, the person skilled in the art can determine whether an activation loop is an “exogenous activation loop”, for example by determining the serotype(s) from which the L-chain and H N  domain are derived. Where the L-chain is a BoNT/B L-chain and the H N  domain is from BoNT/D, the endogenous activation loop may have a portion of a BoNT/B sequence and a portion of a BoNT/D sequence, and if an activation loop (e.g. a C1 activation loop) is different thereto, it is considered an “exogenous activation loop”. 
     Determination of whether an activation loop is an “exogenous activation loop” may be made by aligning the sequence of a subject clostridial neurotoxin with the activation loop, and seeing if the activation loop is present in the subject clostridial neurotoxin sequence. If it is absent, then the activation loop can be identified as an exogenous activation loop. 
     Preferably, the entire endogenous activation loop is replaced by an exogenous activation loop described herein. However, in some embodiments a portion of the endogenous activation loop is replaced, such as at least 5, 10, 15, 20, 25, 30, 35 or 40 amino acid residues of the endogenous activation are replaced. 
     Replacement of an endogenous activation loop may be achieved by any method known in the art. For example, replacement might be achieved by way of an amino acid modification. In one embodiment an endogenous activation loop may be replaced by deleting one or more amino acid residues of the endogenous activation loop. An endogenous activation loop may be replaced by substituting one or more amino acid residues of the endogenous activation loop with amino acid residues of an exogenous activation loop. In some embodiments an endogenous activation loop (or a portion thereof) may be deleted, and an exogenous activation loop inserted, preferably at the position formally occupied by the endogenous activation loop. Alternatively, the endogenous activation loop may be retained in an engineered clostridial neurotoxin of the invention, and preferably inactivated (e.g. by way of mutation). It is preferred that the endogenous activation loop (or a portion thereof, more preferably the entire endogenous activation loop) is not present in the engineered clostridial neurotoxin of the invention. It is preferred that the exogenous activation loop occupies the position in the clostridial neurotoxin formally occupied by the endogenous activation loop. 
     Methods for modifying proteins by substitution, insertion or deletion of amino acid residues are known in the art and may be employed in the practice of the present invention. By way of example, amino acid modifications may be introduced by modification of a DNA sequence encoding a clostridial neurotoxin. This can be achieved using standard molecular cloning techniques, for example by site-directed mutagenesis where short strands of DNA (oligonucleotides) coding for the desired amino acid(s) are used to replace the original coding sequence using a polymerase enzyme, or by inserting/deleting parts of the gene with various enzymes (e.g., ligases and restriction endonucleases). Alternatively a modified gene sequence can be chemically synthesised. 
     In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 70% (e.g. at least 80% or 90%) sequence identity to SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71. In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71. Preferably, an endogenous activation loop comprises a polypeptide sequence shown as SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71. 
     In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 70% (e.g. at least 80% or 90%) sequence identity to SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 68 or SEQ ID NO: 69. In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 68 or SEQ ID NO: 69. Preferably, an endogenous activation loop comprises a polypeptide sequence shown as SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 68 or SEQ ID NO: 69. 
     In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 70% (e.g. at least 80% or 90%) sequence identity to SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 24. In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 24. Preferably, an endogenous activation loop comprises a polypeptide sequence shown as SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 24. 
     Preferably an endogenous activation loop comprises a polypeptide sequence having at least 70% (e.g. at least 80% or 90%) sequence identity to SEQ ID NO: 20. In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 20. More preferably, an endogenous activation loop comprises a polypeptide sequence shown as SEQ ID NO: 20. 
     Preferably an endogenous activation loop comprises a polypeptide sequence having at least 70% (e.g. at least 80% or 90%) sequence identity to SEQ ID NO: 21. In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 21. More preferably, an endogenous activation loop comprises a polypeptide sequence shown as SEQ ID NO: 21. 
     Preferably an endogenous activation loop comprises a polypeptide sequence having at least 70% (e.g. at least 80% or 90%) sequence identity to SEQ ID NO: 24. In one embodiment an endogenous activation loop comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 24. More preferably, an endogenous activation loop comprises a polypeptide sequence shown as SEQ ID NO: 24. 
     The present invention encompasses methods and clostridial neurotoxins in which an endogenous activation loop has been replaced by an exogenous activation loop, such as an exogenous activation loop comprising a polypeptide shown as Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1). Xaa or Yaa can be any amino acid. The number of amino acids at position Xaa and Yaa are indicated by the letters ‘a’ and ‘b’, respectively. In one embodiment ‘a’ and ‘b’ can be any integer that allows for proteolytic cleavage of the activation loop and yields an active di-chain clostridial neurotoxin. In one embodiment ‘a’ is at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In one embodiment ‘b’ is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15. In one embodiment ‘a’ is ≤12, ≤11, ≤10, ≤9, ≤8, ≤7, ≤6, ≤5 or ≤4. In one embodiment ‘b’ is ≤20, ≤19, ≤18, ≤17, ≤16, ≤15, ≤14, ≤13, ≤12, ≤11, ≤10 or ≤9. 
     In one embodiment ‘a’ is 1-12, for example 1-10. Preferably ‘a’ is 1-7, such as 2-4. More preferably ‘a’ is 3. In one embodiment ‘b’ is 1-20, for example 4-15. Preferably ‘b’ is 6-10. More preferably ‘b’ is 8. 
     It is not intended that Xaa or Yaa be limited to only one type of amino acid. Thus, one or more residues present at position Xaa may be independently selected from the standard amino acids: aspartic acid, glutamic acid, arginine, lysine, histidine, asparagine, glutamine, serine, threonine, tyrosine, methionine, tryptophan, cysteine, alanine, glycine, valine, leucine, isoleucine, proline, and phenylalanine. One or more residues present at position Yaa may be independently selected from the standard amino acids: aspartic acid, glutamic acid, arginine, lysine, histidine, asparagine, glutamine, serine, threonine, tyrosine, methionine, tryptophan, cysteine, alanine, glycine, valine, leucine, isoleucine, proline, and phenylalanine. Preferably an amino acid at position Yaa (more preferably immediately C-terminal to the Arg residue of SEQ ID NO: 1) is not proline. 
     Alternatively/additionally, one or more residues present at position Xaa or Yaa may be independently selected from a non-standard amino acid (an amino acid that is not part of the standard set of 20 described above). By way of example, non-standard amino acids may include 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid, isovaline, α-methyl serine, trans-3-methylproline, 2,4-methano-proline, cis-4-hydroxyproline, trans-4-hydroxy-proline, N-methylglycine, allo-threonine, methyl-threonine, hydroxy-ethylcysteine, hydroxyethylhomo-cysteine, nitro-glutamine, homoglutamine, pipecolic acid, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenyl-alanine, 4-azaphenyl-alanine, L-Ornithine, L-2-amino-3-guanidinopropionic acid, or D-isomers of Lysine, Arginine and/or Ornithine, and 4-fluorophenylalanine. Methods for introducing non-standard amino acids into proteins are known in the art, and include recombinant protein synthesis using  E. coli  auxotrophic expression hosts. 
     Properties of the standard amino acids are indicated in the table below: 
     
       
         
           
               
               
               
             
               
                   
                   
               
               
                   
                 AMINO ACID 
                 SIDE CHAIN 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 Aspartic acid 
                 Asp 
                 D 
                 Charged (acidic) 
               
               
                   
                 Glutamic acid 
                 Glu 
                 E 
                 Charged (acidic) 
               
               
                   
                 Arginine 
                 Arg 
                 R 
                 Charged (basic) 
               
               
                   
                 Lysine 
                 Lys 
                 K 
                 Charged (basic) 
               
               
                   
                 Histidine 
                 His 
                 H 
                 Uncharged (polar) 
               
               
                   
                 Asparagine 
                 Asn 
                 N 
                 Uncharged (polar) 
               
               
                   
                 Glutamine 
                 Gln 
                 Q 
                 Uncharged (polar) 
               
               
                   
                 Serine 
                 Ser 
                 S 
                 Uncharged (polar) 
               
               
                   
                 Threonine 
                 Thr 
                 T 
                 Uncharged (polar) 
               
               
                   
                 Tyrosine 
                 Tyr 
                 Y 
                 Uncharged (polar) 
               
               
                   
                 Methionine 
                 Met 
                 M 
                 Uncharged (polar) 
               
               
                   
                 Tryptophan 
                 Trp 
                 W 
                 Uncharged (polar) 
               
               
                   
                 Cysteine 
                 Cys 
                 C 
                 Uncharged (polar) 
               
               
                   
                 Alanine 
                 Ala 
                 A 
                 Uncharged (hydrophobic) 
               
               
                   
                 Glycine 
                 Gly 
                 G 
                 Uncharged (hydrophobic) 
               
               
                   
                 Valine 
                 Val 
                 V 
                 Uncharged (hydrophobic) 
               
               
                   
                 Leucine 
                 Leu 
                 L 
                 Uncharged (hydrophobic) 
               
               
                   
                 Isoleucine 
                 Ile 
                 I 
                 Uncharged (hydrophobic) 
               
               
                   
                 Proline 
                 Pro 
                 P 
                 Uncharged (hydrophobic) 
               
               
                   
                 Phenylalanine 
                 Phe 
                 F 
                 Uncharged (hydrophobic) 
               
               
                   
                   
               
            
           
         
       
     
     The following amino acids are considered charged amino acids: aspartic acid (negative), glutamic acid (negative), arginine (positive), and lysine (positive). 
     The sequence 11e-Asp/Glu-Gly-Arg comprised in SEQ ID NO: 1 refers to the site surprisingly found by the present inventors to be recognised by enterokinase (as well as factor Xa). Preferably the sequence is Ile-Asp-Gly-Arg, e.g. Cys-(Xaa) a -Ile-Asp-Gly-Arg-(Yaa) b -Cys. It is believed that enterokinase and factor Xa hydrolyse a peptide bond immediately C-terminal to Arg of SEQ ID NO: 1 (i.e. the peptide bond between Arg and Yaa). 
     In one embodiment an amino acid residue at Xaa immediately N-terminal to lie of SEQ ID NO: 1 is an uncharged hydrophobic amino acid, preferably alanine. In some embodiments ‘a’ is at least 2, and Xaa comprises at least a C-terminal uncharged polar amino acid and a charged basic amino acid immediately N-terminal thereto. The charged basic amino acid is preferably lysine. Thus in embodiments where ‘a’ is at least 2, Xaa may comprise at least Lys-Ala, wherein Ala is immediately N-terminal to lie of SEQ ID NO: 1. 
     In one embodiment Xaa comprises or consists of the sequence HKA. 
     In one embodiment an amino acid residue at Yaa immediately C-terminal to Arg of SEQ ID NO: 1 is an uncharged polar amino acid, preferably serine. In some embodiments ‘b’ is at least 2, and Yaa comprises at least an N-terminal uncharged polar amino acid and an uncharged hydrophobic amino acid immediately C-terminal thereto. The uncharged hydrophobic amino acid is preferably leucine. Thus in embodiments where ‘b’ is at least 2, Yaa may comprise at least Ser-Leu, wherein Ser is immediately C-terminal to Arg of SEQ ID NO: 1. 
     In one embodiment Yaa comprises or consists of the sequence SLYNKTLDC. 
     In some embodiments an exogenous activation loop has at least 70% sequence identity to SEQ ID NO: 2. In one embodiment an exogenous activation loop has at least 80%, 85% or 90% sequence identity to SEQ ID NO: 2. Preferably an exogenous activation loop has at least 95% sequence identity to SEQ ID NO: 2. More preferably, an exogenous activation loop has at least 99% sequence identity to SEQ ID NO: 2. 
     In a particularly preferred embodiment an exogenous loop comprises SEQ ID NO: 2. More preferably an exogenous loop consists of SEQ ID NO: 2. 
     The exogenous loop may also be a variant of SEQ ID NO: 2, such as SEQ ID NO:3 or a sequence having at least 70% sequence identity thereto. SEQ ID NO: 3 is a variant of SEQ ID NO: 2 in which the enterokinase recognition site IDGR has been mutated to IEGR. In one embodiment an exogenous activation loop has at least 80%, 85% or 90% sequence identity to SEQ ID NO: 3. Preferably an exogenous activation loop has at least 95% sequence identity to SEQ ID NO: 3. More preferably, an exogenous activation loop has at least 99% sequence identity to SEQ ID NO: 3. 
     In a particularly preferred embodiment an exogenous loop comprises SEQ ID NO: 3. More preferably an exogenous loop consists of SEQ ID NO: 3. 
     A clostridial neurotoxin of the present invention (e.g. engineered clostridial neurotoxin) may be encoded by a nucleotide sequence having at least 70% sequence identity to SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. In one embodiment a clostridial neurotoxin of the present invention may be encoded by a nucleotide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. Preferably, a clostridial neurotoxin of the present invention may be encoded by a nucleotide sequence comprising (more preferably consisting of) SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. 
     A clostridial neurotoxin of the present invention (e.g. engineered clostridial neurotoxin) may comprise a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13. In one embodiment a clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13. Preferably, a clostridial neurotoxin of the present invention may comprise (more preferably consist of) a polypeptide sequence shown as SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13. 
     The clostridial neurotoxin of the present invention (e.g. engineered clostridial neurotoxin) is preferably BoNT/X, wherein the clostridial neurotoxin is encoded by a nucleotide sequence having at least 70% sequence identity to SEQ ID NO: 4. In one embodiment the clostridial neurotoxin is encoded by a nucleotide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 4. Preferably the clostridial neurotoxin is encoded by a nucleotide sequence comprising (or consisting of) SEQ ID NO: 4. The clostridial neurotoxin of the present invention is preferably BoNT/X, wherein the clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 5. In one embodiment the clostridial neurotoxin comprises a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 5. Preferably the clostridial neurotoxin comprises (or consists of) a polypeptide sequence shown as SEQ ID NO: 5. 
     The clostridial neurotoxin of the present invention (e.g. engineered clostridial neurotoxin) is preferably BoNT/E, wherein the clostridial neurotoxin is encoded by a nucleotide sequence having at least 70% sequence identity to SEQ ID NO: 10. In one embodiment the clostridial neurotoxin is encoded by a nucleotide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 10. Preferably the clostridial neurotoxin is encoded by a nucleotide sequence comprising (or consisting of) SEQ ID NO: 10. The clostridial neurotoxin of the present invention is preferably BoNT/E, wherein the clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 11. In one embodiment the clostridial neurotoxin comprises a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 11. Preferably the clostridial neurotoxin comprises (or consists of) a polypeptide sequence shown as SEQ ID NO: 11. 
     In some embodiments, the polypeptide sequences of the invention (or the nucleotide sequences encoding the same) may include a purification tag, such as a His-tag. It is intended that the present invention also encompasses polypeptide sequences (and nucleotide sequences encoding the same) where the purification tag is removed. 
     The present invention encompasses contacting a single-chain clostridial neurotoxin (e.g. an engineered clostridial neurotoxin of the invention) with a protease capable of hydrolysing a peptide bond in an activation loop of the single-chain clostridial neurotoxin thereby producing a di-chain clostridial neurotoxin. The protease may be an endopeptidase. The protease may be enterokinase, factor Xa, Lys-C or trypsin. Preferably the protease is enterokinase or factor Xa, more preferably enterokinase. 
     The term “enterokinase” or “EK” encompasses enterokinases described herein, as well as any protease having structural and/or functional similarity (preferably structural and functional similarity) that is capable of hydrolysing a peptide bond of SEQ ID NO: 1. A suitable enterokinase is enterokinase light chain, which is commercially available from NEB (#P8070). One unit may be defined as the amount of enzyme required to cleave 25 μg of a MBP-EK-paramyosin-ΔSal substrate to 95% completion in 16 hours at 25° C. in a total reaction volume of 25 μl (20 mM Tris-HCl, 50 mM NaCl, 2 mM CaCl 2  (pH 8.0 @ 25° C.)). 
     In one embodiment an enterokinase comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 49. In some embodiments an enterokinase comprises a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 49. Preferably an enterokinase comprises (more preferably consists of) SEQ ID NO: 49. 
     In some embodiments, enterokinase may further comprise a heavy chain, wherein the heavy and light-chains are connected by a disulphide bridge. Such enterokinases are commercially available (e.g. from R&amp;D Systems). 
     The term “factor Xa” encompasses factor Xa described herein, as well as any protease having structural and/or functional similarity (preferably structural and functional similarity) that is capable of hydrolysing a peptide bond of SEQ ID NO: 1. A suitable factor Xa is commercially available from NEB (#P8010). One unit may be defined as the amount of factor Xa required to cleave 50 μg of an MBP fusion protein test substrate, MBP-ΔSal (substrate MBP-ΔSal is maltose-binding protein fused to a truncated form of paramyosin, with the amino acids 11e-Glu-Gly-Arg at the fusion joint) to 95% completion in 6 hours or less at 23° C. in a reaction volume of 50 μl (20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl 2  (pH 8.0)). 
     In one embodiment a factor Xa comprises a polypeptide sequence having a heavy chain with at least 70% sequence identity to SEQ ID NO: 50 and a light chain with at least 70% sequence identity to SEQ ID NO: 51, wherein the heavy and light-chain are connected by a disulphide bridge. In some embodiments a factor Xa comprises a polypeptide sequence having a heavy chain with at least 80% or 90% sequence identity to SEQ ID NO: 50 and a light chain with at least 80% or 90% sequence identity to SEQ ID NO: 51, wherein the heavy and light-chain are connected by a disulphide bridge. Preferably a factor Xa comprises (more preferably consists of) SEQ ID NO: 50 and SEQ ID NO: 51, wherein the heavy and light-chain are connected by a disulphide bridge. 
     The contacting can occur under any suitable conditions that result in the production of greater than 30%, 40%, 50% or 60% (preferably greater than 70%) of single-chain clostridial neurotoxin being proteolytically processed into the corresponding di-chain clostridial neurotoxin without, or without substantial, hydrolysis of a peptide bond outside of the activation loop of said clostridial neurotoxin. “Without substantial hydrolysis” may mean less than 5%, 4%, 3%, 2% or 1% of the clostridial neurotoxins contacted contain a peptide bond outside of the activation loop that has been hydrolysed by a protease in a method of the invention. 
     The skilled person can select appropriate reaction times, temperatures, buffers, and molar ratios of protease to single-chain clostridial neurotoxin to achieve the above. Optimisation of such conditions can be determined empirically using routine techniques, such as SDS-PAGE (e.g. stained with Coomassie or a dye of similar sensitivity) visual analysis of the reaction products following said contacting or spectrometric techniques (e.g. mass spectrometry). 
     When assessed by SDS-PAGE (e.g. stained with Coomassie or a dye of similar sensitivity), a method of the invention preferably results in the production of a clostridial neurotoxin L-chain and H-chain only. 
     In one embodiment the proteolytic processing by a protease in a method of the invention results in the production of less than 5 degradation products of a clostridial neurotoxin L-chain or H-chain, more preferably less than 4, 3, 2 or 1 degradation products. Preferably, the L-chain and H-chain produced by a method of the invention are full-length L-chain and H-chain. 
     Therefore, in a particularly preferred embodiment a protease used in a method of the invention (e.g. enterokinase or factor Xa) hydrolyses only a peptide bond of SEQ ID NO: 1, more preferably only the peptide bond between Arg and Yaa of SEQ ID NO: 1. 
     In one embodiment the contacting occurs for at least 1 hour, e.g. at least 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 hours. 
     In one embodiment the contacting occurs at a temperature of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40° C. 
     In one embodiment contacting occurs at a temperature of 1 to 10° C. (preferably about 4° C.). 
     Preferably contacting occurs at a temperature of 1 to 10° C. (more preferably about 4° C.) for 10-25 hours (preferably 15-20 hours). 
     In one embodiment contacting occurs at a temperature of 15-25° C. (preferably about 20° C.). Preferably contacting occurs at a temperature of 15-25° C. (more preferably about 20° C.) for 10-25 hours (preferably 15-20 hours). 
     In one embodiment contacting occurs at a temperature of 20-30° C. (preferably about 25° C.). Preferably contacting occurs at a temperature of 20-30° C. (more preferably about 25° C.) for 10-25 hours (preferably 15-20 hours). 
     A contacting step of a method of the invention may comprise the use of at least 1 μg of protease per mg of clostridial neurotoxin. In one embodiment a contacting step of a method of the invention comprises the use of at least 0.1, 0.2, 0.4, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 μg of protease per mg of clostridial neurotoxin. Preferably a contacting step of a method of the invention comprises the use of at least 2 μg (more preferably at least 4 μg) of protease per mg of clostridial neurotoxin. 
     In one embodiment a contacting step of a method of the invention comprises the use of ≤20 μg of protease per mg of clostridial neurotoxin. In one embodiment a contacting step of a method of the invention comprises the use of ≤15 μg of protease per mg of clostridial neurotoxin. Preferably a contacting step of a method of the invention comprises the use of ≤10 μg of protease per mg of clostridial neurotoxin. More preferably, a contacting step of a method of the invention comprises the use of ≤7 μg of protease per mg of clostridial neurotoxin A contacting step of a method of the invention may comprise the use of 0.1-20 μg of protease per mg of clostridial neurotoxin. In one embodiment a method of the invention may comprise the use of 1-10 μg of protease per mg of clostridial neurotoxin, preferably 4-7 μg of protease per mg of clostridial neurotoxin. 
     A contacting step of a method of the invention may comprise the use of at least 10, 20, 30, 40, 50, 60 or 70 units of enterokinase per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of at least 60 units of enterokinase (more preferably at least 70 units) per mg of clostridial neurotoxin. In some embodiments, a contacting step of a method of the invention may comprise the use of ≤150, ≤140, ≤130, ≤120, ≤110, ≤100, ≤90 units of enterokinase per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of ≤100 units of enterokinase (more preferably ≤90 units) per mg of clostridial neurotoxin. A contacting step of a method of the invention may comprise the use of 50-110 units of enterokinase per mg of clostridial neurotoxin. In one embodiment a method of the invention may comprise the use of 70-90 units of enterokinase per mg of clostridial neurotoxin, e.g. about 80 units of enterokinase per mg of clostridial neurotoxin. 
     A contacting step of a method of the invention may comprise the use of at least 0.5, 1, 2, 3, 4, or 5 units of factor Xa per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of at least 3 units of factor Xa (more preferably at least 4 units) per mg of clostridial neurotoxin. In some embodiments, a contacting step of a method of the invention may comprise the use of ≤15, ≤14, ≤13, ≤12, ≤11, ≤10, ≤9, ≤8 or ≤7 units of factor Xa per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of ≤8 units of factor Xa (more preferably ≤7 units) per mg of clostridial neurotoxin. A contacting step of a method of the invention may comprise the use of 0.5-15 units of factor Xa per mg of clostridial neurotoxin. In one embodiment a method of the invention may comprise the use of 1-10 units (preferably 4-7 units) of factor Xa per mg of clostridial neurotoxin, e.g. about 5 or 6 units of factor Xa per mg of clostridial neurotoxin. 
     A contacting step of a method of the invention may comprise the use of at least 0.02, 0.04, 0.06 or 0.08 units of Lys-C per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of at least 0.04 units of Lys-C per mg of clostridial neurotoxin. In some embodiments, a contacting step of a method of the invention may comprise the use of ≤0.5, ≤0.4 or ≤0.2 units of Lys-C per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of ≤0.2 units of Lys-C per mg of clostridial neurotoxin. A contacting step of a method of the invention may comprise the use of 0.02-0.5 units of Lys-C per mg of clostridial neurotoxin. Preferably, a method of the invention may comprise the use of 0.04-0.2 units of Lys-C per mg of clostridial neurotoxin. 
     A contacting step of a method of the invention may comprise the use of at least 0.1, 0.2, 0.3 or 0.4 units of trypsin per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of at least 0.4 units of trypsin per mg of clostridial neurotoxin. In some embodiments, a contacting step of a method of the invention may comprise the use of ≤2.5, ≤2.3, ≤2.1, ≤1.9 units of trypsin per mg of clostridial neurotoxin. Preferably, a contacting step of a method of the invention may comprise the use of ≤1.8 units of trypsin per mg of clostridial neurotoxin. A contacting step of a method of the invention may comprise the use of 0.1-2.5 units of trypsin per mg of clostridial neurotoxin. Preferably, a method of the invention may comprise the use of 0.3-2 units (more preferably 0.4-1.8 units) of trypsin per mg of clostridial neurotoxin. 
     In one embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/X. A reference BoNT/X sequence is shown as SEQ ID NO: 33. A histidine-tagged version of BoNT/X is presented as SEQ ID NO: 34. A reference nucleotide sequence encoding BoNT/X is shown as SEQ ID NO: 32. 
     In one embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/A. A reference BoNT/A sequence is shown as SEQ ID NO: 35. 
     In another embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/B. A reference BoNT/B sequence is shown as SEQ ID NO: 36. 
     In another embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/C. A reference BoNT/C 1  sequence is shown as SEQ ID NO: 37. 
     In another embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/D. A reference BoNT/D sequence is shown as SEQ ID NO: 38. 
     In another embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/E. A reference BoNT/E sequence is shown as SEQ ID NO: 39. 
     In another embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/F. A reference BoNT/F sequence is shown as SEQ ID NO: 40. 
     In another embodiment the clostridial neurotoxin (e.g. pre-engineering) may be BoNT/G. A reference BoNT/G sequence is shown as SEQ ID NO: 41. 
     In another embodiment the clostridial neurotoxin (e.g. pre-engineering) may be TeNT. A reference TeNT sequence is shown as SEQ ID NO: 42. 
     As discussed above, clostridial neurotoxins are formed from two polypeptide chains, the heavy chain (H-chain), which has a molecular mass of approximately 100 kDa, and the light chain (L-chain), which has a molecular mass of approximately 50 kDa. The H-chain comprises a C-terminal targeting component (receptor binding domain or H C  domain) and an N-terminal translocation component (H N  domain). 
     Examples of light chain reference sequences include:
         Botulinum type A neurotoxin: amino acid residues 1-448   Botulinum type B neurotoxin: amino acid residues 1-440   Botulinum type C1 neurotoxin: amino acid residues 1-441   Botulinum type D neurotoxin: amino acid residues 1-445   Botulinum type E neurotoxin: amino acid residues 1-422   Botulinum type F neurotoxin: amino acid residues 1-439   Botulinum type G neurotoxin: amino acid residues 1-441   Tetanus neurotoxin: amino acid residues 1-457       

     For recently-identified BoNT/X, the L-chain has been reported as corresponding to amino acids 1-439 thereof, with the L-chain boundary potentially varying by approximately 25 amino acids (e.g. 1-414 or 1-464). 
     The above-identified reference sequences should be considered a guide, as slight variations may occur according to sub-serotypes. By way of example, US 2007/0166332 (hereby incorporated by reference in its entirety) cites slightly different clostridial sequences:
         Botulinum type A neurotoxin: amino acid residues M1-K448   Botulinum type B neurotoxin: amino acid residues M1-K441   Botulinum type C1 neurotoxin: amino acid residues M1-K449   Botulinum type D neurotoxin: amino acid residues M1-R445   Botulinum type E neurotoxin: amino acid residues M1-R422   Botulinum type F neurotoxin: amino acid residues M1-K439   Botulinum type G neurotoxin: amino acid residues M1-K446   Tetanus neurotoxin: amino acid residues M1-A457       

     A Translocation Domain is a molecule that enables translocation of a protease into a target cell such that a functional expression of protease activity occurs within the cytosol of the target cell. Whether any molecule (e.g. a protein or peptide) possesses the requisite translocation function of the present invention may be confirmed by any one of a number of conventional assays. 
     For example, Shone C. (1987) describes an in vitro assay employing liposomes, which are challenged with a test molecule. Presence of the requisite translocation function is confirmed by release from the liposomes of K +  and/or labelled NAD, which may be readily monitored [see Shone C. (1987) Eur. J. Biochem; vol. 167(1): pp. 175-180]. 
     A further example is provided by Blaustein R. (1987), which describes a simple in vitro assay employing planar phospholipid bilayer membranes. The membranes are challenged with a test molecule and the requisite translocation function is confirmed by an increase in conductance across said membranes [see Blaustein (1987) FEBS Letts; vol. 226, no. 1: pp. 115-120]. 
     Additional methodology to enable assessment of membrane fusion and thus identification of Translocation Domains suitable for use in the present invention are provided by Methods in Enzymology Vol 220 and 221, Membrane Fusion Techniques, Parts A and B, Academic Press 1993. 
     The present invention also embraces variant translocation domains, so long as the variant domains still demonstrate the requisite translocation activity. By way of example, a variant may have at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% or at least 98% amino acid sequence homology with a reference translocation domain. The term fragment, when used in relation to a translocation domain, means a peptide having at least 20, preferably at least 40, more preferably at least 80, and most preferably at least 100 amino acid residues of the reference translocation domain. In the case of a clostridial translocation domain, the fragment preferably has at least 100, preferably at least 150, more preferably at least 200, and most preferably at least 250 amino acid residues of the reference translocation domain (eg. H N  domain). Translocation ‘fragments’ of the present invention embrace fragments of variant translocation domains based on the reference sequences. 
     The Translocation Domain is preferably capable of formation of ion-permeable pores in lipid membranes under conditions of low pH. Preferably it has been found to use only those portions of the protein molecule capable of pore-formation within the endosomal membrane. 
     The Translocation Domain may be obtained from a microbial protein source, in particular from a bacterial or viral protein source. Hence, in one embodiment, the Translocation Domain is a translocating domain of an enzyme, such as a bacterial toxin or viral protein. 
     It is well documented that certain domains of bacterial toxin molecules are capable of forming such pores. It is also known that certain translocation domains of virally expressed membrane fusion proteins are capable of forming such pores. Such domains may be employed in the present invention. 
     The Translocation Domain may be of a clostridial origin, such as the H N  domain (or a functional component thereof). H N  means a portion or fragment of the H-chain of a clostridial neurotoxin approximately equivalent to the amino-terminal half of the H-chain, or the domain corresponding to that fragment in the intact H-chain. In one embodiment the H C  function of the H-chain may be removed by deletion of the H C  amino acid sequence (either at the DNA synthesis level, or at the post-synthesis level by nuclease or protease treatment). Alternatively, the H C  function may be inactivated by chemical or biological treatment. Thus, in some embodiments the H-chain may be incapable of binding to the Binding Site on a target cell to which native clostridial neurotoxin (i.e. holotoxin) binds. 
     Examples of suitable (reference) Translocation Domains include:
         Botulinum type A neurotoxin—amino acid residues (449-871)   Botulinum type B neurotoxin—amino acid residues (441-858)   Botulinum type C neurotoxin—amino acid residues (442-866)   Botulinum type D neurotoxin—amino acid residues (446-862)   Botulinum type E neurotoxin—amino acid residues (423-845)   Botulinum type F neurotoxin—amino acid residues (440-864)   Botulinum type G neurotoxin—amino acid residues (442-863)   Tetanus neurotoxin—amino acid residues (458-879)       

     The above-identified reference sequence should be considered a guide as slight variations may occur according to sub-serotypes. By way of example, US 2007/0166332 (hereby incorporated by reference thereto) cites slightly different clostridial sequences:
         Botulinum type A neurotoxin—amino acid residues (A449-K871)   Botulinum type B neurotoxin—amino acid residues (A442-S858)   Botulinum type C neurotoxin—amino acid residues (T450-N866)   Botulinum type D neurotoxin—amino acid residues (D446-N862)   Botulinum type E neurotoxin—amino acid residues (K423-K845)   Botulinum type F neurotoxin—amino acid residues (A440-K864)   Botulinum type G neurotoxin—amino acid residues (S447-S863)   Tetanus neurotoxin—amino acid residues (S458-V879)       

     In the context of the present invention, a variety of clostridial neurotoxin H N  regions comprising a translocation domain can be useful in aspects of the present invention with the proviso that these active fragments can facilitate the release of a non-cytotoxic protease (e.g. a clostridial L-chain) from intracellular vesicles into the cytoplasm of the target cell and thus participate in executing the overall cellular mechanism whereby a clostridial neurotoxin proteolytically cleaves a substrate. The H N  regions from the heavy chains of clostridial neurotoxins are approximately 410-430 amino acids in length and comprise a translocation domain. Research has shown that the entire length of a H N  region from a clostridial neurotoxin heavy chain is not necessary for the translocating activity of the translocation domain. Thus, aspects of this embodiment can include clostridial neurotoxin H N  regions comprising a translocation domain having a length of, for example, at least 350 amino acids, at least 375 amino acids, at least 400 amino acids and at least 425 amino acids. Other aspects of this embodiment can include clostridial neurotoxin H N  regions comprising translocation domain having a length of, for example, at most 350 amino acids, at most 375 amino acids, at most 400 amino acids and at most 425 amino acids. 
     For further details on the genetic basis of toxin production in  Clostridium botulinum  and  C. tetani , we refer to Henderson et al (1997) in  The Clostridia: Molecular Biology and Pathogenesis,  Academic press. 
     The term H N  embraces naturally-occurring neurotoxin H N  portions, and modified H N  portions having amino acid sequences that do not occur in nature and/or synthetic amino acid residues, so long as the modified H N  portions still demonstrate the above-mentioned translocation function. 
     Alternatively, the Translocation Domain may be of a non-clostridial origin. Examples of non-clostridial (reference) Translocation Domain origins include, but not be restricted to, the translocation domain of diphtheria toxin [O&#39;Keefe et al., Proc. Natl. Acad. Sci. USA (1992) 89, 6202-6206; Silverman et al., J. Biol. Chem. (1993) 269, 22524-22532; and London, E. (1992)  Biochem. Biophys. Acta.,  1112, pp. 25-51], the translocation domain of  Pseudomonas  exotoxin type A [Prior et al. Biochemistry (1992) 31, 3555-3559], the translocation domains of anthrax toxin [Blanke et al. Proc. Natl. Acad. Sci. USA (1996) 93, 8437-8442], a variety of fusogenic or hydrophobic peptides of translocating function [Plank et al. J. Biol. Chem. (1994) 269, 12918-12924; and Wagner et al (1992)  PNAS,  89, pp. 7934-7938], and amphiphilic peptides [Murata et al (1992)  Biochem.,  31, pp. 1986-1992]. The Translocation Domain may mirror the Translocation Domain present in a naturally-occurring protein, or may include amino acid variations so long as the variations do not destroy the translocating ability of the Translocation Domain. 
     Particular examples of viral (reference) Translocation Domains suitable for use in the present invention include certain translocating domains of virally expressed membrane fusion proteins. For example, Wagner et al. (1992) and Murata et al. (1992) describe the translocation (i.e. membrane fusion and vesiculation) function of a number of fusogenic and amphiphilic peptides derived from the N-terminal region of influenza virus haemagglutinin. Other virally expressed membrane fusion proteins known to have the desired translocating activity are a translocating domain of a fusogenic peptide of Semliki Forest Virus (SFV), a translocating domain of vesicular stomatitis virus (VSV) glycoprotein G, a translocating domain of SER virus F protein and a translocating domain of Foamy virus envelope glycoprotein. Virally encoded Aspike proteins have particular application in the context of the present invention, for example, the E1 protein of SFV and the G protein of the G protein of VSV. 
     Use of the (reference) Translocation Domains listed in Table (below) includes use of sequence variants thereof. A variant may comprise one or more conservative nucleic acid substitutions and/or nucleic acid deletions or insertions, with the proviso that the variant possesses the requisite translocating function. A variant may also comprise one or more amino acid substitutions and/or amino acid deletions or insertions, so long as the variant possesses the requisite translocating function. 
     
       
         
           
               
               
               
             
               
                   
               
               
                 Translocation 
                   
                   
               
               
                 Domain source 
                 Amino acid residues 
                 References 
               
               
                   
               
             
            
               
                 Diphtheria toxin 
                 194-380 
                 Silverman et al., 1994, J. Biol. Chem. 
               
               
                   
                   
                 269, 22524-22532 
               
               
                   
                   
                 London E., 1992, Biochem. Biophys. 
               
               
                   
                   
                 Acta., 1113, 25-51 
               
               
                 Domain II of 
                 405-613 
                 Prior et al., 1992, Biochemistry 31, 3555-3559 
               
               
                 pseudomonas 
                   
                 Kihara &amp; Pastan, 1994, Bioconj Chem. 5, 
               
               
                 exotoxin 
                   
                 532-538 
               
               
                 Influenza virus 
                 GLFGAIAGFIENGWE 
                 Plank et al., 1994, J. Biol. Chem. 269, 
               
               
                 haemagglutinin 
                 GMIDGWYG (SEQ ID 
                 12918-12924 
               
               
                   
                 NO: 73), and 
                 Wagner et al., 1992, PNAS, 89, 7934-7938 
               
               
                   
                 Variants thereof 
                 Murata et al., 1992, Biochemistry 31, 1986-1992 
               
               
                 Semliki Forest virus 
                 Translocation domain 
                 Kielian et al., 1996, J Cell Biol. 134(4), 
               
               
                 fusogenic protein 
                   
                 863-872 
               
               
                 Vesicular Stomatitis 
                 118-139 
                 Yao et al., 2003, Virology 310(2), 319-332 
               
               
                 virus glycoprotein G 
               
               
                 SER virus F protein 
                 Translocation domain 
                 Seth et al., 2003, J Virol 77(11) 6520-6527 
               
               
                 Foamy virus 
                 Translocation domain 
                 Picard-Maureau et al., 2003, J Virol. 
               
               
                 envelope 
                   
                 77(8), 4722-4730 
               
               
                 glycoprotein 
               
               
                   
               
            
           
         
       
     
     Examples of clostridial neurotoxin H C  domain reference sequences include:
         BoNT/A—N872-1L1296   BoNT/B—E859-E1291   BoNT/C1—N867-E1291   BoNT/D—S863-E1276   BoNT/E—R846-K1252   BoNT/F—K865-E1274   BoNT/G—N864-E1297   TeNT—I880-D1315       

     For recently-identified BoNT/X, the H C  domain has been reported as corresponding to amino acids 893-1306 thereof, with the domain boundary potentially varying by approximately 25 amino acids (e.g. 868-1306 or 918-1306). 
     The clostridial neurotoxins described herein may further comprise a translocation facilitating domain. Said domain facilitates delivery of the non-cytotoxic protease into the cytosol of the target cell and are described, for example, in WO 08/008803 and WO 08/008805, each of which is herein incorporated by reference thereto. 
     By way of example, suitable translocation facilitating domains include an enveloped virus fusogenic peptide domain, for example, suitable fusogenic peptide domains include influenzavirus fusogenic peptide domain (eg. influenza A virus fusogenic peptide domain of 23 amino acids), alphavirus fusogenic peptide domain (eg. Semliki Forest virus fusogenic peptide domain of 26 amino acids), vesiculovirus fusogenic peptide domain (eg. vesicular stomatitis virus fusogenic peptide domain of 21 amino acids), respirovirus fusogenic peptide domain (eg. Sendai virus fusogenic peptide domain of 25 amino acids), morbiliivirus fusogenic peptide domain (eg. Canine distemper virus fusogenic peptide domain of 25 amino acids), avulavirus fusogenic peptide domain (eg. Newcastle disease virus fusogenic peptide domain of 25 amino acids), henipavirus fusogenic peptide domain (eg. Hendra virus fusogenic peptide domain of 25 amino acids), metapneumovirus fusogenic peptide domain (eg. Human metapneumovirus fusogenic peptide domain of 25 amino acids) or spumavirus fusogenic peptide domain such as simian foamy virus fusogenic peptide domain; or fragments or variants thereof. 
     By way of further example, a translocation facilitating domain may comprise a clostridial neurotoxin H CN  domain or a fragment or variant thereof. In more detail, a clostridial neurotoxin H CN  translocation facilitating domain may have a length of at least 200 amino acids, at least 225 amino acids, at least 250 amino acids, at least 275 amino acids. In this regard, a clostridial neurotoxin H CN  translocation facilitating domain preferably has a length of at most 200 amino acids, at most 225 amino acids, at most 250 amino acids, or at most 275 amino acids. Specific (reference) examples include:
         Botulinum type A neurotoxin—amino acid residues (872-1110)   Botulinum type B neurotoxin—amino acid residues (859-1097)   Botulinum type C neurotoxin—amino acid residues (867-1111)   Botulinum type D neurotoxin—amino acid residues (863-1098)   Botulinum type E neurotoxin—amino acid residues (846-1085)   Botulinum type F neurotoxin—amino acid residues (865-1105)   Botulinum type G neurotoxin—amino acid residues (864-1105)   Tetanus neurotoxin—amino acid residues (880-1127)       

     The above sequence positions may vary a little according to serotype/sub-type, and further examples of suitable (reference) clostridial neurotoxin H CN  domains include:
         Botulinum type A neurotoxin—amino acid residues (874-1110)   Botulinum type B neurotoxin—amino acid residues (861-1097)   Botulinum type C neurotoxin—amino acid residues (869-1111)   Botulinum type D neurotoxin—amino acid residues (865-1098)   Botulinum type E neurotoxin—amino acid residues (848-1085)   Botulinum type F neurotoxin—amino acid residues (867-1105)   Botulinum type G neurotoxin—amino acid residues (866-1105)   Tetanus neurotoxin—amino acid residues (882-1127)       

     Any of the above-described facilitating domains may be combined with any of the previously described translocation domain peptides that are suitable for use in the present invention. Thus, by way of example, a non-clostridial facilitating domain may be combined with non-clostridial translocation domain peptide or with clostridial translocation domain peptide. Alternatively, a clostridial neurotoxin H CN  translocation facilitating domain may be combined with a non-clostridial translocation domain peptide. Alternatively, a clostridial neurotoxin H CN  facilitating domain may be combined or with a clostridial translocation domain peptide, examples of which include:
         Botulinum type A neurotoxin—amino acid residues (449-1110)   Botulinum type B neurotoxin—amino acid residues (442-1097)   Botulinum type C neurotoxin—amino acid residues (450-1111)   Botulinum type D neurotoxin—amino acid residues (446-1098)   Botulinum type E neurotoxin—amino acid residues (423-1085)   Botulinum type F neurotoxin—amino acid residues (440-1105)   Botulinum type G neurotoxin—amino acid residues (447-1105)   Tetanus neurotoxin—amino acid residues (458-1127)       

     In some embodiments the clostridial neurotoxins of the present invention may lack a functional H C  domain of a clostridial neurotoxin. Accordingly, said clostridial neurotoxins are not able to bind rat synaptosomal membranes (via a clostridial H C  component) in binding assays as described in Shone et al. (1985) Eur. J. Biochem. 151, 75-82. In one embodiment, the clostridial neurotoxins preferably lack the last 50 C-terminal amino acids of a clostridial neurotoxin holotoxin. In another embodiment, the clostridial neurotoxins preferably lack the last 100, preferably the last 150, more preferably the last 200, particularly preferably the last 250, and most preferably the last 300 C-terminal amino acid residues of a clostridial neurotoxin holotoxin. Alternatively, the H C  binding activity may be negated/reduced by mutagenesis—by way of example, referring to BoNT/A for convenience, modification of one or two amino acid residue mutations (W1266 to L and Y1267 to F) in the ganglioside binding pocket causes the H C  region to lose its receptor binding function. Analogous mutations may be made to non-serotype A clostridial peptide components, e.g. a construct based on botulinum B with mutations (W1262 to L and Y1263 to F) or botulinum E (W1224 to L and Y1225 to F). Other mutations to the active site achieve the same ablation of H C  receptor binding activity, e.g. Y1267S in botulinum type A toxin and the corresponding highly conserved residue in the other clostridial neurotoxins. Details of this and other mutations are described in Rummel et al (2004) (Molecular Microbiol. 51:631-634), which is hereby incorporated by reference thereto. 
     The H C  peptide of a native clostridial neurotoxin comprises approximately 400-440 amino acid residues, and consists of two functionally distinct domains of approximately 25 kDa each, namely the N-terminal region (commonly referred to as the H CN  peptide or domain) and the C-terminal region (commonly referred to as the Hoc peptide or domain). This fact is confirmed by the following publications, each of which is herein incorporated in its entirety by reference thereto: Umland TC (1997) Nat. Struct. Biol. 4: 788-792; Herreros J (2000) Biochem. J. 347: 199-204; Halpern J (1993) J. Biol. Chem. 268: 15, pp. 11188-11192; Rummel A (2007) PNAS 104: 359-364; Lacey DB (1998) Nat. Struct. Biol. 5: 898-902; Knapp (1998) Am. Cryst. Assoc. Abstract Papers 25: 90; Swaminathan and Eswaramoorthy (2000) Nat. Struct. Biol. 7: 1751-1759; and Rummel A (2004) Mol. Microbiol. 51(3), 631-643. Moreover, it has been well documented that the C-terminal region (H CC ), which constitutes the C-terminal 160-200 amino acid residues, is responsible for binding of a clostridial neurotoxin to its natural cell receptors, namely to nerve terminals at the neuromuscular junction—this fact is also confirmed by the above publications. Thus, reference throughout this specification to a clostridial heavy-chain lacking a functional heavy chain H C  peptide (or domain) such that the heavy-chain is incapable of binding to cell surface receptors to which a native clostridial neurotoxin binds means that the clostridial heavy-chain simply lacks a functional Hoc peptide. In other words, the Hoc peptide region may be either partially or wholly deleted, or otherwise modified (e.g. through conventional chemical or proteolytic treatment) to inactivate its native binding ability for nerve terminals at the neuromuscular junction. 
     Thus, in one embodiment, a clostridial neurotoxin H N  peptide of the present invention lacks part of a C-terminal peptide portion (H CC ) of a clostridial neurotoxin and thus lacks the H C  binding function of native clostridial neurotoxin. By way of example, in one embodiment, the C-terminally extended clostridial H N  peptide lacks the C-terminal 40 amino acid residues, or the C-terminal 60 amino acid residues, or the C-terminal 80 amino acid residues, or the C-terminal 100 amino acid residues, or the C-terminal 120 amino acid residues, or the C-terminal 140 amino acid residues, or the C-terminal 150 amino acid residues, or the C-terminal 160 amino acid residues of a clostridial neurotoxin heavy-chain. In another embodiment, the clostridial H N  peptide of the present invention lacks the entire C-terminal peptide portion (H CC ) of a clostridial neurotoxin and thus lacks the H C  binding function of native clostridial neurotoxin. By way of example, in one embodiment, the clostridial H N  peptide lacks the C-terminal 165 amino acid residues, or the C-terminal 170 amino acid residues, or the C-terminal 175 amino acid residues, or the C-terminal 180 amino acid residues, or the C-terminal 185 amino acid residues, or the C-terminal 190 amino acid residues, or the C-terminal 195 amino acid residues of a clostridial neurotoxin heavy-chain. By way of further example, the clostridial H N  peptide of the present invention lacks a clostridial H CC  reference sequence selected from the group consisting of:
         Botulinum type A neurotoxin—amino acid residues (Y1111-L1296)   Botulinum type B neurotoxin—amino acid residues (Y1098-E1291)   Botulinum type C neurotoxin—amino acid residues (Y1112-E1291)   Botulinum type D neurotoxin—amino acid residues (Y1099-E1276)   Botulinum type E neurotoxin—amino acid residues (Y1086-K1252)   Botulinum type F neurotoxin—amino acid residues (Y1106-E1274)   Botulinum type G neurotoxin—amino acid residues (Y1106-E1297)   Tetanus neurotoxin—amino acid residues (Y1128-D1315).       

     The above-identified reference sequences should be considered a guide as slight variations may occur according to sub-serotypes. 
     The present invention is suitable for application to many different varieties of clostridial neurotoxin. Thus, in the context of the present invention, the term “clostridial neurotoxin” embraces toxins produced by  C. botulinum  (botulinum neurotoxin serotypes A, B, C1, D, E, F, G, H, and X),  C. tetani  (tetanus neurotoxin),  C. butyricum  (botulinum neurotoxin serotype E), and  C. baratii  (botulinum neurotoxin serotype F), as well as modified clostridial neurotoxins or derivatives derived from any of the foregoing. The term “clostridial neurotoxin” also embraces botulinum neurotoxin serotype H. Preferably the clostridial neurotoxin is not BoNT/C1. 
     Botulinum neurotoxin (BoNT) is produced by  C. botulinum  in the form of a large protein complex, consisting of BoNT itself complexed to a number of accessory proteins. There are at present nine different classes of botulinum neurotoxin, namely: botulinum neurotoxin serotypes A, B, C1, D, E, F, G, H, and X all of which share similar structures and modes of action. Different BoNT serotypes can be distinguished based on inactivation by specific neutralising anti-sera, with such classification by serotype correlating with percentage sequence identity at the amino acid level. BoNT proteins of a given serotype are further divided into different subtypes on the basis of amino acid percentage sequence identity. 
     BoNTs are absorbed in the gastrointestinal tract, and, after entering the general circulation, bind to the presynaptic membrane of cholinergic nerve terminals and prevent the release of their neurotransmitter acetylcholine. BoNT/B, BoNT/D, BoNT/F and BoNT/G cleave synaptobrevin/vesicle-associated membrane protein (VAMP); BoNT/C1, BoNT/A and BoNT/E cleave the synaptosomal-associated protein of 25 kDa (SNAP-25); and BoNT/C1 cleaves syntaxin. BoNT/X has been found to cleave SNAP-25, VAMP1, VAMP2, VAMP3, VAMP4, VAMP5, Ykt6, and syntaxin 1. 
     Tetanus toxin is produced in a single serotype by  C. tetani. C. butyricum  produces BoNT/E, while  C. baratii  produces BoNT/F. 
     The term “clostridial neurotoxin” is also intended to embrace modified clostridial neurotoxins and derivatives thereof, including but not limited to those described below. A modified clostridial neurotoxin or derivative may contain one or more amino acids that has been modified as compared to the native (unmodified) form of the clostridial neurotoxin, or may contain one or more inserted amino acids that are not present in the native (unmodified) form of the clostridial neurotoxin. By way of example, a modified clostridial neurotoxin may have modified amino acid sequences in one or more domains relative to the native (unmodified) clostridial neurotoxin sequence. Such modifications may modify functional aspects of the toxin, for example biological activity or persistence. Thus, in one embodiment, the engineered clostridial neurotoxin of the invention is an engineered modified clostridial neurotoxin, or an engineered modified clostridial neurotoxin derivative, or an engineered clostridial neurotoxin derivative. 
     A modified clostridial neurotoxin may have one or more modifications in the amino acid sequence of the heavy chain (such as a modified H C  domain), wherein said modified heavy chain binds to target nerve cells with a higher or lower affinity than the native (unmodified) clostridial neurotoxin. Such modifications in the H C  domain can include modifying residues in the ganglioside binding site of the H C  domain or in the protein (SV2 or synaptotagmin) binding site that alter binding to the ganglioside receptor and/or the protein receptor of the target nerve cell. Examples of such modified clostridial neurotoxins are described in WO 2006/027207 and WO 2006/114308, both of which are hereby incorporated by reference in their entirety. 
     A modified clostridial neurotoxin may have one or more modifications in the amino acid sequence of the light chain, for example modifications in the substrate binding or catalytic domain which may alter or modify the SNARE protein specificity of the modified L-chain. Examples of such modified clostridial neurotoxins are described in WO 2010/120766 and US 2011/0318385, both of which are hereby incorporated by reference in their entirety. 
     A modified clostridial neurotoxin may comprise one or more modifications that increases or decreases the biological activity and/or the biological persistence of the modified clostridial neurotoxin. For example, a modified clostridial neurotoxin may comprise a leucine- or tyrosine-based motif, wherein said motif increases or decreases the biological activity and/or the biological persistence of the modified clostridial neurotoxin. Suitable leucine-based motifs include xDxxxLL (SEQ ID NO: 74), xExxxLL (SEQ ID NO: 75), xExxxIL (SEQ ID NO: 76), and xExxxLM (SEQ ID NO: 77) (wherein x is any amino acid). Suitable tyrosine-based motifs include Y-x-x-Hy (SEQ ID NO: 78) (wherein Hy is a hydrophobic amino acid). Examples of modified clostridial neurotoxins comprising leucine- and tyrosine-based motifs are described in WO 2002/08268, which is hereby incorporated by reference in its entirety. 
     The term “clostridial neurotoxin” is intended to embrace hybrid and chimeric clostridial neurotoxins. A hybrid clostridial neurotoxin comprises at least a portion of a light chain from one clostridial neurotoxin or subtype thereof, and at least a portion of a heavy chain from another clostridial neurotoxin or clostridial neurotoxin subtype. In one embodiment the hybrid clostridial neurotoxin may contain the entire light chain from one clostridial neurotoxin subtype and the heavy chain from another clostridial neurotoxin subtype. In another embodiment, a chimeric clostridial neurotoxin may contain a portion (e.g. the binding domain) of the heavy chain of one clostridial neurotoxin subtype, with another portion of the heavy chain being from another clostridial neurotoxin subtype. Similarly or alternatively, the therapeutic element may comprise light chain portions from different clostridial neurotoxins. Such hybrid or chimeric clostridial neurotoxins are useful, for example, as a means of delivering the therapeutic benefits of such clostridial neurotoxins to patients who are immunologically resistant to a given clostridial neurotoxin subtype, to patients who may have a lower than average concentration of receptors to a given clostridial neurotoxin heavy chain binding domain, or to patients who may have a protease-resistant variant of the membrane or vesicle toxin substrate (e.g., SNAP-25, VAMP and syntaxin). Hybrid and chimeric clostridial neurotoxins are described in U.S. Pat. No. 8,071,110, which publication is hereby incorporated by reference in its entirety. Thus, in one embodiment, the engineered clostridial neurotoxin of the invention is an engineered hybrid clostridial neurotoxin, or an engineered chimeric clostridial neurotoxin. 
     In a particularly preferred embodiment, a clostridial neurotoxin is BoNT/X comprising at least one domain from a non-BoNT/X clostridial neurotoxin (e.g. a BoNT/X hybrid or chimera). 
     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A BoNT/X L-chain and a non-BoNT/X H N  and H C  domain;   ii. A BoNT/X H N  domain and a non-BoNT/X L-chain and H C  domain   iii. A BoNT/X H C  domain and a non-BoNT/X L-chain and H N  domain;   iv. A BoNT/X L-chain and H N  domain and a non-BoNT/X H C  domain   v. A BoNT/X L-chain and H C  domain and a non-BoNT/X H N  domain; or   vi. A BoNT/X H N  domain and H C  domain and a non-BoNT/X L-chain.       

     In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain is encoded by a nucleotide sequence comprising at least 70% sequence identity to SEQ ID NO: 6. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain is encoded by a nucleotide sequence comprising at least 80% or 90% sequence identity to SEQ ID NO: 6. Preferably an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain is encoded by a nucleotide sequence comprising (more preferably consisting of) SEQ ID NO: 6. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 7. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain comprises a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 7. Preferably an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain comprises (more preferably consists of) a polypeptide sequence shown as SEQ ID NO: 7. 
     In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a BoNT/B H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain is encoded by a nucleotide sequence comprising at least 70% sequence identity to SEQ ID NO: 8. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain is encoded by a nucleotide sequence comprising at least 80% or 90% sequence identity to SEQ ID NO: 8. Preferably an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain is encoded by a nucleotide sequence comprising (more preferably consisting of) SEQ ID NO: 8. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 9. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain comprises a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 9. Preferably an engineered clostridial neurotoxin of the invention comprising a BoNT/X L-chain and H N  domain and a BoNT/A H C  domain comprises (more preferably consists of) a polypeptide sequence shown as SEQ ID NO: 9. 
     In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a BoNT/C H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a BoNT/D H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a BoNT/E H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a BoNT/F H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a BoNT/G H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/X L-chain and H N  domain and a TeNT H C  domain. 
     In one embodiment, a clostridial neurotoxin is BoNT/A comprising at least one domain from a non-BoNT/A clostridial neurotoxin. 
     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A BoNT/A L-chain and a non-BoNT/A H N  and H C  domain;   ii. A BoNT/A H N  domain and a non-BoNT/A L-chain and H C  domain   iii. A BoNT/A H C  domain and a non-BoNT/A L-chain and H N  domain;   iv. A BoNT/A L-chain and H N  domain and a non-BoNT/A H C  domain   v. A BoNT/A L-chain and H C  domain and a non-BoNT/A H N  domain; or   vi. A BoNT/A H N  domain and H C  domain and a non-BoNT/A L-chain.       

     In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a BoNT/C1 H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/A L-chain and H N  domain and a BoNT/C1 H C  domain is encoded by a nucleotide sequence comprising at least 70% sequence identity to SEQ ID NO: 12. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/A L-chain and H N  domain and a BoNT/C1 He domain is encoded by a nucleotide sequence comprising at least 80% or 90% sequence identity to SEQ ID NO: 12. Preferably an engineered clostridial neurotoxin of the invention comprising a BoNT/A L-chain and H N  domain and a BoNT/C1 H C  domain is encoded by a nucleotide sequence comprising (more preferably consisting of) SEQ ID NO: 12. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/A L-chain and H N  domain and a BoNT/C1 H C  domain comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 13. In one embodiment an engineered clostridial neurotoxin of the invention comprising a BoNT/A L-chain and H N  domain and a BoNT/C1 H C  domain comprises a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 13. Preferably an engineered clostridial neurotoxin of the invention comprising a BoNT/A L-chain and H N  domain and a BoNT/C1 H C  domain comprises (more preferably consists of) a polypeptide sequence shown as SEQ ID NO: 13. 
     In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a BoNT/B H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a BoNT/D H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a BoNT/E H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a BoNT/F H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a BoNT/G H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a BoNT/X H C  domain. In one embodiment an engineered clostridial neurotoxin of the invention comprises a BoNT/A L-chain and H N  domain and a TeNT H C  domain. 
     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A BoNT/B L-chain and a non-BoNT/B H N  and H C  domain;   ii. A BoNT/B H N  domain and a non-BoNT/B L-chain and H C  domain   iii. A BoNT/B H C  domain and a non-BoNT/B L-chain and H N  domain;   iv. A BoNT/B L-chain and H N  domain and a non-BoNT/B H C  domain   v. A BoNT/B L-chain and H C  domain and a non-BoNT/B H N  domain; or   vi. A BoNT/B H N  domain and H C  domain and a non-BoNT/B L-chain.       

     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A BoNT/D L-chain and a non-BoNT/XD H N  and H C  domain;   ii. A BoNT/D H N  domain and a non-BoNT/D L-chain and H C  domain   iii. A BoNT/D H C  domain and a non-BoNT/D L-chain and H N  domain;   iv. A BoNT/D L-chain and H N  domain and a non-BoNT/D H C  domain   v. A BoNT/D L-chain and H C  domain and a non-BoNT/D H N  domain; or   vi. A BoNT/D H N  domain and H C  domain and a non-BoNT/D L-chain.       

     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A BoNT/E L-chain and a non-BoNT/E H N  and H C  domain;   ii. A BoNT/E H N  domain and a non-BoNT/E L-chain and H C  domain   iii. A BoNT/E H C  domain and a non-BoNT/E L-chain and H N  domain;   iv. A BoNT/E L-chain and H N  domain and a non-BoNT/E H C  domain   v. A BoNT/E L-chain and H C  domain and a non-BoNT/E H N  domain; or   vi. A BoNT/E H N  domain and H C  domain and a non-BoNT/E L-chain.       

     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A BoNT/F L-chain and a non-BoNT/F H N  and H C  domain;   ii. A BoNT/F H N  domain and a non-BoNT/F L-chain and H C  domain   iii. A BoNT/F H C  domain and a non-BoNT/F L-chain and H N  domain;   iv. A BoNT/F L-chain and H N  domain and a non-BoNT/F H C  domain   v. A BoNT/F L-chain and H C  domain and a non-BoNT/F H N  domain; or   vi. A BoNT/F H N  domain and H C  domain and a non-BoNT/F L-chain.       

     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A BoNT/G L-chain and a non-BoNT/G H N  and H C  domain;   ii. A BoNT/G H N  domain and a non-BoNT/G L-chain and H C  domain   iii. A BoNT/G H C  domain and a non-BoNT/G L-chain and H N  domain;   iv. A BoNT/G L-chain and H N  domain and a non-BoNT/G H C  domain   v. A BoNT/G L-chain and H C  domain and a non-BoNT/G H N  domain; or   vi. A BoNT/G H N  domain and H C  domain and a non-BoNT/G L-chain.       

     For example, in one embodiment a clostridial neurotoxin of the invention (comprising an exogenous activation loop) may comprise:
         i. A TeNT L-chain and a non-TeNT H N  and H C  domain;   ii. A TeNT H N  domain and a non-TeNT L-chain and H C  domain   iii. A TeNT H C  domain and a non-TeNT L-chain and H N  domain;   iv. A TeNT L-chain and H N  domain and a non-TeNT H C  domain   v. A TeNT L-chain and H C  domain and a non-TeNT H N  domain; or   vi. A TeNT H N  domain and H C  domain and a non-TeNT L-chain.       

     The term “clostridial neurotoxin” may also embrace newly discovered botulinum neurotoxin protein family members expressed by non-clostridial microorganisms, such as the  Enterococcus  encoded toxin which has closest sequence identity to BoNT/X, the  Weissella oryzae  encoded toxin called BoNT/Wo (NCBI Ref Seq: WP_027699549.1), which cleaves VAMP2 at W89-W90, the  Enterococcus faecium  encoded toxin (GenBank: OT022244.1), which cleaves VAMP2 and SNAP25, and the  Chryseobacterium pipero  encoded toxin (NCBI Ref.Seq: WP_034687872.1). 
     The term “clostridial neurotoxin” is intended to embrace re-targeted clostridial neurotoxins. In a re-targeted clostridial neurotoxin, the clostridial neurotoxin is modified to include an exogenous ligand known as a Targeting Moiety (TM). The TM is selected to provide binding specificity for a desired target cell, and as part of the re-targeting process the native binding portion of the clostridial neurotoxin (e.g. the H C  domain, or the Hoc domain) may be removed. Re-targeting technology is described, for example, in: EP-B-0689459; WO 1994/021300; EP-B-0939818; U.S. Pat. Nos. 6,461,617; 7,192,596; WO 1998/007864; EP-B-0826051; U.S. Pat. Nos. 5,989,545; 6,395,513; 6,962,703; WO 1996/033273; EP-B-0996468; U.S. Pat. No. 7,052,702; WO 1999/017806; EP-B-1107794; U.S. Pat. No. 6,632,440; WO 2000/010598; WO 2001/21213; WO 2006/059093; WO 2000/62814; WO 2000/04926; WO 1993/15766; WO 2000/61192; and WO 1999/58571; all of which are hereby incorporated by reference in their entirety. Thus, in one embodiment, the engineered clostridial neurotoxin of the invention is an engineered re-targeted clostridial neurotoxin. The engineered clostridial neurotoxin of the present invention may lack a functional H C  domain of a clostridial neurotoxin and also lack any functionally equivalent TM. Accordingly, said polypeptides lack the natural binding function of a clostridial neurotoxin and are not able to bind rat synaptosomal membranes (via a clostridial He component, or via any functionally equivalent TM) in binding assays as described in Shone et al. (1985) Eur. J. Biochem. 151, 75-82. In one embodiment, the TM is preferably not a Wheat Germ Agglutinin (WGA) peptide. 
     In one embodiment an engineered clostridial neurotoxin of the invention may comprise an engineered LH N  polypeptide described herein. 
     In one embodiment an engineered clostridial neurotoxin may comprise an engineered LH N  polypeptide described herein and a targeting moiety (TM). 
     Reference engineered LH N  polypeptide sequences are presented herein as SEQ ID NOs: 53-60, however the engineered LH N  polypeptide sequence may have at least 70% sequence identity to any of SEQ ID NOs: 53-60. In one embodiment the engineered LH N  polypeptide sequence may have at least 80% or 90% sequence identity to any of SEQ ID NOs: 53-60. Preferably the engineered LH N  polypeptide sequence comprises (more preferably consists of) any of SEQ ID NOs: 53-60. 
     In one embodiment a TM may comprise anthrax toxin protective antigen (PA) or a fragment thereof. A reference sequence for PA is shown as SEQ ID NO: 52. In some embodiments PA comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 52 or a fragment thereof. In some embodiments PA comprises a polypeptide sequence having at least 80% or 90% sequence identity to SEQ ID NO: 52 or a fragment thereof. In other embodiments PA comprises (or consists of) a polypeptide sequence shown as SEQ ID NO: 52 or a fragment thereof. 
     Thus, in one embodiment an engineered clostridial neurotoxin of the present invention may comprise: a clostridial neurotoxin non-cytotoxic protease domain, a clostridial neurotoxin translocation domain (e.g. LH N  of a clostridial neurotoxin), and a TM comprising PA or a fragment thereof. Said engineered clostridial neurotoxin comprises an exogenous activation loop comprising polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1). 
     Thus, in one embodiment, an engineered clostridial neurotoxin comprises PA or a fragment thereof and LH N /A, LH N /B, LH N /D, LH N /E, LH N /F, LH N /G, LH N /X or LH N /TeNT, wherein the endogenous clostridial neurotoxin activation loop has been replaced with an exogenous activation loop comprising polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1). 
     Lys-C is not suitable for use with conventional clostridial neurotoxins comprising LH N  and a PA TM, as Lys-C hydrolses one or more peptide bonds outside of the endogenous activation loop of said clostridial neurotoxin, for example it has been found that Lys-C hydrolyses one or more peptide bonds in the PA TM. 
     Thus, in some embodiments, an engineered clostridial neurotoxin comprises PA (or a fragment thereof) and:
         i. Amino acid residues 1-871 of SEQ ID NO: 35   ii. Amino acid residues 1-858 of SEQ ID NO: 36   iii. Amino acid residues 1-862 of SEQ ID NO: 38   iv. Amino acid residues 1-845 of SEQ ID NO: 39   v. Amino acid residues 1-864 of SEQ ID NO: 40   vi. Amino acid residues 1-863 of SEQ ID NO: 41   vii. Amino acid residues 1-879 of SEQ ID NO: 42 or   viii. Amino acid residues 1-924 of SEQ ID NO: 33;       

     wherein the endogenous clostridial neurotoxin activation loop has been replaced with an exogenous activation loop comprising polypeptide sequence Cys-(Xaa) a -Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys (SEQ ID NO: 1). 
     In one embodiment an engineered clostridial neurotoxin has a polypeptide sequence with at least 70% sequence identity to a polypeptide comprising:
         a. SEQ ID NO: 52; and   b. SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 or SEQ ID NO: 60.       

     In one embodiment an engineered clostridial neurotoxin has a polypeptide sequence with at least 80% or 90% sequence identity to a polypeptide comprising:
         a. SEQ ID NO: 52; and   b. SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 or SEQ ID NO: 60.       

     Preferably an engineered clostridial neurotoxin has a polypeptide sequence comprising:
         a. SEQ ID NO: 52; and   b. SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 or SEQ ID NO: 60.       

     In one embodiment an engineered clostridial neurotoxin has a polypeptide sequence with at least 70% sequence identity to a polypeptide comprising:
         a. a fragment of SEQ ID NO: 52; and   b. SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 or SEQ ID NO: 60.       

     In one embodiment an engineered clostridial neurotoxin has a polypeptide sequence with at least 80% or 90% sequence identity to a polypeptide comprising:
         a. a fragment of SEQ ID NO: 52; and   b. SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 or SEQ ID NO: 60.       

     Preferably an engineered clostridial neurotoxin has a polypeptide sequence comprising:
         a. a fragment of SEQ ID NO: 52; and   b. SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 or SEQ ID NO: 60.       

     In one embodiment a PA fragment may be PAd1, which is located at residues 1-258 of SEQ ID NO: 52. In one embodiment a PA fragment may be PAd2, which is located at residues 259-487 of SEQ ID NO: 52. In one embodiment a PA fragment may be PAd3, which is located at residues 488-594 of SEQ ID NO: 52. In one embodiment a PA fragment may be PAd4, which is located at residues 595-735 of SEQ ID NO: 52. In other embodiments a PA fragment may contain any combination of PAd1, PAd2, PAd3 or PAd4. 
     Full-length 83 kDa PA (PA83) may be proteolytically processed by a furin or other furin-like protease thus removing an N-terminal fragment (PA20). The 63 kDa processed form, known as PA63 is an oligomerisable form of PA. 
     In one embodiment the PA fragment may comprise (or consist of) one or more of PA63, PAd3-d4, PAd2-d4, and PAd4. 
     In one embodiment the PA fragment may be a C-terminal receptor-binding domain of PA or a PA fragment (or variant) thereof that retains binding activity to ANTXR2 or a nociceptor neuron binding protein. 
     The present invention also embraces clostridial neurotoxins that have a non-native protease cleavage site. In such clostridial neurotoxins, the native protease cleavage site (also known as the activation site, as described above) is modified or replaced with a protease cleavage site that is not native to that clostridial neurotoxin (i.e. an exogenous cleavage site). Such a site will require an exogenous protease for cleavage, which allows for improved control over the timing and location of cleavage events. Non-native protease cleavage sites that may be employed in clostridial neurotoxins include: 
     
       
         
           
               
               
            
               
                   
                 TEV (Tobacco Etch virus) 
               
               
                   
                 (SEQ ID NO: 79) 
               
               
                   
                 (ENLYFQ↓G) 
               
               
                   
                   
               
               
                   
                 Thrombin 
               
               
                   
                 (SEQ ID NO: 80) 
               
               
                   
                 (LVPR↓GS) 
               
               
                   
                   
               
               
                   
                 PreScission 
               
               
                   
                 (SEQ ID NO: 81) 
               
               
                   
                 (LEVLFQ↓GP). 
               
            
           
         
       
     
     Additional protease cleavage sites include recognition sequences that are cleaved by a non-cytotoxic protease, for example by the light chain of a clostridial neurotoxin. These include the SNARE (e.g. SNAP-25, syntaxin, VAMP) protein recognition sequences that are cleaved by non-cytotoxic proteases such as the light chain of a clostridial neurotoxin. Clostridial neurotoxins comprising non-native protease cleavage sites are described in U.S. Pat. No. 7,132,259, EP 1206554-B2 and US 2007/0166332, all of which are hereby incorporated by reference in their entirety. Also embraced by the term protease cleavage site is an intein, which is a self-cleaving sequence. The self-splicing reaction is controllable, for example by varying the concentration of reducing agent present. 
     The present invention also embraces clostridial neurotoxins comprising a “destructive cleavage site”. In said clostridial neurotoxins, a non-native protease cleavage site is incorporated into the clostridial neurotoxin, at a location chosen such that cleavage at said site will decrease the activity of, or inactivate, the clostridial neurotoxin. The destructive protease cleavage site can be susceptible to cleavage by a local protease, in the event that the clostridial neurotoxin, following administration, migrates to a non-target location. Suitable non-native protease cleavage sites include those described above. Clostridial neurotoxins comprising a destructive cleavage site are described in WO 2010/094905 and WO 2002/044199, both of which are hereby incorporated by reference in their entirety. 
     The engineered clostridial neurotoxins of the present invention, especially the light chain component thereof, may be PEGylated—this may help to increase stability, for example duration of action of the light chain component. PEGylation is particularly preferred when the light chain comprises a BoNT/A, B or C1 protease. PEGylation preferably includes the addition of PEG to the N-terminus of the light chain component. By way of example, the N-terminus of a light chain may be extended with one or more amino acid (e.g. cysteine) residues, which may be the same or different. One or more of said amino acid residues may have its own PEG molecule attached (e.g. covalently attached) thereto. An example of this technology is described in WO2007/104567, which is hereby incorporated by reference in its entirety. 
     The engineered clostridial neurotoxins of the present invention may be free from the complexing proteins that are present in a naturally occurring clostridial neurotoxin complex. 
     The engineered clostridial neurotoxins of the present invention can be produced using recombinant nucleic acid technologies. Thus, in one embodiment, an engineered clostridial neurotoxin (as described above) is a recombinant engineered clostridial neurotoxin. 
     In another aspect, the present invention provides a nucleic acid (for example, a DNA) comprising a nucleic acid sequence encoding an engineered clostridial neurotoxin as described above. In one embodiment, the nucleic acid sequence is prepared as part of a DNA vector comprising a promoter and a terminator. 
     In a preferred embodiment, the vector has a promoter selected from: 
     
       
         
           
               
               
               
             
               
                   
               
               
                 Promoter 
                 Induction Agent 
                 Typical Induction Condition 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 Tac (hybrid) 
                 IPTG 
                 0.2 mM 
                 (0.05-2.0 mM) 
               
               
                 AraBAD 
                 L-arabinose 
                 0.2% 
                 (0.002-0.4%) 
               
               
                 T7-lac operator 
                 IPTG 
                 0.2 mM 
                 (0.05-2.0 mM) 
               
               
                   
               
            
           
         
       
     
     In another preferred embodiment, the vector has a promoter selected from: 
     
       
         
           
               
               
               
             
               
                   
               
               
                 Promoter 
                 Induction Agent 
                 Typical Induction Condition 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 Tac (hybrid) 
                 IPTG 
                 0.2 mM 
                 (0.05-2.0 mM) 
               
               
                 AraBAD 
                 L-arabinose 
                 0.2% 
                 (0.002-0.4%) 
               
               
                 T7-lac operator 
                 IPTG 
                 0.2 mM 
                 (0.05-2.0 mM) 
               
               
                 T5-lac operator 
                 IPTG 
                 0.2 mM 
                 (0.05-2.0 mM) 
               
               
                   
               
            
           
         
       
     
     The nucleic acid molecules of the invention may be made using any suitable process known in the art. Thus, the nucleic acid molecules may be made using chemical synthesis techniques. Alternatively, the nucleic acid molecules of the invention may be made using molecular biology techniques. 
     The DNA construct of the present invention is preferably designed in silico, and then synthesised by conventional DNA synthesis techniques. 
     The above-mentioned nucleic acid sequence information is optionally modified for codon-biasing according to the ultimate host cell (e.g.  E. coli ) expression system that is to be employed. 
     In one aspect the present invention provides a nucleotide sequence encoding an engineered clostridial neurotoxin of the present invention. The nucleotide sequence comprises a sequence having at least 70% sequence identity to SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. In one embodiment the nucleotide sequence comprises a sequence having at least 80% or 90% sequence identity to SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. Preferably the nucleotide sequence comprises (more preferably consists of) SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. 
     The nucleotide sequence of the invention encodes a polypeptide comprising SEQ ID NO: 1. 
     The terms “nucleotide sequence” and “nucleic acid” are used synonymously herein. Preferably the nucleotide sequence is a DNA sequence. 
     The invention provides a method of producing a single-chain (engineered) clostridial neurotoxin protein having a light chain and a heavy chain, the method comprising expressing a nucleic acid described herein in a suitable host cell, lysing the host cell to provide a host cell homogenate containing the single-chain (engineered) clostridial neurotoxin protein, and isolating the single-chain (engineered) clostridial neurotoxin protein. In one aspect, the present invention provides a method for proteolytically processing an (engineered) clostridial neurotoxin of the present invention into a corresponding di-chain clostridial neurotoxin, the method comprising contacting the (engineered) clostridial neurotoxin with a protease (preferably an endopeptidase, such as enterokinase or factor Xa) thereby producing a di-chain clostridial neurotoxin (e.g. wherein the light chain and heavy chain are joined together by a disulphide bond). 
     The present invention therefore provides a di-chain clostridial neurotoxin obtainable by a method of the invention. 
     The term “obtainable” as used herein also encompasses the term “obtained”. In one embodiment the term “obtainable” means obtained. 
     A clostridial neurotoxin of the present invention suitably finds utility in medicine or in cosmetics. In use, the clostridial neurotoxin is preferably in a di-chain form. 
     The (engineered) clostridial neurotoxins of the invention may be used to prevent or treat certain medical or cosmetic diseases and conditions. Thus, in a further aspect, the present invention provides an (engineered) clostridial neurotoxin as described above, for use in medicine. 
     In a related aspect, the present invention provides an (engineered) clostridial neurotoxin as described above, for use in the prevention or treatment of a disease or condition selected from: a condition associated with unwanted immune secretion, strabismus, blepharospasm, squint, dystonia (e.g. spasmodic dystonia, oromandibular dystonia, focal dystonia, tardive dystonia, laryngeal dystonia, limb dystonia, cervical dystonia), torticollis (e.g. spasmodic torticollis), beauty therapy (cosmetic) applications benefiting from cell/muscle incapacitation (via SNARE down-regulation or inactivation), neuromuscular disorder or condition of ocular motility (e.g. concomitant strabismus, vertical strabismus, lateral rectus palsy, nystagmus, dysthyroid myopathy), writer&#39;s cramp, blepharospasm, bruxism, Wilson&#39;s disease, tremor, tics, segmental myoclonus, spasms, spasticity due to chronic multiple sclerosis, spasticity resulting in abnormal bladder control, animus, back spasm, charley horse, tension headaches, levator pelvic syndrome, spina bifida, tardive dyskinesia, Parkinson&#39;s disease, stuttering, hemifacial spasm, eyelid disorder, cerebral palsy, focal spasticity, spasmodic colitis, neurogenic bladder, anismus, limb spasticity, tics, tremors, bruxism, anal fissure, achalasia, dysphagia, lacrimation, hyperhydrosis, excessive salivation, excessive gastrointestinal secretions, muscle pain (e.g. pain from muscle spasms), headache pain (e.g. tension headache), brow furrows, skin wrinkles, cancer, uterine disorders, uro-genital disorders, urogenital-neurological disorders, chronic neurogenic inflammation, and a smooth muscle disorder. 
     Where an (engineered) clostridial neurotoxin of the invention comprises a BoNT/X sequence (or portion thereof) said clostridial neurotoxin may be able to target other types of secretory cells other than neurons, due to its ability to cleave VAMP4, VAMP5 and/or Ykt6. In some embodiments, the secretory cell targeted is a secretory immune cell. A “secretory immune cell” as used herein, refers to immune cells that secrets cytokines, chemokines, or antibodies. Such secretory immune cells may be innate immune cells including, without limitation, natural killer cells, mast cells, eosinophils, basophils, macrophages, neutrophils, and dendritic cells. Secretory immune cells that secret antibodies (e.g. white blood cells) may also be targeted by the clostridial neurotoxins of the present disclosure. Non-limiting examples of antibody secreting cells include, without limitation, plasma B cells, plasmocytes, plasmacytes, and effector B cells. In some embodiments, the clostridial neurotoxin may modulate an immune response. Thus, further contemplated herein are therapeutic use of a clostridial neurotoxin of the invention to treat a condition associated with unwanted secretion, preferably unwanted immune secretion. Conditions associated with unwanted immune secretion include, without limitation: inflammation, psoriasis, allergy, haemophagocytic lymphohistiocytosis, and alcoholic pancreatic disease. 
     In one aspect, the invention provides a pharmaceutical composition comprising an (engineered) clostridial neurotoxin or a di-chain clostridial neurotoxin of the invention and a pharmaceutically acceptable carrier, excipient, adjuvant, propellant and/or salt. 
     The (engineered) clostridial neurotoxins of the present invention may be formulated for oral, parenteral, continuous infusion, inhalation or topical application. Compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use. 
     In the case of an (engineered) clostridial neurotoxin that is to be delivered locally, the (engineered) clostridial neurotoxin may be formulated as a cream (e.g. for topical application), or for sub-dermal injection. 
     Local delivery means may include an aerosol, or other spray (e.g. a nebuliser). In this regard, an aerosol formulation of an (engineered) clostridial neurotoxin enables delivery to the lungs and/or other nasal and/or bronchial or airway passages. (Engineered) clostridial neurotoxins of the invention may be administered to a patient by intrathecal or epidural injection in the spinal column at the level of the spinal segment involved in the innervation of an affected organ. 
     A preferred route of administration is via laproscopic and/or localised, particularly intramuscular, injection. 
     The dosage ranges for administration of the (engineered) clostridial neurotoxins of the present invention are those to produce the desired therapeutic effect. It will be appreciated that the dosage range required depends on the precise nature of the (engineered) clostridial neurotoxin or composition, the route of administration, the nature of the formulation, the age of the patient, the nature, extent or severity of the patient&#39;s condition, contraindications, if any, and the judgement of the attending physician. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation. 
     Suitable daily dosages (per kg weight of patient) are in the range 0.0001-1 ng/kg, preferably 0.0001-0.5 ng/kg, more preferably 0.002-0.5 ng/kg, and particularly preferably 0.004-0.5 ng/kg. The unit dosage can vary from less than 1 picogram to 30 ng, but typically will be in the region of 0.01 to 1 ng per dose, which may be administered daily or preferably less frequently, such as weekly or six monthly. 
     A particularly preferred dosing regimen is based on 0.05 ng of (engineered) clostridial neurotoxin as the 1× dose. In this regard, preferred dosages are in the range 1×-100× (i.e. 0.05-5 ng). 
     Fluid dosage forms are typically prepared utilising the (engineered) clostridial neurotoxin and a pyrogen-free sterile vehicle. The (engineered) clostridial neurotoxin, depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. In preparing solutions the (engineered) clostridial neurotoxin can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and or local anaesthetic agents may be dissolved in the vehicle. 
     Dry powders, which are dissolved or suspended in a suitable vehicle prior to use, may be prepared by filling pre-sterilised ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the ingredients may be dissolved into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically. 
     Parenteral suspensions, suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile components are suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration. The components may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma irradiation. 
     Advantageously, a suspending agent for example polyvinylpyrrolidone is included in the composition(s) to facilitate uniform distribution of the components. 
     Administration in accordance with the present invention may take advantage of a variety of delivery technologies including microparticle encapsulation, viral delivery systems or high-pressure aerosol impingement. 
     Embodiments related to the various methods of the invention are intended to be applied equally to other methods, the clostridial neurotoxins, e.g. engineered clostridial neurotoxins (whether in single-chain or di-chain forms), uses or pharmaceutical compositions, and vice versa. 
     Sequence Homology 
     Any of a variety of sequence alignment methods can be used to determine percent identity, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art. Global methods align sequences from the beginning to the end of the molecule and determine the best alignment by adding up scores of individual residue pairs and by imposing gap penalties. Non-limiting methods include, e.g., CLUSTAL W, see, e.g., Julie D. Thompson et al., CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice, 22(22) Nucleic Acids Research 4673-4680 (1994); and iterative refinement, see, e.g., Osamu Gotoh, Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments, 264(4) J. Mol. Biol. 823-838 (1996). Local methods align sequences by identifying one or more conserved motifs shared by all of the input sequences. Non-limiting methods include, e.g., Match-box, see, e.g., Eric Depiereux and Ernest Feytmans, Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences, 8(5) CABIOS 501-509 (1992); Gibbs sampling, see, e.g., C. E. Lawrence et al., Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment, 262(5131) Science 208-214 (1993); Align-M, see, e.g., Ivo Van Walle et al., Align-M—A New Algorithm for Multiple Alignment of Highly Divergent Sequences, 20(9) Bioinformatics: 1428-1435 (2004). 
     Thus, percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-16, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-19, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the “blosum 62” scoring matrix of Henikoff and Henikoff (ibid.) as shown below (amino acids are indicated by the standard one-letter codes). 
     The “percent sequence identity” between two or more nucleic acid or amino acid sequences is a function of the number of identical positions shared by the sequences. Thus, % identity may be calculated as the number of identical nucleotides/amino acids divided by the total number of nucleotides/amino acids, multiplied by 100. Calculations of % sequence identity may also take into account the number of gaps, and the length of each gap that needs to be introduced to optimize alignment of two or more sequences. Sequence comparisons and the determination of percent identity between two or more sequences can be carried out using specific mathematical algorithms, such as BLAST, which will be familiar to a skilled person. 
     
       
         
           
               
            
               
                   
               
               
                 ALIGNMENT SCORES FOR DETERMINING SEQUENCE IDENTITY 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                 A 
                 R 
                 N 
                 D 
                 C 
                 Q 
                 E 
                 G 
                 H 
                 I 
                 L 
                 K 
                 M 
                 F 
                 P 
                 S 
                 T 
                 W 
                 Y 
                 V 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 A 
                 4 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 R 
                 −1 
                 5 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 N 
                 −2 
                 0 
                 6 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 D  
                 −2 
                 −2 
                 1 
                 6 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 C 
                 0 
                 −3 
                 −3 
                 −3 
                 9 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Q 
                 −1 
                 1 
                 0 
                 0 
                 −3 
                 5 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 E 
                 −1 
                 0 
                 0 
                 2 
                 −4 
                 2 
                 5 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 G 
                 0  
                 −2 
                 0 
                 −1 
                 −3 
                 −2 
                 −2 
                 6 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 H 
                 −2 
                 0 
                 1  
                 −1  
                 −3 
                 0 
                 0 
                 −2 
                 8 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 I  
                 −1 
                 −3 
                 −3 
                 −3 
                 −1 
                 −3  
                 −3  
                 −4  
                 −3 
                 4 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 L  
                 −1  
                 −2  
                 −3 
                 −4  
                 −1 
                 −2  
                 −3 
                 −4 
                 −3 
                 2 
                 4 
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 K  
                 −1 
                 2  
                 0 
                 −1 
                 −3 
                 1  
                 1 
                 −2  
                 −1 
                 −3 
                 −2 
                 5 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 M 
                 −1 
                 −1 
                 −2 
                 −3 
                 −1 
                 0 
                 −2  
                 −3 
                 −2  
                 1 
                 2 
                 −1 
                 5 
                   
                   
                   
                   
                   
                   
                   
               
               
                 F 
                 −2  
                 −3  
                 −3  
                 −3  
                 −2  
                 −3  
                 −3  
                 −3 
                 −1  
                 0 
                 0 
                 −3 
                 0 
                 6 
                   
                   
                   
                   
                   
                   
               
               
                 P 
                 −1  
                 −2  
                 −2 
                 −1 
                 −3  
                 −1 
                 −1  
                 −2  
                 −2  
                 −3  
                 −3  
                 −1 
                 −2 
                 −4 
                 7 
                   
                   
                   
                   
                   
               
               
                 S 
                 1  
                 −1  
                 1 
                 0 
                 −1 
                 0 
                 0 
                 0 
                 −1 
                 −2  
                 −2  
                 0  
                 −1 
                 −2 
                 −1 
                 4 
                   
                   
                   
                   
               
               
                 T 
                 0 
                 −1  
                 0  
                 −1 
                 −1 
                 −1 
                 −1 
                 −2  
                 −2 
                 −1 
                 −1  
                 −1 
                 −1 
                 −2  
                 −1 
                 1 
                 5 
                   
                   
                   
               
               
                 W 
                 −3  
                 −3 
                 −4 
                 −4  
                 −2 
                 −2 
                 −3  
                 −2  
                 −2 
                 −3 
                 −2 
                 −3 
                 −1  
                 1 
                 −4 
                 −3  
                 −2  
                 11 
                   
                   
               
               
                 Y 
                 −2  
                 −2  
                 −2 
                 −3  
                 −2  
                 −1 
                 −2  
                 −3  
                 2  
                 −1  
                 −1  
                 −2 
                 −1 
                 3  
                 −3 
                 −2  
                 −2  
                 2 
                 7 
                   
               
               
                 V 
                 0  
                 −3  
                 −3  
                 −3  
                 −1  
                 −2  
                 −2  
                 −3 
                 −3  
                 3  
                 1  
                 −2  
                 1 
                 −1  
                 −2  
                 −2  
                 0 
                 −3  
                 −1 
                 4 
               
               
                   
               
            
           
         
       
     
     The percent identity is then calculated as: 
     Total number of identical matches 
     ______×100 
     [length of the longer sequence plus the 
     number of gaps introduced into the longer 
     sequence in order to align the two sequences] 
     Substantially homologous polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see below) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag. 
     Conservative Amino Acid Substitutions 
     
       
         
           
               
               
               
             
               
                   
                   
               
             
            
               
                   
                 Basic: 
                 arginine 
               
               
                   
                   
                 lysine 
               
               
                   
                   
                 histidine 
               
               
                   
                 Acidic: 
                 glutamic acid 
               
               
                   
                   
                 aspartic acid 
               
               
                   
                 Polar: 
                 glutamine 
               
               
                   
                   
                 asparagine 
               
               
                   
                 Hydrophobic: 
                 leucine 
               
               
                   
                   
                 isoleucine 
               
               
                   
                   
                 valine 
               
               
                   
                 Aromatic: 
                 phenylalanine 
               
               
                   
                   
                 tryptophan 
               
               
                   
                   
                 tyrosine 
               
               
                   
                 Small: 
                 glycine 
               
               
                   
                   
                 alanine 
               
               
                   
                   
                 serine 
               
               
                   
                   
                 threonine 
               
               
                   
                   
                 methionine 
               
               
                   
                   
               
            
           
         
       
     
     In addition to the 20 standard amino acids, non-standard amino acids (such as 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid, isovaline and α-methyl serine) may be substituted for amino acid residues of the polypeptides of the present invention. A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, and unnatural amino acids may be substituted for polypeptide amino acid residues. The polypeptides of the present invention can also comprise non-naturally occurring amino acid residues. 
     Non-naturally occurring amino acids include, without limitation, trans-3-methylproline, 2,4-methano-proline, cis-4-hydroxyproline, trans-4-hydroxy-proline, N-methylglycine, allo-threonine, methyl-threonine, hydroxy-ethylcysteine, hydroxyethylhomo-cysteine, nitro-glutamine, homoglutamine, pipecolic acid, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenyl-alanine, 4-azaphenyl-alanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an in vitro system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell free system comprising an  E. coli  S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See, for example, Robertson et al., J. Am. Chem. Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991; Chung et al., Science 259:806-9, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA 90:10145-9, 1993). In a second method, translation is carried out in Xenopus oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., J. Biol. Chem. 271:19991-8, 1996). Within a third method,  E. coli  cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the polypeptide in place of its natural counterpart. See, Koide et al., Biochem. 33:7470-6, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by in vitro chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993). 
     A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for amino acid residues of polypeptides of the present invention. 
     Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244: 1081-5, 1989). Sites of biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., Science 255:306-12, 1992; Smith et al., J. Mol. Biol. 224:899-904, 1992; Wlodaver et al., FEBS Lett. 309:59-64, 1992. The identities of essential amino acids can also be inferred from analysis of homologies with related components (e.g. the translocation or protease components) of the polypeptides of the present invention. 
     Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-7, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-6, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., Biochem. 30:10832-7, 1991; Ladner et al., U.S. Pat. No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis (Derbyshire et al., Gene 46:145, 1986; Ner et al., DNA 7:127, 1988). 
     Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale &amp; Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide the skilled person with a general dictionary of many of the terms used in this disclosure. 
     This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written left to right in 5′ to 3′ orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. 
     The headings provided herein are not limitations of the various aspects or embodiments of this disclosure. 
     Amino acids are referred to herein using the name of the amino acid, the three letter abbreviation or the single letter abbreviation. The term “protein”, as used herein, includes proteins, polypeptides, and peptides. As used herein, the term “amino acid sequence” is synonymous with the term “polypeptide” and/or the term “protein”. In some instances, the term “amino acid sequence” is synonymous with the term “peptide”. In some instances, the term “amino acid sequence” is synonymous with the term “enzyme”. The terms “protein” and “polypeptide” are used interchangeably herein. In the present disclosure and claims, the conventional one-letter and three-letter codes for amino acid residues may be used. The 3-letter code for amino acids as defined in conformity with the IUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code. 
     Other definitions of terms may appear throughout the specification. Before the exemplary embodiments are described in more detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be defined only by the appended claims. 
     Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure. 
     It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a clostridial neurotoxin” includes a plurality of such candidate agents and reference to “the clostridial neurotoxin” includes reference to one or more clostridial neurotoxins and equivalents thereof known to those skilled in the art, and so forth. 
     The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       Embodiments of the invention will now be described, by way of example only, with reference to the following Figures and Examples. 
         FIG. 1  shows a comparison of the protein sequence of the activation loop for all BoNT serotypes and a tetanus toxin with two flanking cysteines forming a disulphide bridge connecting the light and heavy chain of a toxin molecule. Factor Xa cleavage site (IDGR) in BoNT/C1 and BoNT/CD underlined. 
         FIG. 2  shows that all four proteases tested: trypsin (TrypZean), Lys-C, factor Xa (FXa) and enterokinase (EK) have the ability to cleave BoNT/C1 activation loop and create a di-chain molecule as compared to C—protease untreated control. (A,B) BoNT/C1(0) (SEQ ID NO: 15) treated with Factor Xa (FXa), enterokinase (EK) and trypsin (1-16 hour time course) as indicated tested by SDS-PAGE in non-reducing (A) and reducing conditions (B). Similarly, proteolytic digest by Lys-C creates di-chain molecules of BoNT/C1 (C). Both trypsin and Lys-C show off-target cleavage within the heavy chain of BoNT/C1. 1-Benchmark (5 ul); 2-Control sample (−LysC) −DTT; 3-Control sample (−LysC) +DTT; 4-Activated −DTT; 5-Activated +DTT. 
         FIG. 3  (A) shows BoNT/X cleavage by Lys-C. Samples were tested in non-reduced and reduced (+DTT) conditions. 1-Benchmark (5 ul); 2-No protease control; 3-LysC 0.125 μg/ml; 4-LysC 0.25 μg/ml; 5-LysC 0.5 μg/ml; 6-LysC 1 μg/ml; 7-LysC 2 μg/ml; 8-LysC 4 μg/ml; 9-No protease control +DTT; 10-LysC 0.125 μg/ml +DTT; 11-LysC 0.25 μg/ml +DTT; 12-LysC 0.5 μg/ml +DTT; 13-LysC 1 μg/ml +DTT; 14-LysC 2 μg/ml +DTT; 15-LysC 4 μg/ml +DTT; and 16-Benchmark (5 ul). (B) shows BoNT/X cleavage by Trypsin (TrypZean), Factor Xa and Enterokinase. Samples were tested in non-reduced and reduced (+DTT) conditions. 1-Benchmark (5 ul); 2-No protease control; 3-TrypZean 0.125 μg/ml; 4-TrypZean 0.25 μg/ml; 5-No protease control; 6-TrypZean 1 μg/ml; 7-TrypZean 2 μg/ml; 8-TrypZean 4 μg/ml; 9-Factor Xa 5 μg/ml; 10-Enterokinase 0.01 μg/ml; 11-No protease control +DTT; 12-TrypZean 0.125 μg/ml +DTT; 13-TrypZean 0.25 μg/ml +DTT; 14-No protease control +DTT; 15-TrypZean 1 μg/ml +DTT; 16-TrypZean 2 μg/ml +DTT; 17-TrypZean 4 μg/ml +DTT; 18-Factor Xa 5 μg/ml; 19-Enterokinase 0.01 μg/ml; and 20-Benchmark (5 ul). 
         FIG. 4  shows engineered BoNT/X (SEQ ID NO: 5) treated with indicated proteases and successful BoNT di-chain formation evident by comparison between non-reduced (−DTT) and reduced (+DTT) conditions. Lanes 4-7 show in-process samples. Lanes 8-11 show final samples after last polishing step. 1-capture HisHP load; 2-control −DTT—protease; 3-control +DTT—protease; 4-activated −DTT +EK; 5-activated +DTT +EK; 6-activated −DTT +FXa; 7-activated +DTT +FXa; 8-final −DTT EK active.; 9-final +DTT EK activ.; 10-final −DTT FXa activ.; 11-final +DTT FXa activ. 
         FIG. 5  (A) shows BoNT/E tested with 10 μg/ml endoproteinase Lys-C from Lysobacter enzymogenes (“Lys-C”) and  Pseudomonas aeruginosa  (“rLys-C”) for 2 h @ 37° C. Samples were tested in non-reduced and reduced (+TCEP) conditions. (B) shows BoNT/E treated with indicated amounts of Trypsin for 7 h at 20° C. (C)—sample stored at −20° C. (T)—no protease control at 20° C. Samples were tested in reduced (+DTT) conditions. 
         FIG. 6  shows engineered BoNT/E (SEQ ID NO: 11) treated with indicated proteases and successful BoNT di-chain formation evident by comparison between non-reduced (−DTT) and reduced (+DTT) conditions. 1-Benchmark (5 ul); 2-Control sample (−EK) −DTT; 3-Control sample (−EK) +DTT; 4-Activated (+EK) −DTT; 5-Activated (+EK) +DTT; 6-Benchmark (5 ul); 7-Control sample (−FXa) −DTT; 8-Control sample (−FXa) +DTT; 9-Activated (+FXa) −DTT; 10-Activated (+FXa) +DTT. 
         FIG. 7  (A) shows engineered BoNT/A1C1 (SEQ ID NO: 13) treated with Factor Xa protease and successful BoNT di-chain formation evident by comparison between non-reduced (−DTT) and reduced (+DTT) conditions. 1-BenchMark ladder; 2-Control (−FXa −DTT); 3-Control (−FXa +DTT); 4-Activated (+FXa −DTT); 5-Activated (+FXa +DTT). (B) shows cleavage of BoNT/A1 with FXa or EK after 2 hours compared to a positive control (di-chain BoNT/A1). 
         FIG. 8  shows BoNT/A1C1 and BoNT/C1 dose dependent inhibition of glutamate release from primary rat neurons. 
         FIG. 9  shows intact mass analysis of non-reduced engineered BoNT/E (SEQ ID NO: 11) activated by enterokinase with an indicated mass of 143853 Da. 
         FIG. 10  shows intact mass analysis of reduced engineered BoNT/E (SEQ ID NO: 11) activated by enterokinase with an indicated mass of 47518 Da and 96338 Da. 
         FIG. 11  shows intact mass analysis of non-reduced engineered BoNT/E (SEQ ID NO: 11) activated by factor Xa with an indicated mass of 143850 Da. 
         FIG. 12  shows intact mass analysis of reduced engineered BoNT/E (SEQ ID NO: 11) activated by factor Xa with an indicated mass of 47518 Da and 96335 Da. 
         FIG. 13  shows LH N /A1 containing an EK cleavage site inserted into the activation loop (SEQ ID NO: 44) and treated with EK compared to a native A1 loop (SEQ ID NO: 46) treated with Lys-C. 1-Benchmark (5 ul); 2-empty; 3-SEQ ID NO: 44+EK −DTT; 4-SEQ ID NO: 44 +EK +DTT; 5-SEQ ID NO: 44 −EK −DTT; 6-SEQ ID NO: 44 −EK +DTT; 7-Benchmark; 8-SEQ ID NO: 46 −LysC −DTT; 9-SEQ ID NO: 46 −LysC −DTT; 10-SEQ ID NO: 46+LysC −DTT; 11-SEQ ID NO: 46 −LysC +DTT; 12-SEQ ID NO: 46 −LysC +DTT; and 13-SEQ ID NO: 46+LysC +DTT. 
         FIG. 14  shows activation of engineered BoNT/XA (SEQ ID NO: 7) with FXa. 
         FIG. 15  shows activation of engineered BoNT/XB (SEQ ID NO: 9) with FXa. 
       
         
           
             
                 
                 
              
                 
                   SEQUENCE LISTING 
                     
                 
                 
                   Where an initial Met amino acid residue or a corresponding initial codon is 
                 
                 
                   indicated in any of the following SEQ ID NOs, said residue/codon is 
                 
                 
                   optional. 
                 
                 
                   (C1 Activation Loop Consensus Sequence) 
                 
                 
                   SEQ ID NO: 1 
                     
                 
                 
                   Cys-(Xaa) a ,-Ile-Asp/Glu-Gly-Arg-(Yaa) b -Cys 
                     
                 
                 
                     
                 
                 
                   (C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 2 
                     
                 
                 
                   CHKAIDGRSLYNKTLDC 
                     
                 
                 
                     
                 
                 
                   (C1 Activation Loop Variant) 
                 
                 
                   SEQ ID NO: 3 
                     
                 
                 
                   CHKAIEGRSLYNKTLDC 
                     
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT/X with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 4 
                     
                 
                 
                   ATGAAACTGGAAATCAACAAATTCAACTACAACGATCCGATCGATGGCATTAATGTTATTACCATGCG 
                     
                 
                 
                     
                 
                 
                   TCCGCCTCGTCATAGCGATAAAATCAATAAAGGTAAAGGTCCGTTCAAAGCCTTTCAGGTGATTAAAA 
                 
                 
                     
                 
                 
                   ACATTTGGATTGTGCCGGAACGCTACAACTTTACCAATAATACCAACGATCTGAACATTCCGAGCGAA 
                 
                 
                     
                 
                 
                   CCGATTATGGAAGCAGATGCCATTTATAACCCGAACTATCTGAATACCCCGAGCGAAAAAGATGAATT 
                 
                 
                     
                 
                 
                   TCTGCAGGGTGTTATCAAAGTGCTGGAACGCATTAAAAGCAAACCGGAAGGTGAAAAACTGCTGGAAC 
                 
                 
                     
                 
                 
                   TGATTAGCAGCAGCATTCCGCTGCCGCTGGTTAGCAATGGTGCACTGACCCTGAGCGATAATGAAACC 
                 
                 
                     
                 
                 
                   ATTGCATATCAAGAGAACAACAACATTGTGAGCAATCTGCAGGCAAACCTGGTTATTTATGGTCCGGG 
                 
                 
                     
                 
                 
                   TCCTGATATTGCAAATAATGCAACCTATGGTCTGTATAGCACCCCGATTAGTAATGGTGAAGGTACAC 
                 
                 
                     
                 
                 
                   TGAGCGAAGTTAGCTTTAGCCCGTTTTATCTGAAACCGTTTGATGAAAGCTATGGCAATTATCGTAGC 
                 
                 
                     
                 
                 
                   CTGGTGAATATCGTGAACAAATTCGTGAAACGTGAATTTGCACCTGATCCGGCAAGCACCCTGATGCA 
                 
                 
                     
                 
                 
                   TGAACTGGTTCATGTTACCCATAATCTGTATGGTATTAGCAACCGCAACTTCTACTATAACTTTGACA 
                 
                 
                     
                 
                 
                   CCGGCAAAATTGAAACCAGCCGTCAGCAGAATAGCCTGATTTTTGAAGAACTGCTGACCTTTGGTGGC 
                 
                 
                     
                 
                 
                   ATTGATAGCAAAGCAATTAGCAGCCTGATCATCAAGAAAATTATCGAAACCGCCAAGAACAACTATAC 
                 
                 
                     
                 
                 
                   CACGCTGATTAGCGAACGCCTGAATACCGTTACCGTTGAAAATGATCTGCTGAAATATATCAAAAACA 
                 
                 
                     
                 
                 
                   AAATCCCGGTTCAGGGTCGTCTGGGTAACTTTAAACTGGATACCGCAGAATTCGAGAAAAAGCTGAAT 
                 
                 
                     
                 
                 
                   ACCATTCTGTTTGTGCTGAACGAAAGCAATCTGGCACAGCGTTTTAGCATTCTGGTTCGTAAACATTA 
                 
                 
                     
                 
                 
                   CCTGAAAGAACGTCCGATTGATCCGATTTATGTGAACATTCTGGATGACAATAGCTACAGCACCCTGG 
                 
                 
                     
                 
                 
                   AAGGTTTTAACATTAGCAGTCAGGGTAGCAATGATTTCCAAGGTCAGCTGCTGGAAAGCAGCTATTTT 
                 
                 
                     
                 
                 
                   GAAAAAATTGAAAGCAATGCCCTGCGTGCCTTTATCAAAATTTGTCATAAAGCCATTGATGGTCGCAG 
                 
                 
                     
                 
                 
                   CCTGTATAACAAAACCCTGGATTGTATTGAGGTGGAAAACAAAGACCTGTTTCTGATTAGCAACAAAG 
                 
                 
                     
                 
                 
                   ATAGCCTGAACGATATTAACCTGAGCGAAGAAAAAATCAAACCGGAAACCACCGTGTTCTTCAAAGAT 
                 
                 
                     
                 
                 
                   AAACTGCCTCCGCAGGATATTACGCTGAGCAATTATGATTTTACCGAAGCCAATAGCATTCCGAGCAT 
                 
                 
                     
                 
                 
                   TAGCCAGCAGAACATTCTGGAACGTAATGAAGAACTGTATGAACCGATTCGCAATAGCCTGTTTGAAA 
                 
                 
                     
                 
                 
                   TCAAAACCATCTATGTGGATAAGCTGACCACCTTTCATTTTCTGGAAGCCCAGAATATTGATGAGAGC 
                 
                 
                     
                 
                 
                   ATTGATAGCAGCAAAATTCGTGTTGAACTGACCGATAGCGTTGATGAAGCACTGAGCAATCCGAATAA 
                 
                 
                     
                 
                 
                   AGTTTATAGCCCGTTCAAGAACATGAGCAACACCATTAATAGCATTGAAACCGGTATTACCAGCACCT 
                 
                 
                     
                 
                 
                   ACATCTTTTATCAGTGGCTGCGTAGCATCGTGAAAGATTTTAGTGATGAAACCGGCAAAATCGACGTG 
                 
                 
                     
                 
                 
                   ATTGATAAAAGCAGCGATACCCTGGCAATTGTTCCGTATATTGGTCCGCTGCTGAATATTGGTAATGA 
                 
                 
                     
                 
                 
                   TATTCGTCATGGCGATTTTGTGGGTGCAATTGAACTGGCAGGCATTACCGCACTGCTGGAATATGTTC 
                 
                 
                     
                 
                 
                   CGGAATTTACCATTCCGATTCTGGTTGGTCTGGAAGTTATTGGTGGCGAACTGGCACGTGAACAGGTT 
                 
                 
                     
                 
                 
                   GAAGCAATTGTTAATAATGCCCTGGATAAACGCGATCAGAAATGGGCAGAAGTTTACAATATTACCAA 
                 
                 
                     
                 
                 
                   AGCACAGTGGTGGGGCACCATTCATTTACAGATTAATACCCGTCTGGCCCATACCTATAAAGCCCTGA 
                 
                 
                     
                 
                 
                   GCCGTCAGGCAAATGCCATTAAAATGAATATGGAATTTCAGCTGGCCAACTACAAAGGCAACATTGAT 
                 
                 
                     
                 
                 
                   GATAAAGCCAAGATCAAAAACGCCATCAGCGAAACCGAAATTCTGCTGAACAAAAGCGTTGAACAGGC 
                 
                 
                     
                 
                 
                   CATGAAAAACACCGAGAAATTCATGATTAAACTGAGCAACAGCTACCTGACCAAAGAAATGATTCCGA 
                 
                 
                     
                 
                 
                   AAGTTCAGGACAACCTGAAAAACTTTGATCTGGAAACCAAAAAGACCCTGGACAAGTTCATCAAAGAG 
                 
                 
                     
                 
                 
                   AAAGAAGATATCCTGGGCACCAATCTGAGCAGCAGCCTGCGTCGTAAAGTTAGCATTCGTCTGAATAA 
                 
                 
                     
                 
                 
                   AAACATTGCCTTCGACATCAACGATATCCCGTTTAGCGAATTTGATGATCTGATCAACCAGTACAAAA 
                 
                 
                     
                 
                 
                   ACGAGATCGAAGATTATGAAGTGCTGAATCTGGGTGCAGAAGATGGCAAAATCAAAGATCTGAGCGGT 
                 
                 
                     
                 
                 
                   ACAACCAGCGATATCAATATTGGTTCAGATATCGAACTGGCCGATGGTCGTGAAAATAAAGCGATTAA 
                 
                 
                     
                 
                 
                   GATTAAAGGCAGCGAGAACAGCACCATCAAAATTGCAATGAACAAATATCTGCGTTTTAGCGCGACCG 
                 
                 
                     
                 
                 
                   ATAACTTTAGCATTAGCTTTTGGATCAAACATCCGAAACCGACCAATCTGCTTAATAACGGTATTGAA 
                 
                 
                     
                 
                 
                   TATACCCTGGTCGAGAACTTTAATCAGCGTGGTTGGAAAATTAGCATCCAGGATAGCAAACTGATTTG 
                 
                 
                     
                 
                 
                   GTATCTGCGCGATCACAATAACAGCATCAAAATCGTTACACCGGATTATATTGCGTTTAATGGCTGGA 
                 
                 
                     
                 
                 
                   ACCTGATTACCATTACAAACAATCGTAGCAAAGGCAGCATCGTGTATGTTAACGGTAGCAAAATTGAA 
                 
                 
                     
                 
                 
                   GAGAAGGACATTAGCAGCATTTGGAATACCGAAGTGGATGATCCGATTATCTTCCGCCTGAAAAATAA 
                 
                 
                     
                 
                 
                   CCGTGATACCCAGGCATTTACCCTGCTGGATCAGTTTAGCATTTATCGCAAAGAACTGAACCAGAACG 
                 
                 
                     
                 
                 
                   AAGTGGTGAAACTGTATAACTACTACTTCAACAGCAACTACATTCGCGATATTTGGGGTAATCCGCTG 
                 
                 
                     
                 
                 
                   CAGTACAACAAAAAATACTATCTGCAGACCCAGGACAAACCTGGTAAAGGTCTGATCCGCGAATATTG 
                 
                 
                     
                 
                 
                   GAGCAGCTTTGGTTATGATTATGTGATTCTGAGCGATAGCAAGACCATTACCTTTCCGAATAATATCC 
                 
                 
                     
                 
                 
                   GTTATGGTGCCCTGTATAATGGTAGCAAAGTGCTGATCAAGAACAGCAAAAAACTGGATGGTCTGGTG 
                 
                 
                     
                 
                 
                   CGCAATAAAGATTTCATTCAGCTGGAAATCGATGGCTATAATATGGGTATTAGCGCAGATCGCTTTAA 
                 
                 
                     
                 
                 
                   CGAGGATACCAACTATATTGGCACCACCTATGGTACAACCCATGATCTGACCACCGATTTTGAAATTA 
                 
                 
                     
                 
                 
                   TTCAGCGCCAAGAGAAATACCGCAATTATTGTCAGCTGAAAACCCCGTATAACATCTTTCATAAAAGC 
                 
                 
                     
                 
                 
                   GGTCTGATGAGCACCGAAACCAGCAAACCGACCTTCCATGATTATCGCGATTGGGTTTATAGCAGCGC 
                 
                 
                     
                 
                 
                   ATGGTATTTTCAGAACTATGAAAATCTGAACCTGCGCAAACATACCAAAACCAACTGGTATTTTATCC 
                 
                 
                     
                 
                 
                   CGAAAGATGAAGGTTGGGATGAAGATCTGGAAGTGCTGTTTCAGGGTCCGCATCATCACCACCATCAC 
                 
                 
                     
                 
                 
                   CATCATCATCACTGA 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/X with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 5 
                     
                 
                 
                   MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNTNDLNIPSE 
                     
                 
                 
                     
                 
                 
                   PIMEADAIYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIPLPLVSNGALTLSDNET 
                 
                 
                     
                 
                 
                   IAYQENNNIVSNLQANLVIYGPGPDIANNATYGLYSTPISNGEGTLSEVSFSPFYLKPFDESYGNYRS 
                 
                 
                     
                 
                 
                   LVNIVNKFVKREFAPDPASTLMHELVHVTHNLYGISNRNFYYNFDTGKIETSRQQNSLIFEELLTFGG 
                 
                 
                     
                 
                 
                   IDSKAISSLIIKKIIETAKNNYTTLISERLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLN 
                 
                 
                     
                 
                 
                   TILFVLNESNLAQRFSILVRKHYLKERPIDPIYVNILDDNSYSTLEGFNISSQGSNDFQGQLLESSYF 
                 
                 
                     
                 
                 
                   EKIESNALRAFIKICHKAIDGRSLYNKTLDCIEVENKDLFLISNKDSLNDINLSEEKIKPETTVFFKD 
                 
                 
                     
                 
                 
                   KLPPQDITLSNYDFTEANSIPSISQQNILERNEELYEPIRNSLFEIKTIYVDKLTTFHFLEAQNIDES 
                 
                 
                     
                 
                 
                   IDSSKIRVELTDSVDEALSNPNKVYSPFKNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDV 
                 
                 
                     
                 
                 
                   IDKSSDTLAIVPYIGPLLNIGNDIRHGDFVGAIELAGITALLEYVPEFTIPILVGLEVIGGELAREQV 
                 
                 
                     
                 
                 
                   EAIVNNALDKRDQKWAEVYNITKAQWWGTIHLQINTRLAHTYKALSRQANAIKMNMEFQLANYKGNID 
                 
                 
                     
                 
                 
                   DKAKIKNAISETEILLNKSVEQAMKNTEKFMIKLSNSYLTKEMIPKVQDNLKNFDLETKKTLDKFIKE 
                 
                 
                     
                 
                 
                   KEDILGTNLSSSLRRKVSIRLNKNIAFDINDIPFSEFDDLINQYKNEIEDYEVLNLGAEDGKIKDLSG 
                 
                 
                     
                 
                 
                   TTSDINIGSDIELADGRENKAIKIKGSENSTIKIAMNKYLRFSATDNFSISFWIKHPKPTNLLNNGIE 
                 
                 
                     
                 
                 
                   YTLVENFNQRGWKISIQDSKLIWYLRDHNNSIKIVTPDYIAFNGWNLITITNNRSKGSIVYVNGSKIE 
                 
                 
                     
                 
                 
                   EKDISSIWNTEVDDPIIFRLKNNRDTQAFTLLDQFSIYRKELNQNEVVKLYNYYFNSNYIRDIWGNPL 
                 
                 
                     
                 
                 
                   QYNKKYYLQTQDKPGKGLIREYWSSFGYDYVILSDSKTITFPNNIRYGALYNGSKVLIKNSKKLDGLV 
                 
                 
                     
                 
                 
                   RNKDFIQLEIDGYNMGISADRFNEDTNYIGTTYGTTHDLTTDFEIIQRQEKYRNYCQLKTPYNIFHKS 
                 
                 
                     
                 
                 
                   GLMSTETSKPTFHDYRDWVYSSAWYFQNYENLNLRKHTKTNWYFIPKDEGWDEDLEVLFQGPHHHHHH 
                 
                 
                     
                 
                 
                   HHHH 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT/XA [LH N X-H C A] with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 6 
                     
                 
                 
                   ATGAAACTGGAAATCAACAAATTCAACTACAACGATCCGATCGATGGCATTAATGTTATTACCATGCG 
                     
                 
                 
                     
                 
                 
                   TCCGCCTCGTCATAGCGATAAAATCAATAAAGGTAAAGGTCCGTTCAAAGCCTTTCAGGTGATTAAAA 
                 
                 
                     
                 
                 
                   ACATTTGGATTGTGCCGGAACGCTACAACTTTACCAATAATACCAACGATCTGAACATTCCGAGCGAA 
                 
                 
                     
                 
                 
                   CCGATTATGGAAGCAGATGCCATTTATAACCCGAACTATCTGAATACCCCGAGCGAAAAAGATGAATT 
                 
                 
                     
                 
                 
                   TCTGCAGGGTGTTATCAAAGTGCTGGAACGCATTAAAAGCAAACCGGAAGGTGAAAAACTGCTGGAAC 
                 
                 
                     
                 
                 
                   TGATTAGCAGCAGCATTCCGCTGCCGCTGGTTAGCAATGGTGCACTGACCCTGAGCGATAATGAAACC 
                 
                 
                     
                 
                 
                   ATTGCATATCAAGAGAACAACAACATTGTGAGCAATCTGCAGGCAAACCTGGTTATTTATGGTCCGGG 
                 
                 
                     
                 
                 
                   TCCTGATATTGCAAATAATGCAACCTATGGTCTGTATAGCACCCCGATTAGTAATGGTGAAGGTACAC 
                 
                 
                     
                 
                 
                   TGAGCGAAGTTAGCTTTAGCCCGTTTTATCTGAAACCGTTTGATGAAAGCTATGGCAATTATCGTAGC 
                 
                 
                     
                 
                 
                   CTGGTGAATATCGTGAACAAATTCGTGAAACGTGAATTTGCACCTGATCCGGCAAGCACCCTGATGCA 
                 
                 
                     
                 
                 
                   TGAACTGGTTCATGTTACCCATAATCTGTATGGTATTAGCAACCGCAACTTCTACTATAACTTTGACA 
                 
                 
                     
                 
                 
                   CCGGCAAAATTGAAACCAGCCGTCAGCAGAATAGCCTGATTTTTGAAGAACTGCTGACCTTTGGTGGC 
                 
                 
                     
                 
                 
                   ATTGATAGCAAAGCAATTAGCAGCCTGATCATCAAGAAAATTATCGAAACCGCCAAGAACAACTATAC 
                 
                 
                     
                 
                 
                   CACGCTGATTAGCGAACGCCTGAATACCGTTACCGTTGAAAATGATCTGCTGAAATATATCAAAAACA 
                 
                 
                     
                 
                 
                   AAATCCCGGTTCAGGGTCGTCTGGGTAACTTTAAACTGGATACCGCAGAATTCGAGAAAAAGCTGAAT 
                 
                 
                     
                 
                 
                   ACCATTCTGTTTGTGCTGAACGAAAGCAATCTGGCACAGCGTTTTAGCATTCTGGTTCGTAAACATTA 
                 
                 
                     
                 
                 
                   CCTGAAAGAACGTCCGATTGATCCGATTTATGTGAACATTCTGGATGACAATAGCTACAGCACCCTGG 
                 
                 
                     
                 
                 
                   AAGGTTTTAACATTAGCAGTCAGGGTAGCAATGATTTTCAGGGCCAGCTGCTGGAAAGCAGCTATTTT 
                 
                 
                     
                 
                 
                   GAAAAAATTGAATCCAATGCGCTGCGTGCCTTTATCAAAATTTGTCATAAAGCCATTGATGGTCGCAG 
                 
                 
                     
                 
                 
                   CCTGTATAACAAAACCCTGGATTGTATTGAAGTGGAAAACAAAGACCTGTTCCTGATTAGCAATAAAG 
                 
                 
                     
                 
                 
                   ATAGCCTGAACGATATCAACCTGAGCGAAGAAAAAATCAAACCGGAAACCACCGTGTTCTTCAAAGAT 
                 
                 
                     
                 
                 
                   AAACTGCCTCCGCAGGATATTACCCTGAGCAATTATGATTTTACCGAAGCCAATAGCATTCCGAGCAT 
                 
                 
                     
                 
                 
                   TAGCCAGCAGAACATTCTGGAACGTAATGAAGAACTGTATGAACCGATTCGCAATAGCCTGTTTGAAA 
                 
                 
                     
                 
                 
                   TCAAAACCATCTATGTGGATAAGCTGACCACCTTTCATTTTCTGGAAGCCCAGAATATTGATGAGAGC 
                 
                 
                     
                 
                 
                   ATTGATAGCAGCAAAATTCGTGTTGAACTGACCGATAGCGTTGATGAAGCACTGAGCAATCCGAATAA 
                 
                 
                     
                 
                 
                   AGTTTATAGCCCGTTCAAGAACATGAGCAACACCATTAATAGCATTGAAACCGGTATTACCAGCACCT 
                 
                 
                     
                 
                 
                   ACATCTTTTATCAGTGGCTGCGTAGCATCGTGAAAGATTTTAGTGATGAAACCGGCAAAATCGACGTG 
                 
                 
                     
                 
                 
                   ATTGATAAAAGCAGCGATACCCTGGCCATTGTTCCGTATATTGGTCCGCTGCTGAATATTGGTAATGA 
                 
                 
                     
                 
                 
                   TATTCGTCATGGCGATTTTGTGGGTGCAATTGAACTGGCAGGCATTACCGCACTGCTGGAATATGTTC 
                 
                 
                     
                 
                 
                   CGGAATTTACCATTCCGATTCTGGTTGGTCTGGAAGTTATTGGTGGCGAACTGGCACGTGAACAGGTT 
                 
                 
                     
                 
                 
                   GAAGCAATTGTTAATAATGCCCTGGATAAACGCGATCAGAAATGGGCAGAAGTTTACAATATTACCAA 
                 
                 
                     
                 
                 
                   AGCACAGTGGTGGGGCACCATTCATTTACAGATTAATACCCGTCTGGCCCATACCTATAAAGCCCTGA 
                 
                 
                     
                 
                 
                   GCCGTCAGGCAAATGCCATTAAAATGAATATGGAATTTCAGCTGGCCAACTACAAAGGCAACATTGAT 
                 
                 
                     
                 
                 
                   GATAAAGCCAAGATCAAAAACGCCATCAGCGAAACCGAAATTCTGCTGAACAAAAGCGTTGAACAGGC 
                 
                 
                     
                 
                 
                   CATGAAAAACACCGAGAAATTCATGATTAAACTGAGCAACAGCTACCTGACCAAAGAAATGATTCCGA 
                 
                 
                     
                 
                 
                   AAGTTCAGGACAACCTGAAAAACTTTGATCTGGAAACCAAAAAGACCCTGGACAAGTTCATCAAAGAG 
                 
                 
                     
                 
                 
                   AAAGAAGATATCCTGGGCACCAATCTGAGCAGCAGCCTGCGTCGTAAAGTTAGCATTCGTCTGAATAA 
                 
                 
                     
                 
                 
                   AAACATTGCCTTCGACATCAACGATATCCCGTTTAGCGAATTTGATGATCTGATCAACCAGTACAAAA 
                 
                 
                     
                 
                 
                   ACGAGATCGAAGATTATGAAGTGCTGAATCTGGGTGCAGAAGATGGCAAAATCAAAGATCTGAGCGGT 
                 
                 
                     
                 
                 
                   ACAACCAGCGATATTAACATTGGTAGCGATATCGAAATCATCAACACCAGCATTCTGAATCTGCGCTA 
                 
                 
                     
                 
                 
                   TGAAAGCAATCATCTGATTGATCTGAGCCGTTATGCGTCCAAAATCAATATTGGCAGCAAAGTGAATT 
                 
                 
                     
                 
                 
                   TCGACCCGATCGATAAAAATCAGATCCAGCTGTTTAATCTGGAAAGCTCCAAAATTGAGGTGATTCTG 
                 
                 
                     
                 
                 
                   AAAAACGCGATTGTGTACAATAGCATGTATGAGAATTTCTCAACCAGCTTCTGGATTCGCATTCCGAA 
                 
                 
                     
                 
                 
                   ATACTTTAACAGCATCAGCCTGAACAACGAGTATACCATTATCAACTGCATGGAAAACAATAGCGGTT 
                 
                 
                     
                 
                 
                   GGAAAGTGAGCCTGAATTATGGTGAAATTATCTGGACCCTGCAGGATACCCAAGAAATCAAACAGCGT 
                 
                 
                     
                 
                 
                   GTTGTGTTCAAATACAGCCAGATGATTAACATCAGCGATTACATTAACCGCTGGATCTTTGTTACCAT 
                 
                 
                     
                 
                 
                   TACCAACAATCGCCTGAATAACAGCAAGATCTATATTAACGGTCGTCTGATTGACCAGAAACCGATTA 
                 
                 
                     
                 
                 
                   GTAATCTGGGTAATATTCATGCCAGCAACAACATCATGTTCAAACTGGATGGTTGTCGTGATACCCAT 
                 
                 
                     
                 
                 
                   CGTTATATTTGGATCAAGTATTTTAACCTGTTTGATAAAGAACTGAACGAAAAAGAAATTAAGGATCT 
                 
                 
                     
                 
                 
                   GTATGATAACCAGTCCAATAGCGGCATCCTGAAGGATTTTTGGGGTGATTATCTGCAGTATGACAAAC 
                 
                 
                     
                 
                 
                   CGTATTATATGCTGAACCTGTACGATCCGAACAAATATGTGGATGTGAATAATGTGGGTATCCGTGGC 
                 
                 
                     
                 
                 
                   TATATGTATCTGAAAGGTCCGCGTGGTAGCGTTATGACCACCAACATTTATCTGAATAGCAGCCTGTA 
                 
                 
                     
                 
                 
                   TCGTGGCACCAAATTCATCATCAAAAAATACGCCAGCGGCAACAAAGATAATATTGTGCGTAATAATG 
                 
                 
                     
                 
                 
                   ACCGCGTGTATATCAATGTGGTGGTGAAGAATAAAGAATATCGTCTGGCAACCAATGCAAGCCAGGCA 
                 
                 
                     
                 
                 
                   GGCGTTGAAAAAATTCTGAGCGCACTGGAAATCCCGGATGTGGGTAATCTGAGCCAGGTTGTTGTTAT 
                 
                 
                     
                 
                 
                   GAAAAGCAAAAATGATCAGGGCATCACCAACAAGTGCAAAATGAATCTGCAGGACAATAACGGCAACG 
                 
                 
                     
                 
                 
                   ACATTGGTTTTATTGGCTTTCACCAGTTTAACAACATTGCCAAACTGGTTGCGAGCAATTGGTATAAT 
                 
                 
                     
                 
                 
                   CGTCAGATTGAACGTAGCAGTCGTACCCTGGGTTGTAGCTGGGAATTTATTCCGGTTGATGATGGTTG 
                 
                 
                     
                 
                 
                   GGGTGAACGTCCGCTGCATCATCACCACCATCACCATCACCACCATTAA 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/XA [LH N X-H C A] with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 7 
                     
                 
                 
                   MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNTNDLNIPSE 
                     
                 
                 
                     
                 
                 
                   PIMEADAIYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIPLPLVSNGALTLSDNET 
                 
                 
                     
                 
                 
                   IAYQENNNIVSNLQANLVIYGPGPDIANNATYGLYSTPISNGEGTLSEVSFSPFYLKPFDESYGNYRS 
                 
                 
                     
                 
                 
                   LVNIVNKFVKREFAPDPASTLMHELVHVTHNLYGISNRNFYYNFDTGKIETSRQQNSLIFEELLTFGG 
                 
                 
                     
                 
                 
                   IDSKAISSLIIKKIIETAKNNYTTLISERLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLN 
                 
                 
                     
                 
                 
                   TILFVLNESNLAQRFSILVRKHYLKERPIDPIYVNILDDNSYSTLEGFNISSQGSNDFQGQLLESSYF 
                 
                 
                     
                 
                 
                   EKIESNALRAFIKICHKAIDGRSLYNKTLDCIEVENKDLFLISNKDSLNDINLSEEKIKPETTVFFKD 
                 
                 
                     
                 
                 
                   KLPPQDITLSNYDFTEANSIPSISQQNILERNEELYEPIRNSLFEIKTIYVDKLTTFHFLEAQNIDES 
                 
                 
                     
                 
                 
                   IDSSKIRVELTDSVDEALSNPNKVYSPFKNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDV 
                 
                 
                     
                 
                 
                   IDKSSDTLAIVPYIGPLLNIGNDIRHGDFVGAIELAGITALLEYVPEFTIPILVGLEVIGGELAREQV 
                 
                 
                     
                 
                 
                   EAIVNNALDKRDQKWAEVYNITKAQWWGTIHLQINTRLAHTYKALSRQANAIKMNMEFQLANYKGNID 
                 
                 
                     
                 
                 
                   DKAKIKNAISETEILLNKSVEQAMKNTEKFMIKLSNSYLTKEMIPKVQDNLKNFDLETKKTLDKFIKE 
                 
                 
                     
                 
                 
                   KEDILGTNLSSSLRRKVSIRLNKNIAFDINDIPFSEFDDLINQYKNEIEDYEVLNLGAEDGKIKDLSG 
                 
                 
                     
                 
                 
                   TTSDINIGSDIEIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVIL 
                 
                 
                     
                 
                 
                   KNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQR 
                 
                 
                     
                 
                 
                   VVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTH 
                 
                 
                     
                 
                 
                   RYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRG 
                 
                 
                     
                 
                 
                   YMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA 
                 
                 
                     
                 
                 
                   GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYN 
                 
                 
                     
                 
                 
                   RQIERSSRTLGCSWEFIPVDDGWGERPLHHHHHHHHHH 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT/XB [LH N X-H C B] with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 8 
                     
                 
                 
                   ATGAAACTGGAAATCAACAAATTCAACTACAACGATCCGATCGATGGCATTAATGTTATTACCATGCG 
                     
                 
                 
                     
                 
                 
                   TCCGCCTCGTCATAGCGATAAAATCAATAAAGGTAAAGGTCCGTTCAAAGCCTTTCAGGTGATTAAAA 
                 
                 
                     
                 
                 
                   ACATTTGGATTGTGCCGGAACGCTACAACTTTACCAATAATACCAACGATCTGAACATTCCGAGCGAA 
                 
                 
                     
                 
                 
                   CCGATTATGGAAGCAGATGCCATTTATAACCCGAACTATCTGAATACCCCGAGCGAAAAAGATGAATT 
                 
                 
                     
                 
                 
                   TCTGCAGGGTGTTATCAAAGTGCTGGAACGCATTAAAAGCAAACCGGAAGGTGAAAAACTGCTGGAAC 
                 
                 
                     
                 
                 
                   TGATTAGCAGCAGCATTCCGCTGCCGCTGGTTAGCAATGGTGCACTGACCCTGAGCGATAATGAAACC 
                 
                 
                     
                 
                 
                   ATTGCATATCAAGAGAACAACAACATTGTGAGCAATCTGCAGGCAAACCTGGTTATTTATGGTCCGGG 
                 
                 
                     
                 
                 
                   TCCTGATATTGCAAATAATGCAACCTATGGTCTGTATAGCACCCCGATTAGTAATGGTGAAGGTACAC 
                 
                 
                     
                 
                 
                   TGAGCGAAGTTAGCTTTAGCCCGTTTTATCTGAAACCGTTTGATGAAAGCTATGGCAATTATCGTAGC 
                 
                 
                     
                 
                 
                   CTGGTGAATATCGTGAACAAATTCGTGAAACGTGAATTTGCACCTGATCCGGCAAGCACCCTGATGCA 
                 
                 
                     
                 
                 
                   TGAACTGGTTCATGTTACCCATAATCTGTATGGTATTAGCAACCGCAACTTCTACTATAACTTTGACA 
                 
                 
                     
                 
                 
                   CCGGCAAAATTGAAACCAGCCGTCAGCAGAATAGCCTGATTTTTGAAGAACTGCTGACCTTTGGTGGC 
                 
                 
                     
                 
                 
                   ATTGATAGCAAAGCAATTAGCAGCCTGATCATCAAGAAAATTATCGAAACCGCCAAGAACAACTATAC 
                 
                 
                     
                 
                 
                   CACGCTGATTAGCGAACGCCTGAATACCGTTACCGTTGAAAATGATCTGCTGAAATATATCAAAAACA 
                 
                 
                     
                 
                 
                   AAATCCCGGTTCAGGGTCGTCTGGGTAACTTTAAACTGGATACCGCAGAATTCGAGAAAAAGCTGAAT 
                 
                 
                     
                 
                 
                   ACCATTCTGTTTGTGCTGAACGAAAGCAATCTGGCACAGCGTTTTAGCATTCTGGTTCGTAAACATTA 
                 
                 
                     
                 
                 
                   CCTGAAAGAACGTCCGATTGATCCGATTTATGTGAACATTCTGGATGACAATAGCTACAGCACCCTGG 
                 
                 
                     
                 
                 
                   AAGGTTTTAACATTAGCAGTCAGGGTAGCAATGATTTTCAGGGCCAGCTGCTGGAAAGCAGCTATTTT 
                 
                 
                     
                 
                 
                   GAAAAAATTGAATCCAATGCGCTGCGTGCCTTTATCAAAATTTGTCATAAAGCCATTGATGGTCGCAG 
                 
                 
                     
                 
                 
                   CCTGTATAACAAAACCCTGGATTGTATTGAAGTGGAAAACAAAGACCTGTTCCTGATTAGCAATAAAG 
                 
                 
                     
                 
                 
                   ATAGCCTGAACGATATCAACCTGAGCGAAGAAAAAATCAAACCGGAAACCACCGTGTTCTTCAAAGAT 
                 
                 
                     
                 
                 
                   AAACTGCCTCCGCAGGATATTACCCTGAGCAATTATGATTTTACCGAAGCCAATAGCATTCCGAGCAT 
                 
                 
                     
                 
                 
                   TAGCCAGCAGAACATTCTGGAACGTAATGAAGAACTGTATGAACCGATTCGCAATAGCCTGTTTGAAA 
                 
                 
                     
                 
                 
                   TCAAAACCATCTATGTGGATAAGCTGACCACCTTTCATTTTCTGGAAGCCCAGAATATTGATGAGAGC 
                 
                 
                     
                 
                 
                   ATTGATAGCAGCAAAATTCGTGTTGAACTGACCGATAGCGTTGATGAAGCACTGAGCAATCCGAATAA 
                 
                 
                     
                 
                 
                   AGTTTATAGCCCGTTCAAGAACATGAGCAACACCATTAATAGCATTGAAACCGGTATTACCAGCACCT 
                 
                 
                     
                 
                 
                   ACATCTTTTATCAGTGGCTGCGTAGCATCGTGAAAGATTTTAGTGATGAAACCGGCAAAATCGACGTG 
                 
                 
                     
                 
                 
                   ATTGATAAAAGCAGCGATACCCTGGCCATTGTTCCGTATATTGGTCCGCTGCTGAATATTGGTAATGA 
                 
                 
                     
                 
                 
                   TATTCGTCATGGCGATTTTGTGGGTGCAATTGAACTGGCAGGCATTACCGCACTGCTGGAATATGTTC 
                 
                 
                     
                 
                 
                   CGGAATTTACCATTCCGATTCTGGTTGGTCTGGAAGTTATTGGTGGCGAACTGGCACGTGAACAGGTT 
                 
                 
                     
                 
                 
                   GAAGCAATTGTTAATAATGCCCTGGATAAACGCGATCAGAAATGGGCAGAAGTTTACAATATTACCAA 
                 
                 
                     
                 
                 
                   AGCACAGTGGTGGGGCACCATTCATTTACAGATTAATACCCGTCTGGCCCATACCTATAAAGCCCTGA 
                 
                 
                     
                 
                 
                   GCCGTCAGGCAAATGCCATTAAAATGAATATGGAATTTCAGCTGGCCAACTACAAAGGCAACATTGAT 
                 
                 
                     
                 
                 
                   GATAAAGCCAAGATCAAAAACGCCATCAGCGAAACCGAAATTCTGCTGAACAAAAGCGTTGAACAGGC 
                 
                 
                     
                 
                 
                   CATGAAAAACACCGAGAAATTCATGATTAAACTGAGCAACAGCTACCTGACCAAAGAAATGATTCCGA 
                 
                 
                     
                 
                 
                   AAGTTCAGGACAACCTGAAAAACTTTGATCTGGAAACCAAAAAGACCCTGGACAAGTTCATCAAAGAG 
                 
                 
                     
                 
                 
                   AAAGAAGATATCCTGGGCACCAATCTGAGCAGCAGCCTGCGTCGTAAAGTTAGCATTCGTCTGAATAA 
                 
                 
                     
                 
                 
                   AAACATTGCCTTCGACATCAACGATATCCCGTTTAGCGAATTTGATGATCTGATCAACCAGTACAAAA 
                 
                 
                     
                 
                 
                   ACGAGATCGAAGATTATGAAGTGCTGAATCTGGGTGCAGAAGATGGCAAAATCAAAGATCTGAGCGGT 
                 
                 
                     
                 
                 
                   ACAACCAGCGATATTAACATTGGTAGCGATATCGAAATCCTGAACAACATTATTCTGAACCTGCGCTA 
                 
                 
                     
                 
                 
                   TAAAGATAACAACCTGATTGATCTGAGTGGCTATGGTGCAAAAGTTGAAGTTTATGATGGTGTGGAAC 
                 
                 
                     
                 
                 
                   TGAACGACAAAAACCAGTTCAAACTGACCAGCAGCGCAAATTCAAAAATTCGCGTTACCCAGAACCAG 
                 
                 
                     
                 
                 
                   AACATCATTTTTAACAGCGTGTTTCTGGATTTCAGCGTGAGCTTTTGGATTCGTATTCCGAAATATAA 
                 
                 
                     
                 
                 
                   GAACGACGGCATCCAGAACTATATCCACAATGAATATACCATCATCAACTGCATGAAGAATAACAGCG 
                 
                 
                     
                 
                 
                   GTTGGAAAATTAGCATCCGTGGCAATCGTATTATTTGGACCCTGATCGATATTAATGGCAAAACCAAG 
                 
                 
                     
                 
                 
                   AGCGTGTTTTTCGAGTATAACATCCGTGAAGATATCAGCGAATACATCAACCGTTGGTTTTTTGTGAC 
                 
                 
                     
                 
                 
                   CATTACCAACAATCTGAACAACGCCAAAATCTACATTAACGGCAAACTGGAAAGCAACACCGATATCA 
                 
                 
                     
                 
                 
                   AAGATATTCGTGAAGTGATTGCCAACGGCGAGATTATCTTTAAACTGGATGGTGATATTGATCGCACC 
                 
                 
                     
                 
                 
                   CAGTTTATTTGGATGAAATACTTCAGCATCTTCAACACCGAACTGAGCCAGAGCAATATTGAAGAACG 
                 
                 
                     
                 
                 
                   CTATAAAATCCAGAGCTACAGCGAGTATCTGAAAGACTTTTGGGGTAATCCGCTGATGTACAACAAAG 
                 
                 
                     
                 
                 
                   AATACTACATGTTTAATGCCGGTAACAAAAACAGCTATATCAAACTGAAAAAGGATAGTCCGGTGGGT 
                 
                 
                     
                 
                 
                   GAAATTCTGACCCGTAGCAAATATAACCAGAATAGCAAGTATATCAACTATCGCGATCTGTACATCGG 
                 
                 
                     
                 
                 
                   CGAGAAATTTATCATTCGTCGTAAAAGCAACTCCCAGAGCATTAACGATGATATTGTGCGCAAAGAGG 
                 
                 
                     
                 
                 
                   ATTACATCTACCTGGATTTTTTCAACCTGAATCAAGAGTGGCGTGTGTACACCTATAAGTACTTCAAA 
                 
                 
                     
                 
                 
                   AAAGAAGAAATGAAACTGTTTCTGGCACCGATCTATGATAGCGACGAATTTTACAATACCATTCAGAT 
                 
                 
                     
                 
                 
                   TAAAGAATATGATGAACAGCCGACCTATAGCTGTCAGCTGCTGTTTAAAAAGGATGAAGAAAGCACGG 
                 
                 
                     
                 
                 
                   ATGAAATTGGCCTGATTGGTATCCATCGTTTTTATGAAAGCGGCATCGTGTTCGAAGAGTACAAAGAT 
                 
                 
                     
                 
                 
                   TATTTCTGCATCAGCAAATGGTATCTTAAAGAGGTGAAACGCAAACCGTATAATCTGAAACTGGGTTG 
                 
                 
                     
                 
                 
                   CAATTGGCAGTTCATCCCGAAAGATGAAGGTTGGACCGAACATCATCACCACCATCACCATCATCATC 
                 
                 
                     
                 
                 
                   ACTGA 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/XB [LH N X-H C B] with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 9 
                     
                 
                 
                   MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNTNDLNIPSE 
                     
                 
                 
                     
                 
                 
                   PIMEADAIYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIPLPLVSNGALTLSDNET 
                 
                 
                     
                 
                 
                   IAYQENNNIVSNLQANLVIYGPGPDIANNATYGLYSTPISNGEGTLSEVSFSPFYLKPFDESYGNYRS 
                 
                 
                     
                 
                 
                   LVNIVNKFVKREFAPDPASTLMHELVHVTHNLYGISNRNFYYNFDTGKIETSRQQNSLIFEELLTFGG 
                 
                 
                     
                 
                 
                   IDSKAISSLIIKKIIETAKNNYTTLISERLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLN 
                 
                 
                     
                 
                 
                   TILFVLNESNLAQRFSILVRKHYLKERPIDPIYVNILDDNSYSTLEGFNISSQGSNDFQGQLLESSYF 
                 
                 
                     
                 
                 
                   EKIESNALRAFIKICHKAIDGRSLYNKTLDCIEVENKDLFLISNKDSLNDINLSEEKIKPETTVFFKD 
                 
                 
                     
                 
                 
                   KLPPQDITLSNYDFTEANSIPSISQQNILERNEELYEPIRNSLFEIKTIYVDKLTTFHFLEAQNIDES 
                 
                 
                     
                 
                 
                   IDSSKIRVELTDSVDEALSNPNKVYSPFKNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDV 
                 
                 
                     
                 
                 
                   IDKSSDTLAIVPYIGPLLNIGNDIRHGDFVGAIELAGITALLEYVPEFTIPILVGLEVIGGELAREQV 
                 
                 
                     
                 
                 
                   EAIVNNALDKRDQKWAEVYNITKAQWWGTIHLQINTRLAHTYKALSRQANAIKMNMEFQLANYKGNID 
                 
                 
                     
                 
                 
                   DKAKIKNAISETEILLNKSVEQAMKNTEKFMIKLSNSYLTKEMIPKVQDNLKNFDLETKKTLDKFIKE 
                 
                 
                     
                 
                 
                   KEDILGTNLSSSLRRKVSIRLNKNIAFDINDIPFSEFDDLINQYKNEIEDYEVLNLGAEDGKIKDLSG 
                 
                 
                     
                 
                 
                   TTSDINIGSDIEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQ 
                 
                 
                     
                 
                 
                   NIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTK 
                 
                 
                     
                 
                 
                   SVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRT 
                 
                 
                     
                 
                 
                   QFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVG 
                 
                 
                     
                 
                 
                   EILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFK 
                 
                 
                     
                 
                 
                   KEEMKLFLAPIYDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKD 
                 
                 
                     
                 
                 
                   YFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTEHHHHHHHHHH 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT/E with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 10 
                     
                 
                 
                   atgccgaaaatcaactctttcaactacaacgacccggttaacgaccgtaccatcctgtatatcaaacc 
                     
                 
                 
                     
                 
                 
                   gggtggttgccaggagttctacaaatctttcaacatcatgaaaaacatctggatcatcccggaacgta 
                 
                 
                     
                 
                 
                   acgttatcggtaccaccccgcaggacttccacccgccgacctctctgaaaaacggtgactcttcttac 
                 
                 
                     
                 
                 
                   tacgacccgaactacctccagtctgacgaagaaaaagaccgtttcctgaaaatcgttaccaaaatctt 
                 
                 
                     
                 
                 
                   caaccgtatcaacaacaacctgtctggtggtatcctgctggaagaactgtctaaagctaacccgtacc 
                 
                 
                     
                 
                 
                   tgggtaacgacaacaccccggacaaccagttccacatcggtgacgcttctgctgttgaaatcaaattc 
                 
                 
                     
                 
                 
                   tctaacggttctcaggacatcctgctgccgaacgttatcatcatgggtgctgaaccggacctgttcga 
                 
                 
                     
                 
                 
                   aaccaactcttctaacatctctctgcgtaacaactacatgccgtctaaccacggtttcggttctatcg 
                 
                 
                     
                 
                 
                   ctatcgttaccttctctccggaatactctttccgtttcaacgacaacagcatgaacgagttcatccag 
                 
                 
                     
                 
                 
                   gacccggctctgaccctgatgcaccaactgatctattctctgcacggtctgtacggtgctaaaggtat 
                 
                 
                     
                 
                 
                   caccaccaaatacaccatcacccagaaacagaacccgctgatcaccaacatccgtggtaccaacatcg 
                 
                 
                     
                 
                 
                   aagagttcctgaccttcggtggtaccgacctgaacatcatcacctctgctcagtctaacgacatctac 
                 
                 
                     
                 
                 
                   accaacctgctggctgactacaaaaaaatcgcttctaaactgtctaaagttcaggtttctaacccgct 
                 
                 
                     
                 
                 
                   gctgaacccgtacaaagacgttttcgaagctaaatacggtctggacaaagacgcttctggtatctact 
                 
                 
                     
                 
                 
                   ctgttaacatcaacaaattcaacgacatcttcaaaaaactgtactctttcaccgagttcgacctggcg 
                 
                 
                     
                 
                 
                   accaaattccaggttaaatgccgtcagacctacatcggtcagtacaaatacttcaaactgtctaacct 
                 
                 
                     
                 
                 
                   gctgaacgactctatctacaacatctctgaaggttacaacatcaacaacctgaaagttaacttccgtg 
                 
                 
                     
                 
                 
                   gtcagaacgctaacctgaacccgcgtatcatcaccccgatcaccggtcgtggtctggttaaaaaaatc 
                 
                 
                     
                 
                 
                   atccgtttcTGCCACAAAGCGATTGATGGCCGCTCTCTCTATAACAAAACGCTGGATTGCatcgaaat 
                 
                 
                     
                 
                 
                   caacaacggtgaactgttcttcgttgcttctgaaaactcttacaacgacgacaacatcaacaccccga 
                 
                 
                     
                 
                 
                   aagaaatcgacgacaccgttacctctaacaacaactacgaaaacgacctggaccaggttatcctgaac 
                 
                 
                     
                 
                 
                   ttcaactctgaatctgctccgggtctgtctgacgaaaaactgaacctgaccatccagaacgacgctta 
                 
                 
                     
                 
                 
                   catcccgaaatacgactctaacggtacctctgacatcgaacagcacgacgttaacgaactgaacgttt 
                 
                 
                     
                 
                 
                   tcttctacctggacgctcagaaagttccggaaggtgaaaacaacgttaacctgacctcttctatcgac 
                 
                 
                     
                 
                 
                   accgctctgctggaacagccgaaaatctacaccttcttctcttctgagttcatcaacaacgttaacaa 
                 
                 
                     
                 
                 
                   accggttcaggctgctctgttcgtttcttggattcagcaggttctggttgacttcaccaccgaagcta 
                 
                 
                     
                 
                 
                   accagaaatctaccgttgacaaaatcgctgacatctctatcgttgttccgtacatcggtctggctctg 
                 
                 
                     
                 
                 
                   aacatcggtaacgaagctcagaaaggtaacttcaaagacgctctggaactgctgggtgctggtatcct 
                 
                 
                     
                 
                 
                   gctggagttcgaaccggaactgctgatcccgaccatcctggttttcaccatcaaatctttcctgggtt 
                 
                 
                     
                 
                 
                   cttctgacaacaaaaacaaagttatcaaagctatcaacaacgctctgaaagaacgtgacgaaaaatgg 
                 
                 
                     
                 
                 
                   aaagaagtttactctttcatcgtttctaactggatgaccaaaatcaacacccagttcaacaaacgtaa 
                 
                 
                     
                 
                 
                   agaacagatgtaccaggctctccagaaccaggttaacgctatcaaaaccatcatcgaatctaaataca 
                 
                 
                     
                 
                 
                   actcttacaccctggaagaaaaaaacgaactgaccaacaaatacgacatcaaacagatcgaaaacgaa 
                 
                 
                     
                 
                 
                   ctgaaccagaaagtttctatcgctatgaacaacatcgaccgtttcctgaccgaatcttctatctctta 
                 
                 
                     
                 
                 
                   cctgatgaaactcatcaacgaagttaaaatcaacaaactgcgtgaatacgacgaaaacgttaaaacct 
                 
                 
                     
                 
                 
                   acctgctgaactacatcatccagcacggttctatcctgggtgaatctcagcaggaactgaactctatg 
                 
                 
                     
                 
                 
                   gttaccgacaccctgaacaactctatcccgttcaaactgtcttcttacaccgacgacaaaatcctGAT 
                 
                 
                     
                 
                 
                   CTCTTACTTCAACAAATTCTTTAAAcgcATTAAGAGTTCATCGGTTctgaatATGCGGTACAAAAATG 
                 
                 
                     
                 
                 
                   ATAAAtatGTCGATACTTCTGGATATgatAGCAATATCAACATTAACGGCGACGTGTATAAATATccg 
                 
                 
                     
                 
                 
                   ACAAATAAAAACCAGTTTGGGATATATAACGACAAGctgTCGGAGGTCAATattTCTCAAAACGACta 
                 
                 
                     
                 
                 
                   tATCattTACGATAATaaaTATAAAAACTTTAGCATTAGTtttTGGGTTcgtATACCTAATtatGACA 
                 
                 
                     
                 
                 
                   ATaaaattGTAAATGTGAATAACGAGTATACCATTATAAACTGTATGcgcGACAATAACAGTGGTTGG 
                 
                 
                     
                 
                 
                   AAGGTATCGctgAACCATAATGAGATTATCTGGACCctgcagGATAATgcaGGTATAAACCAGAAACT 
                 
                 
                     
                 
                 
                   GGCTTTTAACTATGGAAACGCAAATGGGATCTCAGATTACATTaataaaTGGatttttGTTaccATTA 
                 
                 
                     
                 
                 
                   CGAACGATcgcTTAGGCGACTCAAAACTTTATATTAATggcAATctgATAGATCAGAAATCAATCTTA 
                 
                 
                     
                 
                 
                   AATTTGGGCAATATTCATGTCTCTgatAACATCTTGTTCAAGATCGTTAATTGCAGTTACACTcgtTA 
                 
                 
                     
                 
                 
                   TATTGGCATTCGTTACTTTAATATCTTCgataaaGAActgGACGAGACGGAAATCcagACTCTGTATT 
                 
                 
                     
                 
                 
                   CAAACGAGCCCAATACTAATATATTGAAAGATTTTTGGGGTAACTATCTTTTATATGATAAAGAATAC 
                 
                 
                     
                 
                 
                   TATCTCCTGaatGTATTGAAGCCAAACAATTTCATAGATAGACGCAAGGATAGCACATTAAGTATCAA 
                 
                 
                     
                 
                 
                   CAATATCAGATCTACTATActgttaGCAAATCGCCTcTACTCCggtATTAAAGTGAAGATTcagCGGG 
                 
                 
                     
                 
                 
                   TTAATAACTCCAGTACCAATGATAATCTGGTCCGTAAGAACGATCAGGTATACATCaatTTCGTCGCG 
                 
                 
                     
                 
                 
                   AGCAAAACTcatCTCTTCCCGCTTTACGCCgatACAGCTACGACAAACAAGGAAAAAACCATAAAAAT 
                 
                 
                     
                 
                 
                   TTCCAGCTCCGGAAACAGATTCAATCAAGTAGTTGTAATGAACTCTGTGGGTaatAATTGTACGATGA 
                 
                 
                     
                 
                 
                   ACTTTaagAATAACAATGGGAACAATattGGACTTTTGGGCTTcAAAGCCGACACAGTGGTGGCGTCC 
                 
                 
                     
                 
                 
                   ACCTGGTATTACACGcacATGcggGACCATACGAATTCGAACGGTTGCTTCTGGAACTTTATCTCGGA 
                 
                 
                     
                 
                 
                   AgaaCACGGGTGGCAAGAAAAA 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/E with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 11 
                     
                 
                 
                   MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGTTPQDFHPPTSLKNGDSSY 
                     
                 
                 
                     
                 
                 
                   YDPNYLQSDEEKDRFLKIVTKIFNRINNNLSGGILLEELSKANPYLGNDNTPDNQFHIGDASAVEIKF 
                 
                 
                     
                 
                 
                   SNGSQDILLPNVIIMGAEPDLFETNSSNISLRNNYMPSNHGFGSIAIVTFSPEYSFRFNDNSMNEFIQ 
                 
                 
                     
                 
                 
                   DPALTLMHQLIYSLHGLYGAKGITTKYTITQKQNPLITNIRGTNIEEFLTFGGTDLNIITSAQSNDIY 
                 
                 
                     
                 
                 
                   TNLLADYKKIASKLSKVQVSNPLLNPYKDVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLA 
                 
                 
                     
                 
                 
                   TKFQVKCRQTYIGQYKYFKLSNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPITGRGLVKKI 
                 
                 
                     
                 
                 
                   IRF CHKAIDGRSLYNKTLDC IEINNGELFFVASENSYNDDNINTPKEIDDTVTSNNNYENDLDQVILN 
                 
                 
                     
                 
                 
                   FNSESAPGLSDEKLNLTIQNDAYIPKYDSNGTSDIEQHDVNELNVFFYLDAQKVPEGENNVNLTSSID 
                 
                 
                     
                 
                 
                   TALLEQPKIYTFFSSEFINNVNKPVQAALFVSWIQQVLVDFTTEANQKSTVDKIADISIVVPYIGLAL 
                 
                 
                     
                 
                 
                   NIGNEAQKGNFKDALELLGAGILLEFEPELLIPTILVFTIKSFLGSSDNKNKVIKAINNALKERDEKW 
                 
                 
                     
                 
                 
                   KEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNAIKTIIESKYNSYTLEEKNELTNKYDIKQIENE 
                 
                 
                     
                 
                 
                   LNQKVSIAMNNIDRFLTESSISYLMKLINEVKINKLREYDENVKTYLLNYIIQHGSILGESQQELNSM 
                 
                 
                     
                 
                 
                   VTDTLNNSIPFKLSSYTDDKILISYFNKFFKRIKSSSVLNMRYKNDKYVDTSGYDSNININGDVYKYP 
                 
                 
                     
                 
                 
                   TNKNQFGIYNDKLSEVNISQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNNSGW 
                 
                 
                     
                 
                 
                   KVSLNHNEIIWTLQDNAGINQKLAFNYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDQKSIL 
                 
                 
                     
                 
                 
                   NLGNIHVSDNILFKIVNCSYTRYIGIRYFNIFDKELDETEIQTLYSNEPNTNILKDFWGNYLLYDKEY 
                 
                 
                     
                 
                 
                   YLLNVLKPNNFIDRRKDSTLSINNIRSTILLANRLYSGIKVKIQRVNNSSTNDNLVRKNDQVYINFVA 
                 
                 
                     
                 
                 
                   SKTHLFPLYADTATTNKEKTIKISSSGNRFNQVVVMNSVGNNCTMNFKNNNGNNIGLLGFKADTVVAS 
                 
                 
                     
                 
                 
                   TWYYTHMRDHTNSNGCFWNFISEEHGWQEK. 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT/A1C1 with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 12 
                     
                 
                 
                   ATGCCATTCGTCAACAAGCAATTCAACTACAAAGACCCAGTCAACGGCGTCGACATCGCATACATCAA 
                     
                 
                 
                     
                 
                 
                   GATTCCGAACGCCGGTCAAATGCAGCCGGTTAAGGCTTTTAAGATCCACAACAAGATTTGGGTTATCC 
                 
                 
                     
                 
                 
                   CGGAGCGTGACACCTTCACGAACCCGGAAGAAGGCGATCTGAACCCGCCACCGGAAGCGAAGCAAGTC 
                 
                 
                     
                 
                 
                   CCTGTCAGCTACTACGATTCGACGTACCTGAGCACGGATAACGAAAAAGATAACTACCTGAAAGGTGT 
                 
                 
                     
                 
                 
                   GACCAAGCTGTTCGAACGTATCTACAGCACGGATCTGGGTCGCATGCTGCTGACTAGCATTGTTCGCG 
                 
                 
                     
                 
                 
                   GTATCCCGTTCTGGGGTGGTAGCACGATTGACACCGAACTGAAGGTTATCGACACTAACTGCATTAAC 
                 
                 
                     
                 
                 
                   GTTATTCAACCGGATGGTAGCTATCGTAGCGAAGAGCTGAATCTGGTCATCATTGGCCCGAGCGCAGA 
                 
                 
                     
                 
                 
                   CATTATCCAATTCGAGTGCAAGAGCTTTGGTCACGAGGTTCTGAATCTGACCCGCAATGGCTATGGTA 
                 
                 
                     
                 
                 
                   GCACCCAGTACATTCGTTTTTCGCCGGATTTTACCTTCGGCTTTGAAGAGAGCCTGGAGGTTGATACC 
                 
                 
                     
                 
                 
                   AATCCGTTGCTGGGTGCGGGCAAATTCGCTACCGATCCGGCTGTCACGCTGGCCCATgAACTGATCcA 
                 
                 
                     
                 
                 
                   CGCAGGCCACCGCCTGTACGGCATTGCCATCAACCCAAACCGTGTGTTCAAGGTTAATACGAATGCAT 
                 
                 
                     
                 
                 
                   ACTACGAGATGAGCGGCCTGGAAGTCAGCTTCGAAGAACTGCGCACCTTCGGTGGCCATGACGCTAAA 
                 
                 
                     
                 
                 
                   TTCATTGACAGCTTGCAAGAGAATGAGTTCCGTCTGTACTACTATAACAAATTCAAAGACATTGCAAG 
                 
                 
                     
                 
                 
                   CACGTTGAACAAGGCCAAAAGCATCGTTGGTACTACCGCGTCGTTGCAGTATATGAAGAATGTGTTTA 
                 
                 
                     
                 
                 
                   AAGAGAAGTACCTGCTGTCCGAGGATACCTCCGGCAAGTTTAGCGTTGATAAGCTGAAGTTTGACAAA 
                 
                 
                     
                 
                 
                   CTGTACAAGATGCTGACCGAGATTTACACCGAGGACAACTTTGTGAAATTCTTCAAAGTGTTGAATCG 
                 
                 
                     
                 
                 
                   TAAAACCTATCTGAATTTTGACAAAGCGGTTTTCAAGATTAACATCGTGCCGAAGGTGAACTACACCA 
                 
                 
                     
                 
                 
                   TCTATGACGGTTTTAACCTGCGTAACACCAACCTGGCGGCGAACTTTAACGGTCAGAATACGGAAATC 
                 
                 
                     
                 
                 
                   AACAACATGAATTTCACGAAGTTGAAGAACTTCACGGGTCTGTTCGAGTTCTATAAGCTGCTGTGCCA 
                 
                 
                     
                 
                 
                   CAAAGCGATTGATGGCCGCTCTCTCTATAACAAAACGCTGGATTGCATTAAGGTAAACAATTGGGATC 
                 
                 
                     
                 
                 
                   TGTTCTTTTCGCCATCCGAAGATAATTTTACCAACGACCTGAACAAGGGTGAAGAAATCACCAGCGAT 
                 
                 
                     
                 
                 
                   ACGAATATTGAAGCAGCGGAAGAGAATATCAGCCTGGATCTGATCCAGCAGTACTATCTGACCTTTAA 
                 
                 
                     
                 
                 
                   CTTCGACAATGAACCGGAGAACATTAGCATTGAGAATCTGAGCAGCGACATTATCGGTCAGCTGGAAC 
                 
                 
                     
                 
                 
                   TGATGCCGAATATCGAACGTTTCCCGAACGGCAAAAAGTACGAGCTGGACAAGTACACTATGTTCCAT 
                 
                 
                     
                 
                 
                   TACCTGCGTGCACAGGAGTTTGAACACGGTAAAAGCCGTATCGCGCTGACCAACAGCGTTAACGAGGC 
                 
                 
                     
                 
                 
                   CCTGCTGAACCCGAGCCGTGTCTATACCTTCTTCAGCAGCGACTATGTTAAGAAAGTGAACAAAGCCA 
                 
                 
                     
                 
                 
                   CTGAGGCCGCGATGTTCCTGGGCTGGGTGGAACAGCTGGTATATGACTTCACGGACGAGACGAGCGAA 
                 
                 
                     
                 
                 
                   GTGAGCACTACCGACAAAATTGCTGATATTACCATCATTATCCCGTATATTGGTCCGGCACTGAACAT 
                 
                 
                     
                 
                 
                   TGGCAACATGCTGTACAAAGACGATTTTGTGGGTGCCCTGATCTTCTCCGGTGCCGTGATTCTGCTGG 
                 
                 
                     
                 
                 
                   AGTTCATTCCGGAGATTGCGATCCCGGTGTTGGGTACCTTCGCGCTGGTGTCCTACATCGCGAATAAG 
                 
                 
                     
                 
                 
                   GTTCTGACGGTTCAGACCATCGATAACGCGCTGTCGAAACGTAATGAAAAATGGGACGAGGTTTACAA 
                 
                 
                     
                 
                 
                   ATACATTGTTACGAATTGGCTGGCGAAAGTCAATACCCAGATCGACCTGATCCGTAAGAAAATGAAAG 
                 
                 
                     
                 
                 
                   AGGCGCTGGAGAATCAGGCGGAGGCCACCAAAGCAATTATCAACTACCAATACAACCAGTACACGGAA 
                 
                 
                     
                 
                 
                   GAAGAGAAGAATAACATTAACTTCAATATCGATGATTTGAGCAGCAAGCTGAATGAATCTATCAACAA 
                 
                 
                     
                 
                 
                   AGCGATGATCAATATCAACAAGTTTTTGAATCAGTGTAGCGTTTCGTACCTGATGAATAGCATGATTC 
                 
                 
                     
                 
                 
                   CGTATGGCGTCAAACGTCTGGAGGACTTCGACGCCAGCCTGAAAGATGCGTTGCTGAAATACATTTAC 
                 
                 
                     
                 
                 
                   GACAATCGTGGTACGCTGATTGGCCAAGTTGACCGCTTGAAAGACAAAGTTAACAATACCCTGAGCAC 
                 
                 
                     
                 
                 
                   CGACATCCCATTTCAACTGAGCAAGTATGTTGATAATCAACGTCTGTTGAGCACTTTCACCGAGTATA 
                 
                 
                     
                 
                 
                   TCAAAAACATTAATGACAGCAAAATTCTGAGCCTGCAGAATCGTAAGAATACGCTGGTAGATACCAGT 
                 
                 
                     
                 
                 
                   GGATATAATGCGGAAGTCTCAGAAGAGGGTGATGTACAGCTGAACCCGATCTTTCCGTTCGACTTTAA 
                 
                 
                     
                 
                 
                   ACTGGGGTCTAGTGGTGAAGATCGCGGTAAAGTGATCGTTACCCAAAACGAGAACATTGTGTATAACA 
                 
                 
                     
                 
                 
                   GCATGTACGAGAGTTTCTCAATTTCTTTCTGGATTCGCATCAATAAATGGGTTTCTAATTTGCCTGGC 
                 
                 
                     
                 
                 
                   TATACCATCATTGATAGCGTCAAAAACAACTCGGGCTGGTCGATTGGCATTATTAGCAACTTTCTGGT 
                 
                 
                     
                 
                 
                   GTTTACCCTGAAACAGAATGAGGATTCGGAACAGAGCATTAACTTCTCCTACGACATCAGCAACAATG 
                 
                 
                     
                 
                 
                   CACCAGGGTATAACAAATGGTTCTTCGTAACGGTGACGAACAATATGATGGGCAATATGAAAATCTAC 
                 
                 
                     
                 
                 
                   ATTAACGGGAAACTTATCGACACCATTAAAGTGAAAGAGCTTACTGGGATCAATTTTAGTAAAACCAT 
                 
                 
                     
                 
                 
                   TACCTTTGAGATCAACAAAATTCCGGACACGGGTCTGATTACCTCCGATTCGGATAATATCAATATGT 
                 
                 
                     
                 
                 
                   GGATTCGCGACTTTTATATCTTCGCCAAAGAACTTGATGGCAAAGATATCAACATTTTGTTTAATTCC 
                 
                 
                     
                 
                 
                   CTGCAGTATACCAATGTCGTTAAGGACTATTGGGGCAATGATCTCCGCTACAATAAAGAATACTACAT 
                 
                 
                     
                 
                 
                   GGTTAACATCGACTATCTCAATCGCTACATGTATGCTAACTCGCGTCAAATTGTGTTTAACACACGTC 
                 
                 
                     
                 
                 
                   GTAACAACAACGATTTTAACGAAGGTTATAAAATCATTATCAAACGGATCCGCGGCAATACGAACGAT 
                 
                 
                     
                 
                 
                   ACTCGTGTTCGTGGCGGTGACATTCTGTATTTCGACATGACGATTAATAATAAAGCGTACAATCTGTT 
                 
                 
                     
                 
                 
                   CATGAAGAACGAAACCATGTACGCCGATAACCATTCCACTGAAGATATCTACGCAATCGGACTTCGCG 
                 
                 
                     
                 
                 
                   AACAGACCAAAGACATTAACGACAACATCATCTTTCAGATTCAACCGATGAATAATACCTACTACTAT 
                 
                 
                     
                 
                 
                   GCCTCCCAGATCTTCAAAAGTAATTTCAACGGCGAAAACATTTCAGGCATTTGCTCAATCGGCACTTA 
                 
                 
                     
                 
                 
                   TCGGTTCCGGTTAGGTGGTGATTGGTATCGTCACAACTACCTTGTTCCCACAGTGAAACAAGGCAACT 
                 
                 
                     
                 
                 
                   ATGCATCGCTCTTAGAAAGCACATCTACGCATTGGGGTTTTGTGCCAGTCAGTGAATAA 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/A1C1 with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 13 
                     
                 
                 
                   MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQV 
                     
                 
                 
                     
                 
                 
                   PVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCIN 
                 
                 
                     
                 
                 
                   VIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDT 
                 
                 
                     
                 
                 
                   NPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAK 
                 
                 
                     
                 
                 
                   FIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDK 
                 
                 
                     
                 
                 
                   LYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEI 
                 
                 
                     
                 
                 
                   NNMNFTKLKNFTGLFEFYKLL CHKAIDGRSLYNKTLDC IKVNNWDLFFSPSEDNFTNDLNKGEEITSD 
                 
                 
                     
                 
                 
                   TNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFH 
                 
                 
                     
                 
                 
                   YLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSE 
                 
                 
                     
                 
                 
                   VSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANK 
                 
                 
                     
                 
                 
                   VLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTE 
                 
                 
                     
                 
                 
                   EEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIY 
                 
                 
                     
                 
                 
                   DNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNINDSKILSLQNRKNTLVDTS 
                 
                 
                     
                 
                 
                   GYNAEVSEEGDVQLNPIFPFDFKLGSSGEDRGKVIVTQNENIVYNSMYESFSISFWIRINKWVSNLPG 
                 
                 
                     
                 
                 
                   YTIIDSVKNNSGWSIGIISNFLVFTLKQNEDSEQSINFSYDISNNAPGYNKWFFVTVTNNMMGNMKIY 
                 
                 
                     
                 
                 
                   INGKLIDTIKVKELTGINFSKTITFEINKIPDTGLITSDSDNINMWIRDFYIFAKELDGKDINILFNS 
                 
                 
                     
                 
                 
                   LQYTNVVKDYWGNDLRYNKEYYMVNIDYLNRYMYANSRQIVFNTRRNNNDFNEGYKIIIKRIRGNTND 
                 
                 
                     
                 
                 
                   TRVRGGDILYFDMTINNKAYNLFMKNETMYADNHSTEDIYAIGLREQTKDINDNIIFQIQPMNNTYYY 
                 
                 
                     
                 
                 
                   ASQIFKSNFNGENISGICSIGTYRFRLGGDWYRHNYLVPTVKQGNYASLLESTSTHWGFVPVSE 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT/C1(0) (Endonedative)) 
                 
                 
                   SEQ ID NO: 14 
                     
                 
                 
                   ATGCCGATCACGATTAATAATTTCAACTATAGCGATCCGGTGGACAATAAGAATATTCTGTATCTGGA 
                     
                 
                 
                     
                 
                 
                   TACTCATCTGAATACGCTGGCTAACGAACCGGAGAAAGCGTTCCGCATCACAGGCAACATCTGGGTTA 
                 
                 
                     
                 
                 
                   TTCCCGATCGCTTTTCACGCAACAGCAACCCTAATCTGAACAAACCTCCTCGTGTCACCAGTCCTAAA 
                 
                 
                     
                 
                 
                   TCCGGTTATTACGACCCAAACTATCTGAGTACGGATAGCGATAAAGATCCCTTTCTGAAAGAGATCAT 
                 
                 
                     
                 
                 
                   TAAGCTGTTCAAACGCATTAACTCTCGCGAAATTGGGGAAGAGCTGATCTATCGGCTTTCGACAGATA 
                 
                 
                     
                 
                 
                   TCCCGTTCCCAGGTAACAATAATACCCCGATTAATACTTTCGACTTTGATGTTGATTTCAATTCTGTG 
                 
                 
                     
                 
                 
                   GATGTGAAAACGCGTCAAGGCAATAATTGGGTGAAAACTGGTAGCATTAACCCGAGTGTAATTATCAC 
                 
                 
                     
                 
                 
                   AGGTCCCCGTGAGAACATCATCGACCCGGAAACCTCTACCTTCAAGCTGACGAACAACACGTTTGCTG 
                 
                 
                     
                 
                 
                   CACAGGAAGGGTTTGGTGCCCTGTCAATCATTTCCATCTCACCGCGTTTCATGTTAACCTACTCCAAT 
                 
                 
                     
                 
                 
                   GCCACAAATGATGTTGGCGAAGGACGTTTTAGCAAATCAGAATTTTGCATGGACCCAATTCTCATTCT 
                 
                 
                     
                 
                 
                   GATGggCacGCTGAACaATGCGATGCACAACTTGTATGGCATTGCTATTCCAAACGATCAAACCATTA 
                 
                 
                     
                 
                 
                   GCTCCGTTACCAGTAATATCTTCTATAGCCAGTATAATGTCAAATTGGAGTATGCCGAAATTTACGCC 
                 
                 
                     
                 
                 
                   TTTGGAGGCCCGACCATTGACCTGATTCCGAAATCTGCACGCAAATACTTCGAAGAAAAGGCGTTAGA 
                 
                 
                     
                 
                 
                   TTACTATCGCAGCATCGCGAAACGCCTGAACTCGATTACCACGGCCAATCCGTCGTCGTTCAACAAAT 
                 
                 
                     
                 
                 
                   ACATTGGTGAATATAAACAGAAACTGATTCGCAAATATCGGTTTGTCGTAGAAAGCTCTGGTGAAGTG 
                 
                 
                     
                 
                 
                   ACTGTAAACCGCAACAAATTTGTCGAACTCTACAACGAGTTGACCCAAATCTTTACCGAGTTTAACTA 
                 
                 
                     
                 
                 
                   CGCAAAGATCTATAACGTACAGAACCGCAAGATTTATCTTAGCAATGTATACACACCGGTTACTGCGA 
                 
                 
                     
                 
                 
                   ACATCTTAGACGACAATGTGTATGATATTCAGAATGGCTTTAACATCCCGAAATCAAATCTGAACGTT 
                 
                 
                     
                 
                 
                   CTGTTTATGGGCCAGAACCTGAGTCGTAATCCAGCACTGCGTAAAGTGAACCCGGAAAATATGCTCTA 
                 
                 
                     
                 
                 
                   CTTGTTTACCAAATTTTGCCACAAAGCGATTGATGGCCGCTCTCTCTATAACAAAACGCTGGATTGTC 
                 
                 
                     
                 
                 
                   GTGAGTTACTTGTGAAGAACACTGATTTACCGTTCATTGGGGATATCTCCGACGTGAAAACCGATATC 
                 
                 
                     
                 
                 
                   TTCCTGCGCAAAGACATTAATGAAGAAACGGAAGTCATCTATTACCCCGACAATGTGAGCGTTGATCA 
                 
                 
                     
                 
                 
                   GGTCATTTTATCGAAGAACACCTCCGAACATGGTCAGTTGGATTTGCTGTACCCTAGCATTGACTCGG 
                 
                 
                     
                 
                 
                   AGAGTGAAATCCTTCCGGGCGAAAATCAAGTGTTTTACGACAACCGTACCCAAAATGTTGATTATTTG 
                 
                 
                     
                 
                 
                   AATTCTTATTACTACCTGGAATCTCAGAAATTGAGCGACAATGTGGAAGATTTCACGTTCACACGCTC 
                 
                 
                     
                 
                 
                   CATTGAGGAAGCGCTGGATAATAGCGCGAAAGTGTATACGTATTTCCCTACCTTGGCGAATAAAGTAA 
                 
                 
                     
                 
                 
                   ATGCTGGTGTCCAGGGAGGCTTATTTCTGATGTGGGCGAATGATGTGGTAGAAGATTTTACGACCAAT 
                 
                 
                     
                 
                 
                   ATTTTGCGTAAGGACACCTTAGATAAAATTAGCGATGTTAGCGCCATCATCCCCTATATTGGCCCAGC 
                 
                 
                     
                 
                 
                   ACTGAATATCTCGAACTCTGTGCGTCGCGGAAACTTCACCGAAGCATTTGCGGTGACCGGGGTTACTA 
                 
                 
                     
                 
                 
                   TTCTGTTGGAAGCCTTTCCGGAGTTTACTATTCCGGCGCTGGGTGCGTTTGTGATTTATTCGAAAGTA 
                 
                 
                     
                 
                 
                   CAAGAACGCAATGAAATTATCAAAACCATCGATAATTGCCTGGAACAACGCATTAAACGCTGGAAGGA 
                 
                 
                     
                 
                 
                   TTCTTATGAATGGATGATGGGCACCTGGTTATCCCGTATTATCACACAGTTTAACAACATCTCGTATC 
                 
                 
                     
                 
                 
                   AGATGTACGATTCACTGAACTACCAAGCAGGGGCGATCAAAGCCAAGATCGACTTAGAATACAAGAAA 
                 
                 
                     
                 
                 
                   TATTCAGGTAGCGATAAAGAGAATATTAAAAGCCAGGTTGAAAACCTGAAGAACTCTCTGGATGTCAA 
                 
                 
                     
                 
                 
                   AATTTCAGAGGCTATGAACAACATTAACAAATTTATCCGCGAATGTAGCGTCACGTATCTGTTTAAAA 
                 
                 
                     
                 
                 
                   ACATGCTCCCGAAAGTGATTGATGAGCTCAACGAGTTTGATCGCAACACAAAGGCCAAACTGATTAAC 
                 
                 
                     
                 
                 
                   CTGATTGATAGTCACAATATTATTTTAGTCGGTGAAGTTGACAAGCTGAAGGCTAAGGTCAATAACAG 
                 
                 
                     
                 
                 
                   CTTTCAGAACACTATTCCGTTTAATATTTTCTCCTATACGAACAATAGTCTGCTGAAAGACATTATCA 
                 
                 
                     
                 
                 
                   ACGAATACTTCAACAATATTAATGACAGCAAAATTCTGAGCCTGCAGAATCGTAAGAATACGCTGGTA 
                 
                 
                     
                 
                 
                   GATACCAGTGGATATAATGCGGAAGTCTCAGAAGAGGGTGATGTACAGCTGAACCCGATCTTTCCGTT 
                 
                 
                     
                 
                 
                   CGACTTTAAACTGGGGTCTAGTGGTGAAGATCGCGGTAAAGTGATCGTTACCCAAAACGAGAACATTG 
                 
                 
                     
                 
                 
                   TGTATAACAGCATGTACGAGAGTTTCTCAATTTCTTTCTGGATTCGCATCAATAAATGGGTTTCTAAT 
                 
                 
                     
                 
                 
                   TTGCCTGGCTATACCATCATTGATAGCGTCAAAAACAACTCGGGCTGGTCGATTGGCATTATTAGCAA 
                 
                 
                     
                 
                 
                   CTTTCTGGTGTTTACCCTGAAACAGAATGAGGATTCGGAACAGAGCATTAACTTCTCCTACGACATCA 
                 
                 
                     
                 
                 
                   GCAACAATGCACCAGGGTATAACAAATGGTTCTTCGTAACGGTGACGAACAATATGATGGGCAATATG 
                 
                 
                     
                 
                 
                   AAAATCTACATTAACGGGAAACTTATCGACACCATTAAAGTGAAAGAGCTTACTGGGATCAATTTTAG 
                 
                 
                     
                 
                 
                   TAAAACCATTACCTTTGAGATCAACAAAATTCCGGACACGGGTCTGATTACCTCCGATTCGGATAATA 
                 
                 
                     
                 
                 
                   TCAATATGTGGATTCGCGACTTTTATATCTTCGCCAAAGAACTTGATGGCAAAGATATCAACATTTTG 
                 
                 
                     
                 
                 
                   TTTAATTCCCTGCAGTATACCAATGTCGTTAAGGACTATTGGGGCAATGATCTCCGCTACAATAAAGA 
                 
                 
                     
                 
                 
                   ATACTACATGGTTAACATCGACTATCTCAATCGCTACATGTATGCTAACTCGCGTCAAATTGTGTTTA 
                 
                 
                     
                 
                 
                   ACACACGTCGTAACAACAACGATTTTAACGAAGGTTATAAAATCATTATCAAACGGATCCGCGGCAAT 
                 
                 
                     
                 
                 
                   ACGAACGATACTCGTGTTCGTGGCGGTGACATTCTGTATTTCGACATGACGATTAATAATAAAGCGTA 
                 
                 
                     
                 
                 
                   CAATCTGTTCATGAAGAACGAAACCATGTACGCCGATAACCATTCCACTGAAGATATCTACGCAATCG 
                 
                 
                     
                 
                 
                   GACTTCGCGAACAGACCAAAGACATTAACGACAACATCATCTTTCAGATTCAACCGATGAATAATACC 
                 
                 
                     
                 
                 
                   TACTACTATGCCTCCCAGATCTTCAAAAGTAATTTCAACGGCGAAAACATTTCAGGCATTTGCTCAAT 
                 
                 
                     
                 
                 
                   CGGCACTTATCGGTTCCGGTTAGGTGGTGATTGGTATCGTCACAACTACCTTGTTCCCACAGTGAAAC 
                 
                 
                     
                 
                 
                   AAGGCAACTATGCATCGCTCTTAGAAAGCACATCTACGCATTGGGGTTTTGTGCCAGTCAGTGAAtaa 
                 
                 
                     
                 
                 
                   tg 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/C1(0) (Endoneqative)) 
                 
                 
                   SEQ ID NO: 15 
                     
                 
                 
                   MPITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPK 
                     
                 
                 
                     
                 
                 
                   SGYYDPNYLSTDSDKDPFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSV 
                 
                 
                     
                 
                 
                   DVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSN 
                 
                 
                     
                 
                 
                   ATNDVGEGRFSKSEFCMDPILILMGTLNNAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYA 
                 
                 
                     
                 
                 
                   FGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEV 
                 
                 
                     
                 
                 
                   TVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNV 
                 
                 
                     
                 
                 
                   LFMGQNLSRNPALRKVNPENMLYLFTKFCHKAIDGRSLYNKTLDCRELLVKNTDLPFIGDISDVKTDI 
                 
                 
                     
                 
                 
                   FLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYL 
                 
                 
                     
                 
                 
                   NSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTN 
                 
                 
                     
                 
                 
                   ILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKV 
                 
                 
                     
                 
                 
                   QERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKK 
                 
                 
                     
                 
                 
                   YSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLIN 
                 
                 
                     
                 
                 
                   LIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNNINDSKILSLQNRKNTLV 
                 
                 
                     
                 
                 
                   DTSGYNAEVSEEGDVQLNPIFPFDFKLGSSGEDRGKVIVTQNENIVYNSMYESFSISFWIRINKWVSN 
                 
                 
                     
                 
                 
                   LPGYTIIDSVKNNSGWSIGIISNFLVFTLKQNEDSEQSINFSYDISNNAPGYNKWFFVTVTNNMMGNM 
                 
                 
                     
                 
                 
                   KIYINGKLIDTIKVKELTGINFSKTITFEINKIPDTGLITSDSDNINMWIRDFYIFAKELDGKDINIL 
                 
                 
                     
                 
                 
                   FNSLQYTNVVKDYWGNDLRYNKEYYMVNIDYLNRYMYANSRQIVFNTRRNNNDFNEGYKIIIKRIRGN 
                 
                 
                     
                 
                 
                   TNDTRVRGGDILYFDMTINNKAYNLFMKNETMYADNHSTEDIYAIGLREQTKDINDNIIFQIQPMNNT 
                 
                 
                     
                 
                 
                   YYYASQIFKSNFNGENISGICSIGTYRFRLGGDWYRHNYLVPTVKQGNYASLLESTSTHWGFVPVSE 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT/C1) 
                 
                 
                   SEQ ID NO: 16 
                     
                 
                 
                   ATGCCGATCACGATTAATAATTTCAACTATAGCGATCCGGTGGACAATAAGAATATTCTGTATCTGGA 
                     
                 
                 
                     
                 
                 
                   TACTCATCTGAATACGCTGGCTAACGAACCGGAGAAAGCGTTCCGCATCACAGGCAACATCTGGGTTA 
                 
                 
                     
                 
                 
                   TTCCCGATCGCTTTTCACGCAACAGCAACCCTAATCTGAACAAACCTCCTCGTGTCACCAGTCCTAAA 
                 
                 
                     
                 
                 
                   TCCGGTTATTACGACCCAAACTATCTGAGTACGGATAGCGATAAAGATCCCTTTCTGAAAGAGATCAT 
                 
                 
                     
                 
                 
                   TAAGCTGTTCAAACGCATTAACTCTCGCGAAATTGGGGAAGAGCTGATCTATCGGCTTTCGACAGATA 
                 
                 
                     
                 
                 
                   TCCCGTTCCCAGGTAACAATAATACCCCGATTAATACTTTCGACTTTGATGTTGATTTCAATTCTGTG 
                 
                 
                     
                 
                 
                   GATGTGAAAACGCGTCAAGGCAATAATTGGGTGAAAACTGGTAGCATTAACCCGAGTGTAATTATCAC 
                 
                 
                     
                 
                 
                   AGGTCCCCGTGAGAACATCATCGACCCGGAAACCTCTACCTTCAAGCTGACGAACAACACGTTTGCTG 
                 
                 
                     
                 
                 
                   CACAGGAAGGGTTTGGTGCCCTGTCAATCATTTCCATCTCACCGCGTTTCATGTTAACCTACTCCAAT 
                 
                 
                     
                 
                 
                   GCCACAAATGATGTTGGCGAAGGACGTTTTAGCAAATCAGAATTTTGCATGGACCCAATTCTCATTCT 
                 
                 
                     
                 
                 
                   GATGCACGAGCTGAACCATGCGATGCACAACTTGTATGGCATTGCTATTCCAAACGATCAAACCATTA 
                 
                 
                     
                 
                 
                   GCTCCGTTACCAGTAATATCTTCTATAGCCAGTATAATGTCAAATTGGAGTATGCCGAAATTTACGCC 
                 
                 
                     
                 
                 
                   TTTGGAGGCCCGACCATTGACCTGATTCCGAAATCTGCACGCAAATACTTCGAAGAAAAGGCGTTAGA 
                 
                 
                     
                 
                 
                   TTACTATCGCAGCATCGCGAAACGCCTGAACTCGATTACCACGGCCAATCCGTCGTCGTTCAACAAAT 
                 
                 
                     
                 
                 
                   ACATTGGTGAATATAAACAGAAACTGATTCGCAAATATCGGTTTGTCGTAGAAAGCTCTGGTGAAGTG 
                 
                 
                     
                 
                 
                   ACTGTAAACCGCAACAAATTTGTCGAACTCTACAACGAGTTGACCCAAATCTTTACCGAGTTTAACTA 
                 
                 
                     
                 
                 
                   CGCAAAGATCTATAACGTACAGAACCGCAAGATTTATCTTAGCAATGTATACACACCGGTTACTGCGA 
                 
                 
                     
                 
                 
                   ACATCTTAGACGACAATGTGTATGATATTCAGAATGGCTTTAACATCCCGAAATCAAATCTGAACGTT 
                 
                 
                     
                 
                 
                   CTGTTTATGGGCCAGAACCTGAGTCGTAATCCAGCACTGCGTAAAGTGAACCCGGAAAATATGCTCTA 
                 
                 
                     
                 
                 
                   CTTGTTTACCAAATTTTGCCACAAAGCGATTGATGGCCGCTCTCTCTATAACAAAACGCTGGATTGTC 
                 
                 
                     
                 
                 
                   GTGAGTTACTTGTGAAGAACACTGATTTACCGTTCATTGGGGATATCTCCGACGTGAAAACCGATATC 
                 
                 
                     
                 
                 
                   TTCCTGCGCAAAGACATTAATGAAGAAACGGAAGTCATCTATTACCCCGACAATGTGAGCGTTGATCA 
                 
                 
                     
                 
                 
                   GGTCATTTTATCGAAGAACACCTCCGAACATGGTCAGTTGGATTTGCTGTACCCTAGCATTGACTCGG 
                 
                 
                     
                 
                 
                   AGAGTGAAATCCTTCCGGGCGAAAATCAAGTGTTTTACGACAACCGTACCCAAAATGTTGATTATTTG 
                 
                 
                     
                 
                 
                   AATTCTTATTACTACCTGGAATCTCAGAAATTGAGCGACAATGTGGAAGATTTCACGTTCACACGCTC 
                 
                 
                     
                 
                 
                   CATTGAGGAAGCGCTGGATAATAGCGCGAAAGTGTATACGTATTTCCCTACCTTGGCGAATAAAGTAA 
                 
                 
                     
                 
                 
                   ATGCTGGTGTCCAGGGAGGCTTATTTCTGATGTGGGCGAATGATGTGGTAGAAGATTTTACGACCAAT 
                 
                 
                     
                 
                 
                   ATTTTGCGTAAGGACACCTTAGATAAAATTAGCGATGTTAGCGCCATCATCCCCTATATTGGCCCAGC 
                 
                 
                     
                 
                 
                   ACTGAATATCTCGAACTCTGTGCGTCGCGGAAACTTCACCGAAGCATTTGCGGTGACCGGGGTTACTA 
                 
                 
                     
                 
                 
                   TTCTGTTGGAAGCCTTTCCGGAGTTTACTATTCCGGCGCTGGGTGCGTTTGTGATTTATTCGAAAGTA 
                 
                 
                     
                 
                 
                   CAAGAACGCAATGAAATTATCAAAACCATCGATAATTGCCTGGAACAACGCATTAAACGCTGGAAGGA 
                 
                 
                     
                 
                 
                   TTCTTATGAATGGATGATGGGCACCTGGTTATCCCGTATTATCACACAGTTTAACAACATCTCGTATC 
                 
                 
                     
                 
                 
                   AGATGTACGATTCACTGAACTACCAAGCAGGGGCGATCAAAGCCAAGATCGACTTAGAATACAAGAAA 
                 
                 
                     
                 
                 
                   TATTCAGGTAGCGATAAAGAGAATATTAAAAGCCAGGTTGAAAACCTGAAGAACTCTCTGGATGTCAA 
                 
                 
                     
                 
                 
                   AATTTCAGAGGCTATGAACAACATTAACAAATTTATCCGCGAATGTAGCGTCACGTATCTGTTTAAAA 
                 
                 
                     
                 
                 
                   ACATGCTCCCGAAAGTGATTGATGAGCTCAACGAGTTTGATCGCAACACAAAGGCCAAACTGATTAAC 
                 
                 
                     
                 
                 
                   CTGATTGATAGTCACAATATTATTTTAGTCGGTGAAGTTGACAAGCTGAAGGCTAAGGTCAATAACAG 
                 
                 
                     
                 
                 
                   CTTTCAGAACACTATTCCGTTTAATATTTTCTCCTATACGAACAATAGTCTGCTGAAAGACATTATCA 
                 
                 
                     
                 
                 
                   ACGAATACTTCAACAATATTAATGACAGCAAAATTCTGAGCCTGCAGAATCGTAAGAATACGCTGGTA 
                 
                 
                     
                 
                 
                   GATACCAGTGGATATAATGCGGAAGTCTCAGAAGAGGGTGATGTACAGCTGAACCCGATCTTTCCGTT 
                 
                 
                     
                 
                 
                   CGACTTTAAACTGGGGTCTAGTGGTGAAGATCGCGGTAAAGTGATCGTTACCCAAAACGAGAACATTG 
                 
                 
                     
                 
                 
                   TGTATAACAGCATGTACGAGAGTTTCTCAATTTCTTTCTGGATTCGCATCAATAAATGGGTTTCTAAT 
                 
                 
                     
                 
                 
                   TTGCCTGGCTATACCATCATTGATAGCGTCAAAAACAACTCGGGCTGGTCGATTGGCATTATTAGCAA 
                 
                 
                     
                 
                 
                   CTTTCTGGTGTTTACCCTGAAACAGAATGAGGATTCGGAACAGAGCATTAACTTCTCCTACGACATCA 
                 
                 
                     
                 
                 
                   GCAACAATGCACCAGGGTATAACAAATGGTTCTTCGTAACGGTGACGAACAATATGATGGGCAATATG 
                 
                 
                     
                 
                 
                   AAAATCTACATTAACGGGAAACTTATCGACACCATTAAAGTGAAAGAGCTTACTGGGATCAATTTTAG 
                 
                 
                     
                 
                 
                   TAAAACCATTACCTTTGAGATCAACAAAATTCCGGACACGGGTCTGATTACCTCCGATTCGGATAATA 
                 
                 
                     
                 
                 
                   TCAATATGTGGATTCGCGACTTTTATATCTTCGCCAAAGAACTTGATGGCAAAGATATCAACATTTTG 
                 
                 
                     
                 
                 
                   TTTAATTCCCTGCAGTATACCAATGTCGTTAAGGACTATTGGGGCAATGATCTCCGCTACAATAAAGA 
                 
                 
                     
                 
                 
                   ATACTACATGGTTAACATCGACTATCTCAATCGCTACATGTATGCTAACTCGCGTCAAATTGTGTTTA 
                 
                 
                     
                 
                 
                   ACACACGTCGTAACAACAACGATTTTAACGAAGGTTATAAAATCATTATCAAACGGATCCGCGGCAAT 
                 
                 
                     
                 
                 
                   ACGAACGATACTCGTGTTCGTGGCGGTGACATTCTGTATTTCGACATGACGATTAATAATAAAGCGTA 
                 
                 
                     
                 
                 
                   CAATCTGTTCATGAAGAACGAAACCATGTACGCCGATAACCATTCCACTGAAGATATCTACGCAATCG 
                 
                 
                     
                 
                 
                   GACTTCGCGAACAGACCAAAGACATTAACGACAACATCATCTTTCAGATTCAACCGATGAATAATACC 
                 
                 
                     
                 
                 
                   TACTACTATGCCTCCCAGATCTTCAAAAGTAATTTCAACGGCGAAAACATTTCAGGCATTTGCTCAAT 
                 
                 
                     
                 
                 
                   CGGCACTTATCGGTTCCGGTTAGGTGGTGATTGGTATCGTCACAACTACCTTGTTCCCACAGTGAAAC 
                 
                 
                     
                 
                 
                   AAGGCAACTATGCATCGCTCTTAGAAAGCACATCTACGCATTGGGGTTTTGTGCCAGTCAGTGAAtaa 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/C1) 
                 
                 
                   SEQ ID NO: 17 
                     
                 
                 
                   MPITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPK 
                     
                 
                 
                     
                 
                 
                   SGYYDPNYLSTDSDKDPFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSV 
                 
                 
                     
                 
                 
                   DVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSN 
                 
                 
                     
                 
                 
                   ATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYA 
                 
                 
                     
                 
                 
                   FGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEV 
                 
                 
                     
                 
                 
                   TVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNV 
                 
                 
                     
                 
                 
                   LFMGQNLSRNPALRKVNPENMLYLFTKFCHKAIDGRSLYNKTLDCRELLVKNTDLPFIGDISDVKTDI 
                 
                 
                     
                 
                 
                   FLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYL 
                 
                 
                     
                 
                 
                   NSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTN 
                 
                 
                     
                 
                 
                   ILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKV 
                 
                 
                     
                 
                 
                   QERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKK 
                 
                 
                     
                 
                 
                   YSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLIN 
                 
                 
                     
                 
                 
                   LIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNNINDSKILSLQNRKNTLV 
                 
                 
                     
                 
                 
                   DTSGYNAEVSEEGDVQLNPIFPFDFKLGSSGEDRGKVIVTQNENIVYNSMYESFSISFWIRINKWVSN 
                 
                 
                     
                 
                 
                   LPGYTIIDSVKNNSGWSIGIISNFLVFTLKQNEDSEQSINFSYDISNNAPGYNKWFFVTVTNNMMGNM 
                 
                 
                     
                 
                 
                   KIYINGKLIDTIKVKELTGINFSKTITFEINKIPDTGLITSDSDNINMWIRDFYIFAKELDGKDINIL 
                 
                 
                     
                 
                 
                   FNSLQYTNVVKDYWGNDLRYNKEYYMVNIDYLNRYMYANSRQIVFNTRRNNNDFNEGYKIIIKRIRGN 
                 
                 
                     
                 
                 
                   TNDTRVRGGDILYFDMTINNKAYNLFMKNETMYADNHSTEDIYAIGLREQTKDINDNIIFQIQPMNNT 
                 
                 
                     
                 
                 
                   YYYASQIFKSNFNGENISGICSIGTYRFRLGGDWYRHNYLVPTVKQGNYASLLESTSTHWGFVPVSE 
                 
                 
                     
                 
                 
                   (Enterokinase and Factor Xa Cleavage Site) 
                 
                 
                   SEQ ID NO: 18 
                     
                 
                 
                   IDGR 
                     
                 
                 
                     
                 
                 
                   (Enterokinase and Factor Xa Cleavage Site Variant) 
                 
                 
                   SEQ ID NO: 19 
                     
                 
                 
                   IEGR 
                     
                 
                 
                     
                 
                 
                   (BoNT/X Activation Loop) 
                 
                 
                   SEQ ID NO: 20 
                     
                 
                 
                   CPRNGLLYNAIYRNSKNYLNNIDLEDKKTTSKTNVSYPCSLLNGC 
                     
                 
                 
                     
                 
                 
                   (BoNT/A1 &amp; A6 Activation Loop) 
                 
                 
                   SEQ ID NO: 21 
                     
                 
                 
                   CVRGIITSKTKSLDKGYNKALNDLC 
                     
                 
                 
                     
                 
                 
                   (BoNT/B2, B3 &amp; B6 Activation Loop) 
                 
                 
                   SEQ ID NO: 22 
                     
                 
                 
                   CKSVRAPGIC 
                     
                 
                 
                     
                 
                 
                   (BoNT/D Activation Loop) 
                 
                 
                   SEQ ID NO: 23 
                     
                 
                 
                   CLRLTKNSRDDSTC 
                     
                 
                 
                     
                 
                 
                   (BoNT/E1 to E5, E9 &amp; E12 Activation Loop) 
                 
                 
                   SEQ ID NO: 24 
                     
                 
                 
                   CKNIVSVKGIRKSIC 
                     
                 
                 
                     
                 
                 
                   (BoNT/F1 and F6 Activation Loop) 
                 
                 
                   SEQ ID NO: 25 
                     
                 
                 
                   CKSVIPRKGTKAPPRLC 
                     
                 
                 
                     
                 
                 
                   (BoNT/F2 and F3 Activation Loop) 
                 
                 
                   SEQ ID NO: 26 
                     
                 
                 
                   CKSIIPRKGTKQSPSLC 
                     
                 
                 
                     
                 
                 
                   (BoNT/F4 Activation Loop) 
                 
                 
                   SEQ ID NO: 27 
                     
                 
                 
                   CKSIIPRKGTKAPPRLC 
                     
                 
                 
                     
                 
                 
                   (BoNT/F5 Activation Loop) 
                 
                 
                   SEQ ID NO: 28 
                     
                 
                 
                   CLNSSFKKNTKKPLC 
                     
                 
                 
                     
                 
                 
                   (BoNT/F7 Activation Loop) 
                 
                 
                   SEQ ID NO: 29 
                     
                 
                 
                   CKSIVSKKGTKNSLC 
                     
                 
                 
                     
                 
                 
                   (TeNT Activation Loop) 
                 
                 
                   SEQ ID NO: 30 
                     
                 
                 
                   CKKIIPPTNIRENLYNRTASLTDLGGELC 
                     
                 
                 
                     
                 
                 
                   (BoNT/G Activation Loop) 
                 
                 
                   SEQ ID NO: 31 
                     
                 
                 
                   CKPVMYKNTGKSEQC 
                     
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of Wild-Type BoNT/X-10HT) 
                 
                 
                   SEQ ID NO: 32 
                     
                 
                 
                   ATGAAACTGGAAATCAACAAATTCAACTACAACGATCCGATCGATGGCATTAATGTTATTACCATGCGTCCGCCT 
                     
                 
                 
                     
                 
                 
                   CGTCATAGCGATAAAATCAATAAAGGTAAAGGTCCGTTCAAAGCCTTTCAGGTGATTAAAAACATTTGGATTGTG 
                 
                 
                     
                 
                 
                   CCGGAACGCTACAACTTTACCAATAATACCAACGATCTGAACATTCCGAGCGAACCGATTATGGAAGCAGATGCC 
                 
                 
                     
                 
                 
                   ATTTATAACCCGAACTATCTGAATACCCCGAGCGAAAAAGATGAATTTCTGCAGGGTGTTATCAAAGTGCTGGAA 
                 
                 
                     
                 
                 
                   CGCATTAAAAGCAAACCGGAAGGTGAAAAACTGCTGGAACTGATTAGCAGCAGCATTCCGCTGCCGCTGGTTAGC 
                 
                 
                     
                 
                 
                   AATGGTGCACTGACCCTGAGCGATAATGAAACCATTGCATATCAAGAGAACAACAACATTGTGAGCAATCTGCAG 
                 
                 
                     
                 
                 
                   GCAAACCTGGTTATTTATGGTCCGGGTCCTGATATTGCAAATAATGCAACCTATGGTCTGTATAGCACCCCGATT 
                 
                 
                     
                 
                 
                   AGTAATGGTGAAGGTACACTGAGCGAAGTTAGCTTTAGCCCGTTTTATCTGAAACCGTTTGATGAAAGCTATGGC 
                 
                 
                     
                 
                 
                   AATTATCGTAGCCTGGTGAATATCGTGAACAAATTCGTGAAACGTGAATTTGCACCTGATCCGGCAAGCACCCTG 
                 
                 
                     
                 
                 
                   ATGCATGAACTGGTTCATGTTACCCATAATCTGTATGGTATTAGCAACCGCAACTTCTACTATAACTTTGACACC 
                 
                 
                     
                 
                 
                   GGCAAAATTGAAACCAGCCGTCAGCAGAATAGCCTGATTTTTGAAGAACTGCTGACCTTTGGTGGCATTGATAGC 
                 
                 
                     
                 
                 
                   AAAGCAATTAGCAGCCTGATCATCAAGAAAATTATCGAAACCGCCAAGAACAACTATACCACGCTGATTAGCGAA 
                 
                 
                     
                 
                 
                   CGCCTGAATACCGTTACCGTTGAAAATGATCTGCTGAAATATATCAAAAACAAAATCCCGGTTCAGGGTCGTCTG 
                 
                 
                     
                 
                 
                   GGTAACTTTAAACTGGATACCGCAGAATTCGAGAAAAAGCTGAATACCATTCTGTTTGTGCTGAACGAAAGCAAT 
                 
                 
                     
                 
                 
                   CTGGCACAGCGTTTTAGCATTCTGGTTCGTAAACATTACCTGAAAGAACGTCCGATTGATCCGATTTATGTGAAC 
                 
                 
                     
                 
                 
                   ATTCTGGATGACAATAGCTACAGCACCCTGGAAGGTTTTAACATTAGCAGTCAGGGTAGCAATGATTTCCAAGGT 
                 
                 
                     
                 
                 
                   CAGCTGCTGGAAAGCAGCTATTTTGAAAAAATTGAAAGCAATGCCCTGCGTGCCTTCATTAAAATCTGTCCGCGT 
                 
                 
                     
                 
                 
                   AATGGTCTGCTGTATAATGCCATTTATCGCAACAGCAAAAACTACCTGAACAACATTGATCTGGAAGATAAAAAG 
                 
                 
                     
                 
                 
                   ACCACGAGCAAAACCAATGTTAGCTATCCGTGTAGCCTGCTGAATGGTTGTATTGAAGTTGAAAACAAAGACCTG 
                 
                 
                     
                 
                 
                   TTCCTGATTAGCAACAAAGATAGCCTGAACGATATTAACCTGAGCGAAGAAAAAATCAAACCGGAAACCACCGTG 
                 
                 
                     
                 
                 
                   TTCTTCAAAGATAAACTGCCTCCGCAGGATATTACGCTGAGCAATTATGATTTTACCGAAGCCAATAGCATTCCG 
                 
                 
                     
                 
                 
                   AGCATTAGCCAGCAGAACATTCTGGAACGTAATGAAGAACTGTATGAACCGATTCGCAATAGCCTGTTTGAAATC 
                 
                 
                     
                 
                 
                   AAAACCATCTATGTGGATAAGCTGACCACCTTTCATTTTCTGGAAGCCCAGAATATTGATGAGAGCATTGATAGC 
                 
                 
                     
                 
                 
                   AGCAAAATTCGTGTTGAACTGACCGATAGCGTTGATGAAGCACTGAGCAATCCGAATAAAGTTTATAGCCCGTTC 
                 
                 
                     
                 
                 
                   AAGAACATGAGCAACACCATTAATAGCATTGAAACCGGTATTACCAGCACCTACATCTTTTATCAGTGGCTGCGT 
                 
                 
                     
                 
                 
                   AGCATCGTGAAAGATTTTAGTGATGAAACCGGCAAAATCGACGTGATTGATAAAAGCAGCGATACCCTGGCAATT 
                 
                 
                     
                 
                 
                   GTTCCGTATATTGGTCCGCTGCTGAATATTGGTAATGATATTCGTCATGGCGATTTTGTGGGTGCAATTGAACTG 
                 
                 
                     
                 
                 
                   GCAGGCATTACCGCACTGCTGGAATATGTTCCGGAATTTACCATTCCGATTCTGGTTGGTCTGGAAGTTATTGGT 
                 
                 
                     
                 
                 
                   GGCGAACTGGCACGTGAACAGGTTGAAGCAATTGTTAATAATGCCCTGGATAAACGCGATCAGAAATGGGCAGAA 
                 
                 
                     
                 
                 
                   GTTTACAATATTACCAAAGCACAGTGGTGGGGCACCATTCATTTACAGATTAATACCCGTCTGGCCCATACCTAT 
                 
                 
                     
                 
                 
                   AAAGCCCTGAGCCGTCAGGCAAATGCCATTAAAATGAATATGGAATTTCAGCTGGCCAACTACAAAGGCAACATC 
                 
                 
                     
                 
                 
                   GATGATAAAGCCAAAATCAAAAACGCCATCAGCGAAACCGAAATCCTGCTGAACAAAAGCGTTGAACAGGCAATG 
                 
                 
                     
                 
                 
                   AAAAACACCGAGAAATTCATGATCAAACTGAGCAACAGCTATCTGACCAAAGAAATGATTCCGAAAGTGCAGGAT 
                 
                 
                     
                 
                 
                   AACCTGAAAAATTTCGATCTGGAAACCAAGAAAACCCTGGACAAATTTATCAAAGAGAAAGAGGACATTCTGGGC 
                 
                 
                     
                 
                 
                   ACCAATCTGAGCAGCAGCCTGCGTCGTAAAGTTAGCATTCGTCTGAATAAAAACATTGCCTTCGACATCAACGAT 
                 
                 
                     
                 
                 
                   ATCCCGTTTAGCGAATTTGATGATCTGATCAACCAGTACAAAAACGAGATCGAAGATTATGAAGTGCTGAATCTG 
                 
                 
                     
                 
                 
                   GGTGCAGAAGATGGGAAAATCAAAGATCTGAGCGGTACAACCAGCGATATCAATATTGGTTCAGATATCGAACTG 
                 
                 
                     
                 
                 
                   GCCGATGGTCGTGAAAATAAAGCCATTAAGATTAAAGGCAGCGAGAACAGCACCATCAAAATTGCAATGAACAAA 
                 
                 
                     
                 
                 
                   TATCTGCGTTTTAGCGCGACCGATAACTTTAGCATTAGCTTTTGGATCAAACATCCGAAACCGACCAATCTGCTT 
                 
                 
                     
                 
                 
                   AATAACGGTATTGAATATACCCTGGTCGAGAACTTTAATCAGCGTGGTTGGAAAATTAGCATCCAGGATAGCAAA 
                 
                 
                     
                 
                 
                   CTGATTTGGTATCTGCGCGATCACAATAACAGCATCAAAATCGTTACACCGGATTATATTGCGTTTAATGGCTGG 
                 
                 
                     
                 
                 
                   AACCTGATTACCATTACAAACAATCGTAGCAAAGGCAGCATTGTGTATGTGAACGGTAGCAAAATTGAAGAGAAG 
                 
                 
                     
                 
                 
                   GATATTAGCAGCATCTGGAATACCGAAGTGGATGATCCGATTATCTTTCGCCTGAAAAACAATCGCGATACCCAG 
                 
                 
                     
                 
                 
                   GCGTTTACCCTGCTGGATCAGTTTAGCATTTATCGGAAAGAACTGAACCAGAACGAAGTGGTGAAACTGTATAAC 
                 
                 
                     
                 
                 
                   TACTACTTCAACAGCAACTACATTCGCGATATTTGGGGTAATCCGCTGCAGTACAACAAAAAATACTATCTGCAG 
                 
                 
                     
                 
                 
                   ACCCAGGACAAACCTGGTAAAGGTCTGATCCGCGAATATTGGAGCAGCTTTGGTTATGATTATGTGATTCTGAGC 
                 
                 
                     
                 
                 
                   GATAGCAAGACGATTACCTTTCCGAATAATATCCGTTATGGTGCCCTGTATAACGGCAGCAAAGTTCTGATCAAA 
                 
                 
                     
                 
                 
                   AATAGCAAAAAACTGGATGGTCTGGTGCGCAATAAAGATTTCATTCAGCTGGAAATCGATGGCTATAATATGGGT 
                 
                 
                     
                 
                 
                   ATTAGCGCAGATCGCTTTAACGAGGATACCAACTATATTGGCACCACCTATGGTACAACCCATGATCTGACCACC 
                 
                 
                     
                 
                 
                   GATTTTGAAATTATTCAGCGCCAAGAGAAATACCGCAATTATTGTCAGCTGAAAACCCCGTATAACATCTTTCAT 
                 
                 
                     
                 
                 
                   AAAAGCGGTCTGATGAGCACCGAAACCAGCAAACCGACCTTTCATGATTATCGTGACTGGGTTTATAGCAGCGCA 
                 
                 
                     
                 
                 
                   TGGTATTTTCAGAACTATGAAAATCTGAACCTGCGCAAACATACCAAAACCAACTGGTATTTTATCCCGAAAGAT 
                 
                 
                     
                 
                 
                   GAAGGTTGGGATGAAGATCTTGAAGTTCTGTTTCAGGGTCCGCATCATCACCACCATCACCATCATCATCAC 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT/X) 
                 
                 
                   SEQ ID NO: 33 
                     
                 
                 
                   MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNT 
                     
                 
                 
                     
                 
                 
                   NDLNIPSEPIMEADAIYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIP 
                 
                 
                     
                 
                 
                   LPLVSNGALTLSDNETIAYQENNNIVSNLQANLVIYGPGPDIANNATYGLYSTPISNGEG 
                 
                 
                     
                 
                 
                   TLSEVSFSPFYLKPFDESYGNYRSLVNIVNKFVKREFAPDPASTLMHELVHVTHNLYGIS 
                 
                 
                     
                 
                 
                   NRNFYYNFDTGKIETSRQQNSLIFEELLTFGGIDSKAISSLIIKKIIETAKNNYTTLISE 
                 
                 
                     
                 
                 
                   RLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLNTILFVLNESNLAQRFSILVR 
                 
                 
                     
                 
                 
                   KHYLKERPIDPIYVNILDDNSYSTLEGFNISSQGSNDFQGQLLESSYFEKIESNALRAFI 
                 
                 
                     
                 
                 
                   KICPRNGLLYNAIYRNSKNYLNNIDLEDKKTTSKTNVSYPCSLLNGCIEVENKDLFLISN 
                 
                 
                     
                 
                 
                   KDSLNDINLSEEKIKPETTVFFKDKLPPQDITLSNYDFTEANSIPSISQQNILERNEELY 
                 
                 
                     
                 
                 
                   EPIRNSLFEIKTIYVDKLTTFHFLEAQNIDESIDSSKIRVELTDSVDEALSNPNKVYSPF 
                 
                 
                     
                 
                 
                   KNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDVIDKSSDTLAIVPYIGPLLNI 
                 
                 
                     
                 
                 
                   GNDIRHGDFVGAIELAGITALLEYVPEFTIPILVGLEVIGGELAREQVEAIVNNALDKRD 
                 
                 
                     
                 
                 
                   QKWAEVYNITKAQWWGTIHLQINTRLAHTYKALSRQANAIKMNMEFQLANYKGNIDDKAK 
                 
                 
                     
                 
                 
                   IKNAISETEILLNKSVEQAMKNTEKFMIKLSNSYLTKEMIPKVQDNLKNFDLETKKTLDK 
                 
                 
                     
                 
                 
                   FIKEKEDILGTNLSSSLRRKVSIRLNKNIAFDINDIPFSEFDDLINQYKNEIEDYEVLNL 
                 
                 
                     
                 
                 
                   GAEDGKIKDLSGTTSDINIGSDIELADGRENKAIKIKGSENSTIKIAMNKYLRFSATDNF 
                 
                 
                     
                 
                 
                   SISFWIKHPKPTNLLNNGIEYTLVENFNQRGWKISIQDSKLIWYLRDHNNSIKIVTPDYI 
                 
                 
                     
                 
                 
                   AFNGWNLITITNNRSKGSIVYVNGSKIEEKDISSIWNTEVDDPIIFRLKNNRDTQAFTLL 
                 
                 
                     
                 
                 
                   DQFSIYRKELNQNEVVKLYNYYFNSNYIRDIWGNPLQYNKKYYLQTQDKPGKGLIREYWS 
                 
                 
                     
                 
                 
                   SFGYDYVILSDSKTITFPNNIRYGALYNGSKVLIKNSKKLDGLVRNKDFIQLEIDGYNMG 
                 
                 
                     
                 
                 
                   ISADRFNEDTNYIGTTYGTTHDLTTDFEIIQRQEKYRNYCQLKTPYNIFHKSGLMSTETS 
                 
                 
                     
                 
                 
                   KPTFHDYRDWVYSSAWYFQNYENLNLRKHTKTNWYFIPKDEGWDED 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of Wild-Type BoNT/X-10HT) 
                 
                 
                   SEQ ID NO: 34 
                     
                 
                 
                   MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNTNDLNIPSEPIMEADA 
                     
                 
                 
                     
                 
                 
                   IYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIPLPLVSNGALTLSDNETIAYQENNNIVSNLQ 
                 
                 
                     
                 
                 
                   ANLVIYGPGPDIANNATYGLYSTPISNGEGTLSEVSFSPFYLKPFDESYGNYRSLVNIVNKFVKREFAPDPASTL 
                 
                 
                     
                 
                 
                   MHELVHVTHNLYGISNRNFYYNFDTGKIETSRQQNSLIFEELLTFGGIDSKAISSLIIKKIIETAKNNYTTLISE 
                 
                 
                     
                 
                 
                   RLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLNTILFVLNESNLAQRFSILVRKHYLKERPIDPIYVN 
                 
                 
                     
                 
                 
                   ILDDNSYSTLEGFNISSQGSNDFQGQLLESSYFEKIESNALRAFIKICPRNGLLYNAIYRNSKNYLNNIDLEDKK 
                 
                 
                     
                 
                 
                   TTSKTNVSYPCSLLNGCIEVENKDLFLISNKDSLNDINLSEEKIKPETTVFFKDKLPPQDITLSNYDFTEANSIP 
                 
                 
                     
                 
                 
                   SISQQNILERNEELYEPIRNSLFEIKTIYVDKLTTFHFLEAQNIDESIDSSKIRVELTDSVDEALSNPNKVYSPF 
                 
                 
                     
                 
                 
                   KNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDVIDKSSDTLAIVPYIGPLLNIGNDIRHGDFVGAIEL 
                 
                 
                     
                 
                 
                   AGITALLEYVPEFTIPILVGLEVIGGELAREQVEAIVNNALDKRDQKWAEVYNITKAQWWGTIHLQINTRLAHTY 
                 
                 
                     
                 
                 
                   KALSRQANAIKMNMEFQLANYKGNIDDKAKIKNAISETEILLNKSVEQAMKNTEKFMIKLSNSYLTKEMIPKVQD 
                 
                 
                     
                 
                 
                   NLKNEDLETKKTLDKFIKEKEDILGTNLSSSLRRKVSIRLNKNIAFDINDIPFSEFDDLINQYKNEIEDYEVLNL 
                 
                 
                     
                 
                 
                   GAEDGKIKDLSGTTSDINIGSDIELADGRENKAIKIKGSENSTIKIAMNKYLRFSATDNESISFWIKHPKPTNLL 
                 
                 
                     
                 
                 
                   NNGIEYTLVENFNQRGWKISIQDSKLIWYLRDHNNSIKIVTPDYIAFNGWNLITITNNRSKGSIVYVNGSKIEEK 
                 
                 
                     
                 
                 
                   DISSIWNTEVDDPIIFRLKNNRDTQAFTLLDQFSIYRKELNQNEVVKLYNYYFNSNYIRDIWGNPLQYNKKYYLQ 
                 
                 
                     
                 
                 
                   TQDKPGKGLIREYWSSFGYDYVILSDSKTITFPNNIRYGALYNGSKVLIKNSKKLDGLVRNKDFIQLEIDGYNMG 
                 
                 
                     
                 
                 
                   ISADRFNEDTNYIGTTYGTTHDLTTDFEIIQRQEKYRNYCQLKTPYNIFHKSGLMSTETSKPTFHDYRDWVYSSA 
                 
                 
                     
                 
                 
                   WYFQNYENLNLRKHTKTNWYFIPKDEGWDEDLEVLFQGPHHHHHHHHHH 
                 
                 
                     
                 
                 
                   (BoNT/A - UniProt P10845) 
                 
                 
                   SEQ ID NO: 35 
                     
                 
                 
                   MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN 
                     
                 
                 
                     
                 
                 
                   PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG 
                 
                 
                     
                 
                 
                   STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY 
                 
                 
                     
                 
                 
                   GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN 
                 
                 
                     
                 
                 
                   RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA 
                 
                 
                     
                 
                 
                   KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV 
                 
                 
                     
                 
                 
                   LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT 
                 
                 
                     
                 
                 
                   GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE 
                 
                 
                     
                 
                 
                   ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG 
                 
                 
                     
                 
                 
                   KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA 
                 
                 
                     
                 
                 
                   AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG 
                 
                 
                     
                 
                 
                   AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK 
                 
                 
                     
                 
                 
                   VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA 
                 
                 
                     
                 
                 
                   MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK 
                 
                 
                     
                 
                 
                   VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI 
                 
                 
                     
                 
                 
                   GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN 
                 
                 
                     
                 
                 
                   EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT 
                 
                 
                     
                 
                 
                   NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN 
                 
                 
                     
                 
                 
                   EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR 
                 
                 
                     
                 
                 
                   GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA 
                 
                 
                     
                 
                 
                   GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK 
                 
                 
                     
                 
                 
                   LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL 
                 
                 
                     
                 
                 
                   (BoNT/B - UniProt P10844) 
                 
                 
                   SEQ ID NO: 36 
                     
                 
                 
                   MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN 
                     
                 
                 
                     
                 
                 
                   KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG 
                 
                 
                     
                 
                 
                   DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH 
                 
                 
                     
                 
                 
                   FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY 
                 
                 
                     
                 
                 
                   GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV 
                 
                 
                     
                 
                 
                   DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN 
                 
                 
                     
                 
                 
                   IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA 
                 
                 
                     
                 
                 
                   YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN 
                 
                 
                     
                 
                 
                   YIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY 
                 
                 
                     
                 
                 
                   LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND 
                 
                 
                     
                 
                 
                   FVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI 
                 
                 
                     
                 
                 
                   PVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY 
                 
                 
                     
                 
                 
                   KALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV 
                 
                 
                     
                 
                 
                   SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL 
                 
                 
                     
                 
                 
                   SIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK 
                 
                 
                     
                 
                 
                   LTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS 
                 
                 
                     
                 
                 
                   GWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING 
                 
                 
                     
                 
                 
                   KLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY 
                 
                 
                     
                 
                 
                   SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY 
                 
                 
                     
                 
                 
                   IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD 
                 
                 
                     
                 
                 
                   SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS 
                 
                 
                     
                 
                 
                   KWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE 
                 
                 
                     
                 
                 
                   (BoNT/C - UniProt P18640) 
                 
                 
                   SEQ ID NO: 37 
                     
                 
                 
                   MPITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNK 
                     
                 
                 
                     
                 
                 
                   PPRVTSPKSGYYDPNYLSTDSDKDPFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNN 
                 
                 
                     
                 
                 
                   NTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTF 
                 
                 
                     
                 
                 
                   AAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYG 
                 
                 
                     
                 
                 
                   IAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSI 
                 
                 
                     
                 
                 
                   AKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTE 
                 
                 
                     
                 
                 
                   FNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPA 
                 
                 
                     
                 
                 
                   LRKVNPENMLYLFTKFCHKAIDGRSLYNKTLDCRELLVKNTDLPFIGDISDVKTDIFLRK 
                 
                 
                     
                 
                 
                   DINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQN 
                 
                 
                     
                 
                 
                   VDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLM 
                 
                 
                     
                 
                 
                   WANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILL 
                 
                 
                     
                 
                 
                   EAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQF 
                 
                 
                     
                 
                 
                   NNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNIN 
                 
                 
                     
                 
                 
                   KFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSF 
                 
                 
                     
                 
                 
                   QNTIPFNIFSYTNNSLLKDIINEYFNNINDSKILSLQNRKNTLVDTSGYNAEVSEEGDVQ 
                 
                 
                     
                 
                 
                   LNPIFPFDFKLGSSGEDRGKVIVTQNENIVYNSMYESFSISFWIRINKWVSNLPGYTIID 
                 
                 
                     
                 
                 
                   SVKNNSGWSIGIISNFLVFTLKQNEDSEQSINFSYDISNNAPGYNKWFFVTVTNNMMGNM 
                 
                 
                     
                 
                 
                   KIYINGKLIDTIKVKELTGINFSKTITFEINKIPDTGLITSDSDNINMWIRDFYIFAKEL 
                 
                 
                     
                 
                 
                   DGKDINILFNSLQYTNVVKDYWGNDLRYNKEYYMVNIDYLNRYMYANSRQIVFNTRRNNN 
                 
                 
                     
                 
                 
                   DFNEGYKIIIKRIRGNTNDTRVRGGDILYFDMTINNKAYNLFMKNETMYADNHSTEDIYA 
                 
                 
                     
                 
                 
                   IGLREQTKDINDNIIFQIQPMNNTYYYASQIFKSNFNGENISGICSIGTYRFRLGGDWYR 
                 
                 
                     
                 
                 
                   HNYLVPTVKQGNYASLLESTSTHWGFVPVSE 
                 
                 
                     
                 
                 
                   (BoNT/D - UniProt P19321) 
                 
                 
                   SEQ ID NO: 38 
                     
                 
                 
                   MTWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSK 
                     
                 
                 
                     
                 
                 
                   PPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDS 
                 
                 
                     
                 
                 
                   STPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSN 
                 
                 
                     
                 
                 
                   PSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYG 
                 
                 
                     
                 
                 
                   INIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDI 
                 
                 
                     
                 
                 
                   AKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSE 
                 
                 
                     
                 
                 
                   VVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPA 
                 
                 
                     
                 
                 
                   LQKLSSESVVDLFTKVCLRLTKNSRDDSTCIKVKNNRLPYVADKDSISQEIFENKIITDE 
                 
                 
                     
                 
                 
                   TNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYL 
                 
                 
                     
                 
                 
                   NSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANE 
                 
                 
                     
                 
                 
                   VVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFP 
                 
                 
                     
                 
                 
                   EFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHIN 
                 
                 
                     
                 
                 
                   YQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIR 
                 
                 
                     
                 
                 
                   ECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTM 
                 
                 
                     
                 
                 
                   PFNIFSYTNNSLLKDIINEYFNSINDSKILSLQNKKNALVDTSGYNAEVRVGDNVQLNTI 
                 
                 
                     
                 
                 
                   YTNDFKLSSSGDKIIVNLNNNILYSAIYENSSVSFWIKISKDLTNSHNEYTIINSIEQNS 
                 
                 
                     
                 
                 
                   GWKLCIRNGNIEWILQDVNRKYKSLIFDYSESLSHTGYTNKWFFVTITNNIMGYMKLYIN 
                 
                 
                     
                 
                 
                   GELKQSQKIEDLDEVKLDKTIVFGIDENIDENQMLWIRDFNIFSKELSNEDINIVYEGQI 
                 
                 
                     
                 
                 
                   LRNVIKDYWGNPLKFDTEYYIINDNYIDRYIAPESNVLVLVQYPDRSKLYTGNPITIKSV 
                 
                 
                     
                 
                 
                   SDKNPYSRILNGDNIILHMLYNSRKYMIIRDTDTIYATQGGECSQNCVYALKLQSNLGNY 
                 
                 
                     
                 
                 
                   GIGIFSIKNIVSKNKYCSQIFSSFRENTMLLADIYKPWRFSFKNAYTPVAVTNYETKLLS 
                 
                 
                     
                 
                 
                   TSSFWKFISRDPGWVE 
                 
                 
                     
                 
                 
                   (BoNT/E - UniProt Q00496) 
                 
                 
                   SEQ ID NO: 39 
                     
                 
                 
                   MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGTTPQDFHPPTS 
                     
                 
                 
                     
                 
                 
                   LKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSGGILLEELSKANPYLGNDNTP 
                 
                 
                     
                 
                 
                   DNQFHIGDASAVEIKFSNGSQDILLPNVIIMGAEPDLFETNSSNISLRNNYMPSNHRFGS 
                 
                 
                     
                 
                 
                   IAIVTFSPEYSFRFNDNCMNEFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPL 
                 
                 
                     
                 
                 
                   ITNIRGTNIEEFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNPLLNPYK 
                 
                 
                     
                 
                 
                   DVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLRTKFQVKCRQTYIGQYKYFKL 
                 
                 
                     
                 
                 
                   SNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPITGRGLVKKIIRFCKNIVSVKG 
                 
                 
                     
                 
                 
                   IRKSICIEINNGELFFVASENSYNDDNINTPKEIDDTVTSNNNYENDLDQVILNFNSESA 
                 
                 
                     
                 
                 
                   PGLSDEKLNLTIQNDAYIPKYDSNGTSDIEQHDVNELNVFFYLDAQKVPEGENNVNLTSS 
                 
                 
                     
                 
                 
                   IDTALLEQPKIYTFFSSEFINNVNKPVQAALFVSWIQQVLVDFTTEANQKSTVDKIADIS 
                 
                 
                     
                 
                 
                   IVVPYIGLALNIGNEAQKGNFKDALELLGAGILLEFEPELLIPTILVFTIKSFLGSSDNK 
                 
                 
                     
                 
                 
                   NKVIKAINNALKERDEKWKEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNAIKTIIE 
                 
                 
                     
                 
                 
                   SKYNSYTLEEKNELTNKYDIKQIENELNQKVSIAMNNIDRFLTESSISYLMKIINEVKIN 
                 
                 
                     
                 
                 
                   KLREYDENVKTYLLNYIIQHGSILGESQQELNSMVTDTLNNSIPFKLSSYTDDKILISYF 
                 
                 
                     
                 
                 
                   NKFFKRIKSSSVLNMRYKNDKYVDTSGYDSNININGDVYKYPTNKNQFGIYNDKLSEVNI 
                 
                 
                     
                 
                 
                   SQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNNSGWKVSLNHNEII 
                 
                 
                     
                 
                 
                   WTFEDNRGINQKLAFNYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDQKSILNL 
                 
                 
                     
                 
                 
                   GNIHVSDNILFKIVNCSYTRYIGIRYFNIFDKELDETEIQTLYSNEPNTNILKDFWGNYL 
                 
                 
                     
                 
                 
                   LYDKEYYLLNVLKPNNFIDRRKDSTLSINNIRSTILLANRLYSGIKVKIQRVNNSSTNDN 
                 
                 
                     
                 
                 
                   LVRKNDQVYINFVASKTHLFPLYADTATTNKEKTIKISSSGNRFNQVVVMNSVGNCTMNF 
                 
                 
                     
                 
                 
                   KNNNGNNIGLLGFKADTVVASTWYYTHMRDHTNSNGCFWNFISEEHGWQEK 
                 
                 
                     
                 
                 
                   (BoNT/F - UniProt A7GBG3) 
                 
                 
                   SEQ ID NO: 40 
                     
                 
                 
                   MPVVINSFNYNDPVNDDTILYMQIPYEEKSKKYYKAFEIMRNVWIIPERNTIGTDPSDFD 
                     
                 
                 
                     
                 
                 
                   PPASLENGSSAYYDPNYLTTDAEKDRYLKTTIKLFKRINSNPAGEVLLQEISYAKPYLGN 
                 
                 
                     
                 
                 
                   EHTPINEFHPVTRTTSVNIKSSTNVKSSIILNLLVLGAGPDIFENSSYPVRKLMDSGGVY 
                 
                 
                     
                 
                 
                   DPSNDGFGSINIVTESPEYEYTENDISGGYNSSTESFIADPAISLAHELIHALHGLYGAR 
                 
                 
                     
                 
                 
                   GVTYKETIKVKQAPLMIAEKPIRLEEFLTEGGQDLNIITSAMKEKIYNNLLANYEKIATR 
                 
                 
                     
                 
                 
                   LSRVNSAPPEYDINEYKDYFQWKYGLDKNADGSYTVNENKFNEIYKKLYSFTEIDLANKF 
                 
                 
                     
                 
                 
                   KVKCRNTYFIKYGFLKVPNLLDDDIYTVSEGFNIGNLAVNNRGQNIKLNPKIIDSIPDKG 
                 
                 
                     
                 
                 
                   LVEKIVKFCKSVIPRKGTKAPPRLCIRVNNRELFFVASESSYNENDINTPKEIDDTTNLN 
                 
                 
                     
                 
                 
                   NNYRNNLDEVILDYNSETIPQISNQTLNTLVQDDSYVPRYDSNGTSEIEEHNVVDLNVFF 
                 
                 
                     
                 
                 
                   YLHAQKVPEGETNISLTSSIDTALSEESQVYTFFSSEFINTINKPVHAALFISWINQVIR 
                 
                 
                     
                 
                 
                   DFTTEATQKSTFDKIADISLVVPYVGLALNIGNEVQKENFKEAFELLGAGILLEFVPELL 
                 
                 
                     
                 
                 
                   IPTILVFTIKSFIGSSENKNKIIKAINNSLMERETKWKEIYSWIVSNWLTRINTQFNKRK 
                 
                 
                     
                 
                 
                   EQMYQALQNQVDAIKTVIEYKYNNYTSDERNRLESEYNINNIREELNKKVSLAMENIERF 
                 
                 
                     
                 
                 
                   ITESSIFYLMKLINEAKVSKLREYDEGVKEYLLDYISEHRSILGNSVQELNDLVTSTLNN 
                 
                 
                     
                 
                 
                   SIPFELSSYTNDKILILYFNKLYKKIKDNSILDMRYENNKFIDISGYGSNISINGDVYIY 
                 
                 
                     
                 
                 
                   STNRNQFGIYSSKPSEVNIAQNNDIIYNGRYQNFSISFWVRIPKYFNKVNLNNEYTIIDC 
                 
                 
                     
                 
                 
                   IRNNNSGWKISLNYNKIIWTLQDTAGNNQKLVFNYTQMISISDYINKWIFVTITNNRLGN 
                 
                 
                     
                 
                 
                   SRIYINGNLIDEKSISNLGDIHVSDNILFKIVGCNDTRYVGIRYFKVFDTELGKTEIETL 
                 
                 
                     
                 
                 
                   YSDEPDPSILKDFWGNYLLYNKRYYLLNLLRTDKSITQNSNFLNINQQRGVYQKPNIFSN 
                 
                 
                     
                 
                 
                   TRLYTGVEVIIRKNGSTDISNTDNFVRKNDLAYINVVDRDVEYRLYADISIAKPEKIIKL 
                 
                 
                     
                 
                 
                   IRTSNSNNSLGQIIVMDSIGNNCTMNFQNNNGGNIGLLGFHSNNLVASSWYYNNIRKNTS 
                 
                 
                     
                 
                 
                   SNGCFWSFISKEHGWQEN 
                 
                 
                     
                 
                 
                   (BoNT/G - UniProt Q60393) 
                 
                 
                   SEQ ID NO: 41 
                     
                 
                 
                   MPVNIKXFNYNDPINNDDIIMMEPFNDPGPGTYYKAFRIIDRIWIVPERFTYGFQPDQFN 
                     
                 
                 
                     
                 
                 
                   ASTGVFSKDVYEYYDPTYLKTDAEKDKFLKTMIKLFNRINSKPSGQRLLDMIVDAIPYLG 
                 
                 
                     
                 
                 
                   NASTPPDKFAANVANVSINKKIIQPGAEDQIKGLMTNLIIFGPGPVLSDNFTDSMIMNGH 
                 
                 
                     
                 
                 
                   SPISEGFGARMMIRFCPSCLNVFNNVQENKDTSIFSRRAYFADPALTLMHELIHVLHGLY 
                 
                 
                     
                 
                 
                   GIKISNLPITPNTKEFFMQHSDPVQAEELYTFGGHDPSVISPSTDMNIYNKALQNFQDIA 
                 
                 
                     
                 
                 
                   NRLNIVSSAQGSGIDISLYKQIYKNKYDFVEDPNGKYSVDKDKFDKLYKALMFGFTETNL 
                 
                 
                     
                 
                 
                   AGEYGIKTRYSYFSEYLPPIKTEKLLDNTIYTQNEGFNIASKNLKTEFNGQNKAVNKEAY 
                 
                 
                     
                 
                 
                   EEISLEHLVIYRIAMCKPVMYKNTGKSEQCIIVNNEDLFFIANKDSFSKDLAKAETIAYN 
                 
                 
                     
                 
                 
                   TQNNTIENNFSIDQLILDNDLSSGIDLPNENTEPFTNFDDIDIPVYIKQSALKKIFVDGD 
                 
                 
                     
                 
                 
                   SLFEYLHAQTFPSNIENLQLTNSLNDALRNNNKVYTFFSTNLVEKANTVVGASLFVNWVK 
                 
                 
                     
                 
                 
                   GVIDDFTSESTQKSTIDKVSDVSIIIPYIGPALNVGNETAKENFKNAFEIGGAAILMEFI 
                 
                 
                     
                 
                 
                   PELIVPIVGFFTLESYVGNKGHIIMTISNALKKRDQKWTDMYGLIVSQWLSTVNTQFYTI 
                 
                 
                     
                 
                 
                   KERMYNALNNQSQAIEKIIEDQYNRYSEEDKMNINIDFNDIDFKLNQSINLAINNIDDFI 
                 
                 
                     
                 
                 
                   NQCSISYLMNRMIPLAVKKLKDFDDNLKRDLLEYIDTNELYLLDEVNILKSKVNRHLKDS 
                 
                 
                     
                 
                 
                   IPFDLSLYTKDTILIQVFNNYISNISSNAILSLSYRGGRLIDSSGYGATMNVGSDVIFND 
                 
                 
                     
                 
                 
                   IGNGQFKLNNSENSNITAHQSKFVVYDSMFDNFSINFWVRTPKYNNNDIQTYLQNEYTII 
                 
                 
                     
                 
                 
                   SCIKNDSGWKVSIKGNRIIWTLIDVNAKSKSIFFEYSIKDNISDYINKWFSITITNDRLG 
                 
                 
                     
                 
                 
                   NANIYINGSLKKSEKILNLDRINSSNDIDFKLINCTDTTKFVWIKDFNIFGRELNATEVS 
                 
                 
                     
                 
                 
                   SLYWIQSSTNTLKDFWGNPLRYDTQYYLFNQGMQNIYIKYFSKASMGETAPRTNFNNAAI 
                 
                 
                     
                 
                 
                   NYQNLYLGLRFIIKKASNSRNINNDNIVREGDYIYLNIDNISDESYRVYVLVNSKEIQTQ 
                 
                 
                     
                 
                 
                   LFLAPINDDPTFYDVLQIKKYYEKTTYNCQILCEKDTKTFGLFGIGKFVKDYGYVWDTYD 
                 
                 
                     
                 
                 
                   NYFCISQWYLRRISENINKLRLGCNWQFIPVDEGWTE 
                 
                 
                     
                 
                 
                   (TeNT - UniProt P04958) 
                 
                 
                   SEQ ID NO: 42 
                     
                 
                 
                   MPITINNFRYSDPVNNDTIIMMEPPYCKGLDIYYKAFKITDRIWIVPERYEFGTKPEDFN 
                     
                 
                 
                     
                 
                 
                   PPSSLIEGASEYYDPNYLRTDSDKDRFLQTMVKLFNRIKNNVAGEALLDKIINAIPYLGN 
                 
                 
                     
                 
                 
                   SYSLLDKFDTNSNSVSFNLLEQDPSGATTKSAMLTNLIIFGPGPVLNKNEVRGIVLRVDN 
                 
                 
                     
                 
                 
                   KNYFPCRDGFGSIMQMAFCPEYVPTFDNVIENITSLTIGKSKYFQDPALLLMHELIHVLH 
                 
                 
                     
                 
                 
                   GLYGMQVSSHEIIPSKQEIYMQHTYPISAEELFTFGGQDANLISIDIKNDLYEKTLNDYK 
                 
                 
                     
                 
                 
                   AIANKLSQVTSCNDPNIDIDSYKQIYQQKYQFDKDSNGQYIVNEDKFQILYNSIMYGFTE 
                 
                 
                     
                 
                 
                   IELGKKFNIKTRLSYFSMNHDPVKIPNLLDDTIYNDTEGFNIESKDLKSEYKGQNMRVNT 
                 
                 
                     
                 
                 
                   NAFRNVDGSGLVSKLIGLCKKIIPPTNIRENLYNRTASLTDLGGELCIKIKNEDLTFIAE 
                 
                 
                     
                 
                 
                   KNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAP 
                 
                 
                     
                 
                 
                   EYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVI 
                 
                 
                     
                 
                 
                   SKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGN 
                 
                 
                     
                 
                 
                   FIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYK 
                 
                 
                     
                 
                 
                   LVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKN 
                 
                 
                     
                 
                 
                   KLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIG 
                 
                 
                     
                 
                 
                   ITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDVILKKSTILNLDINNDIISDIS 
                 
                 
                     
                 
                 
                   GFNSSVITYPDAQLVPGINGKAIHLVNNESSEVIVHKAMDIEYNDMFNNFTVSFWLRVPK 
                 
                 
                     
                 
                 
                   VSASHLEQYGTNEYSIISSMKKHSLSIGSGWSVSLKGNNLIWTLKDSAGEVRQITFRDLP 
                 
                 
                     
                 
                 
                   DKFNAYLANKWVFITITNDRLSSANLYINGVLMGSAEITGLGAIREDNNITLKLDRCNNN 
                 
                 
                     
                 
                 
                   NQYVSIDKFRIFCKALNPKEIEKLYTSYLSITFLRDFWGNPLRYDTEYYLIPVASSSKDV 
                 
                 
                     
                 
                 
                   QLKNITDYMYLTNAPSYTNGKLNIYYRRLYNGLKFIIKRYTPNNEIDSFVKSGDFIKLYV 
                 
                 
                     
                 
                 
                   SYNNNEHIVGYPKDGNAFNNLDRILRVGYNAPGIPLYKKMEAVKLRDLKTYSVQLKLYDD 
                 
                 
                     
                 
                 
                   KNASLGLVGTHNGQIGNDPNRDILIASNWYFNHLKDKILGCDWYFVPTDEGWTND 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of LH N /A1 with an EK Cleavage Site) 
                 
                 
                   SEQ ID NO: 43 
                     
                 
                 
                   ATGGAGTTCGTTAACAAACAGTTCAACTATAAAGACCCAGTTAACGGTGTTGACATTGCTTACATCAAAATCCCG 
                     
                 
                 
                     
                 
                 
                   AACGCTGGCCAGATGCAGCCGGTAAAGGCATTCAAAATCCACAACAAAATCTGGGTTATCCCGGAACGTGATACC 
                 
                 
                     
                 
                 
                   TTTACTAACCCGGAAGAAGGTGACCTGAACCCGCCACCGGAAGCGAAACAGGTGCCGGTATCTTACTATGACTCC 
                 
                 
                     
                 
                 
                   ACCTACCTGTCTACCGATAACGAAAAGGACAACTACCTGAAAGGTGTTACTAAACTGTTCGAGCGTATTTACTCC 
                 
                 
                     
                 
                 
                   ACCGACCTGGGCCGTATGCTGCTGACTAGCATCGTTCGCGGTATCCCGTTCTGGGGCGGTTCTACCATCGATACC 
                 
                 
                     
                 
                 
                   GAACTGAAAGTAATCGACACTAACTGCATCAACGTTATTCAGCCGGACGGTTCCTATCGTTCCGAAGAACTGAAC 
                 
                 
                     
                 
                 
                   CTGGTGATCATCGGCCCGTCTGCTGATATCATCCAGTTCGAGTGTAAGAGCTTTGGTCACGAAGTTCTGAACCTC 
                 
                 
                     
                 
                 
                   ACCCGTAACGGCTACGGTTCCACTCAGTACATCCGTTTCTCTCCGGACTTCACCTTCGGTTTTGAAGAATCCCTG 
                 
                 
                     
                 
                 
                   GAAGTAGACACGAACCCACTGCTGGGCGCTGGTAAATTCGCAACTGATCCTGCGGTTACCCTGGCTCACGAACTG 
                 
                 
                     
                 
                 
                   ATTCATGCAGGCCACCGCCTGTACGGTATCGCCATCAATCCGAACCGTGTCTTCAAAGTTAACACCAACGCGTAT 
                 
                 
                     
                 
                 
                   TACGAGATGTCCGGTCTGGAAGTTAGCTTCGAAGAACTGCGTACTTTTGGCGGTCACGACGCTAAATTCATCGAC 
                 
                 
                     
                 
                 
                   TCTCTGCAAGAAAACGAGTTCCGTCTGTACTACTATAACAAGTTCAAAGATATCGCATCCACCCTGAACAAAGCG 
                 
                 
                     
                 
                 
                   AAATCCATCGTGGGTACCACTGCTTCTCTCCAGTACATGAAGAACGTTTTTAAAGAAAAATACCTGCTCAGCGAA 
                 
                 
                     
                 
                 
                   GACACCTCCGGCAAATTCTCTGTAGACAAGTTGAAATTCGATAAACTTTACAAAATGCTGACTGAAATTTACACC 
                 
                 
                     
                 
                 
                   GAAGACAACTTCGTTAAGTTCTTTAAAGTTCTGAACCGCAAAACCTATCTGAACTTCGACAAGGCAGTATTCAAA 
                 
                 
                     
                 
                 
                   ATCAACATCGTGCCGAAAGTTAACTACACTATCTACGATGGTTTCAACCTGCGTAACACCAACCTGGCTGCTAAT 
                 
                 
                     
                 
                 
                   TTTAACGGCCAGAACACGGAAATCAACAACATGAACTTCACAAAACTGAAAAACTTCACTGGTCTGTTCGAGTTT 
                 
                 
                     
                 
                 
                   TACAAGCTGCTGTGCGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAACAAAGCGCTG 
                 
                 
                     
                 
                 
                   AACCTGCAGTGTATCAAGGTTAACAACTGGGATTTATTCTTCAGCCCGAGTGAAGACAACTTCACCAACGACCTG 
                 
                 
                     
                 
                 
                   AACAAAGGTGAAGAAATCACCTCAGATACTAACATCGAAGCAGCCGAAGAAAACATCTCGCTGGACCTGATCCAG 
                 
                 
                     
                 
                 
                   CAGTACTACCTGACCTTTAATTTCGACAACGAGCCGGAAAACATTTCTATCGAAAACCTGAGCTCTGATATCATC 
                 
                 
                     
                 
                 
                   GGCCAGCTGGAACTGATGCCGAACATCGAACGTTTCCCAAACGGTAAAAAGTACGAGCTGGACAAATATACCATG 
                 
                 
                     
                 
                 
                   TTCCACTACCTGCGCGCGCAGGAATTTGAACACGGCAAATCCCGTATCGCACTGACTAACTCCGTTAACGAAGCT 
                 
                 
                     
                 
                 
                   CTGCTCAACCCGTCCCGTGTATACACCTTCTTCTCTAGCGACTACGTGAAAAAGGTCAACAAAGCGACTGAAGCT 
                 
                 
                     
                 
                 
                   GCAATGTTCTTGGGTTGGGTTGAACAGCTTGTTTATGATTTTACCGACGAGACGTCCGAAGTATCTACTACCGAC 
                 
                 
                     
                 
                 
                   AAAATTGCGGATATCACTATCATCATCCCGTACATCGGTCCGGCTCTGAACATTGGCAACATGCTGTACAAAGAC 
                 
                 
                     
                 
                 
                   GACTTCGTTGGCGCACTGATCTTCTCCGGTGCGGTGATCCTGCTGGAGTTCATCCCGGAAATCGCCATCCCGGTA 
                 
                 
                     
                 
                 
                   CTGGGCACCTTTGCTCTGGTTTCTTACATTGCAAACAAGGTTCTGACTGTACAAACCATCGACAACGCGCTGAGC 
                 
                 
                     
                 
                 
                   AAACGTAACGAAAAATGGGATGAAGTTTACAAATATATCGTGACCAACTGGCTGGCTAAGGTTAATACTCAGATC 
                 
                 
                     
                 
                 
                   GACCTCATCCGCAAAAAAATGAAAGAAGCACTGGAAAACCAGGCGGAAGCTACCAAGGCAATCATTAACTACCAG 
                 
                 
                     
                 
                 
                   TACAACCAGTACACCGAGGAAGAAAAAAACAACATCAACTTCAACATCGACGATCTGTCCTCTAAACTGAACGAA 
                 
                 
                     
                 
                 
                   TCCATCAACAAAGCTATGATCAACATCAACAAGTTCCTGAACCAGTGCTCTGTAAGCTATCTGATGAACTCCATG 
                 
                 
                     
                 
                 
                   ATCCCGTACGGTGTTAAACGTCTGGAGGACTTCGATGCGTCTCTGAAAGACGCCCTGCTGAAATACATTTACGAC 
                 
                 
                     
                 
                 
                   AACCGTGGCACTCTGATCGGTCAGGTTGATCGTCTGAAGGACAAAGTGAACAATACCTTATCGACCGACATCCCT 
                 
                 
                     
                 
                 
                   TTTCAGCTCAGTAAATATGTCGATAACCAACGCCTTTTGTCCACTCTAGAAGCACACCATCATCACCACCATCAC 
                 
                 
                     
                 
                 
                   CATCACCAT 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of LH N /A1 with an EK Cleavage Site) 
                 
                 
                   SEQ ID NO: 44 
                     
                 
                 
                   MEFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDS 
                     
                 
                 
                     
                 
                 
                   TYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELN 
                 
                 
                     
                 
                 
                   LVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHEL 
                 
                 
                     
                 
                 
                   IHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTEGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA 
                 
                 
                     
                 
                 
                   KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFK 
                 
                 
                     
                 
                 
                   INIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKAL 
                 
                 
                     
                 
                 
                   NLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDII 
                 
                 
                     
                 
                 
                   GQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA 
                 
                 
                     
                 
                 
                   AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPV 
                 
                 
                     
                 
                 
                   LGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQ 
                 
                 
                     
                 
                 
                   YNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYD 
                 
                 
                     
                 
                 
                   NRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEAHHHHHHHHHH 
                 
                 
                     
                 
                 
                   (Nucleotide Sequence of BoNT with a Native A1 Loop) 
                 
                 
                   SEQ ID NO: 45 
                     
                 
                 
                   ATGAAACTGGAAATCAACAAATTCAACTACAACGATCCGATCGATGGCATTAATGTTATTACCATGCGTCCGCCT 
                     
                 
                 
                     
                 
                 
                   CGTCATAGCGATAAAATCAATAAAGGTAAAGGTCCGTTCAAAGCCTTTCAGGTGATTAAAAACATTTGGATTGTG 
                 
                 
                     
                 
                 
                   CCGGAACGCTACAACTTTACCAATAATACCAACGATCTGAACATTCCGAGCGAACCGATTATGGAAGCAGATGCC 
                 
                 
                     
                 
                 
                   ATTTATAACCCGAACTATCTGAATACCCCGAGCGAAAAAGATGAATTTCTGCAGGGTGTTATCAAAGTGCTGGAA 
                 
                 
                     
                 
                 
                   CGCATTAAAAGCAAACCGGAAGGTGAAAAACTGCTGGAACTGATTAGCAGCAGCATTCCGCTGCCGCTGGTTAGC 
                 
                 
                     
                 
                 
                   AATGGTGCACTGACCCTGAGCGATAATGAAACCATTGCATATCAAGAGAACAACAACATTGTGAGCAATCTGCAG 
                 
                 
                     
                 
                 
                   GCAAACCTGGTTATTTATGGTCCGGGTCCTGATATTGCAAATAATGCAACCTATGGTCTGTATAGCACCCCGATT 
                 
                 
                     
                 
                 
                   AGTAATGGTGAAGGTACACTGAGCGAAGTTAGCTTTAGCCCGTTTTATCTGAAACCGTTTGATGAAAGCTATGGC 
                 
                 
                     
                 
                 
                   AATTATCGTAGCCTGGTGAATATCGTGAACAAATTCGTGAAACGTGAATTTGCACCTGATCCGGCAAGCACCCTG 
                 
                 
                     
                 
                 
                   ATGCATGAACTGGTTCATGTTACCCATAATCTGTATGGTATTAGCAACCGCAACTTCTACTATAACTTTGACACC 
                 
                 
                     
                 
                 
                   GGCAAAATTGAAACCAGCCGTCAGCAGAATAGCCTGATTTTTGAAGAACTGCTGACCTTTGGTGGCATTGATAGC 
                 
                 
                     
                 
                 
                   AAAGCAATTAGCAGCCTGATCATCAAGAAAATTATCGAAACCGCCAAGAACAACTATACCACGCTGATTAGCGAA 
                 
                 
                     
                 
                 
                   CGCCTGAATACCGTTACCGTTGAAAATGATCTGCTGAAATATATCAAAAACAAAATCCCGGTTCAGGGTCGTCTG 
                 
                 
                     
                 
                 
                   GGTAACTTTAAACTGGATACCGCAGAATTCGAGAAAAAGCTGAATACCATTCTGTTTGTGCTGAACGAAAGCAAT 
                 
                 
                     
                 
                 
                   CTGGCACAGCGTTTTAGCATTCTGGTTCGTAAACATTACCTGAAAGAACGTCCGATTGATCCGATTTATGTGAAC 
                 
                 
                     
                 
                 
                   ATTCTGGATGACAATAGCTACAGCACCCTGGAAGGTTTTAACATTAGCAGTCAGGGTAGCAATGATTTCCAAGGT 
                 
                 
                     
                 
                 
                   CAGCTGCTGGAAAGCAGCTATTTTGAAAAAATTGAAAGCAATGCCCTGCGTGCCTTCATTAAAATCTGTCCGCGT 
                 
                 
                     
                 
                 
                   AATGGTCTGCTGTATAATGCCATTTATCGCAACAGCAAAAATCTGGAAGTTCTGTTTCAGGGTCCGCATCATCAC 
                 
                 
                     
                 
                 
                   CACCATCACCATCATCATCACCTGGAAGTGTTATTTCAGGGACCGTATCTGAATAACATTGATCTGGAAGATAAA 
                 
                 
                     
                 
                 
                   AAGACCACGAGCAAAACCAATGTTAGCTATCCGTGTAGCCTGCTGAATGGTTGTATTGAAGTTGAAAACAAAGAC 
                 
                 
                     
                 
                 
                   CTGTTCCTGATTAGCAACAAAGATAGCCTGAACGATATTAACCTGAGCGAAGAAAAAATCAAACCGGAAACCACC 
                 
                 
                     
                 
                 
                   GTGTTCTTCAAAGATAAACTGCCTCCGCAGGATATTACGCTGAGCAATTATGATTTTACCGAAGCCAATAGCATT 
                 
                 
                     
                 
                 
                   CCGAGCATTAGCCAGCAGAACATTCTGGAACGTAATGAAGAACTGTATGAACCGATTCGCAATAGCCTGTTTGAA 
                 
                 
                     
                 
                 
                   ATCAAAACCATCTATGTGGATAAGCTGACCACCTTTCATTTTCTGGAAGCCCAGAATATTGATGAGAGCATTGAT 
                 
                 
                     
                 
                 
                   AGCAGCAAAATTCGTGTTGAACTGACCGATAGCGTTGATGAAGCACTGAGCAATCCGAATAAAGTTTATAGCCCG 
                 
                 
                     
                 
                 
                   TTCAAGAACATGAGCAACACCATTAATAGCATTGAAACCGGTATTACCAGCACCTACATCTTTTATCAGTGGCTG 
                 
                 
                     
                 
                 
                   CGTAGCATCGTGAAAGATTTTAGTGATGAAACCGGCAAAATCGACGTGATTGATAAAAGCAGCGATACCCTGGCA 
                 
                 
                     
                 
                 
                   ATTGTTCCGTATATTGGTCCGCTGCTGAATATTGGTAATGATATTCGTCATGGCGATTTTGTGGGTGCAATTGAA 
                 
                 
                     
                 
                 
                   CTGGCAGGCATTACCGCACTGCTGGAATATGTTCCGGAATTTACCATTCCGATTCTGGTTGGTCTGGAAGTGATT 
                 
                 
                     
                 
                 
                   GGTGGCGAACTGGCACGTGAACAGGTTGAAGCAATTGTTAATAATGCCCTGGATAAACGCGATCAGAAATGGGCA 
                 
                 
                     
                 
                 
                   GAAGTTTACAATATTACCAAAGCACAGTGGTGGGGCACCATTCATTTACAGATTAATACCCGTCTGGCCCATACC 
                 
                 
                     
                 
                 
                   TATAAAGCCCTGAGCCGTCAGGCAAATGCCATTAAAATGAATATGGAATTTCAGCTGGCCAACTACAAAGGCAAC 
                 
                 
                     
                 
                 
                   ATTGATGATAAAGCCAAGATCAAAAACGCCATCAGCGAAACCGAAATTCTGCTGAACAAAAGCGTTGAACAGGCC 
                 
                 
                     
                 
                 
                   ATGAAAAACACCGAGAAATTCATGATTAAACTGAGCAACAGCTACCTGACCAAAGAAATGATTCCGAAAGTTCAG 
                 
                 
                     
                 
                 
                   GACAACCTGAAAAACTTTGACCTGGAAACCAAAAAAACCCTGGACAAGTTCATCAAAGAGAAAGAAGATATCCTG 
                 
                 
                     
                 
                 
                   GGCACCAATCTGAGCAGCAGCCTGCGTCGTAAAGTTAGCATTCGTCTGAATAAAAACATTGCCTTCGACATCAAC 
                 
                 
                     
                 
                 
                   GATATCCCGTTTAGCGAATTTGATGATCTGATCAACCAGTACAAAAACGAGATCGAAGATTATGAAGTGCTGAAT 
                 
                 
                     
                 
                 
                   CTGGGTGCAGAAGATGGCAAAATCAAAGATCTGAGCGGTACAACCAGCGATATCAATATTGGTTCAGATATCGAA 
                 
                 
                     
                 
                 
                   CTGGCCGATGGTCGTGAAAATAAAGCCATTAAGATTAAAGGCAGCGAGAACAGCACCATCAAAATTGCAATGAAC 
                 
                 
                     
                 
                 
                   AAATATCTGCGTTTTAGCGCCACCGATAACTTTAGCATTAGCTTTTGGATCAAACATCCGAAACCGACCAATCTG 
                 
                 
                     
                 
                 
                   CTTAATAACGGTATTGAATATACCCTGGTCGAGAACTTTAATCAGCGTGGTTGGAAAATTAGCATCCAGGATAGC 
                 
                 
                     
                 
                 
                   AAACTGATTTGGTATCTGCGCGATCACAATAACAGCATCAAAATCGTTACACCGGATTATATTGCGTTTAATGGC 
                 
                 
                     
                 
                 
                   TGGAACCTGATCACCATTACGAATAATCGTAGCAAAGGCAGCATCGTGTATGTGAATGGTAGCAAAATTGAAGAG 
                 
                 
                     
                 
                 
                   AAGGACATTAGCAGCATTTGGAATACCGAAGTGGATGATCCGATTATCTTCCGCCTGAAAAATAACCGTGATACC 
                 
                 
                     
                 
                 
                   CAGGCATTTACCCTGCTGGATCAGTTTAGCATTTATCGGAAAGAACTGAACCAGAACGAAGTGGTGAAACTGTAT 
                 
                 
                     
                 
                 
                   AACTACTACTTCAACAGCAACTACATTCGCGATATTTGGGGTAATCCGCTGCAGTACAACAAAAAATACTATCTG 
                 
                 
                     
                 
                 
                   CAGACCCAGGACAAACCTGGTAAAGGTCTGATCCGCGAATATTGGAGCAGCTTTGGTTATGATTATGTGATTCTG 
                 
                 
                     
                 
                 
                   AGCGATAGCAAGACGATTACCTTTCCGAACAATATCCGTTATGGTGCCCTGTATAACGGTAGCAAAGTTCTGATC 
                 
                 
                     
                 
                 
                   AAGAACAGCAAGAAATTAGATGGTCTGGTGCGCAATAAAGATTTCATTCAGCTGGAAATCGATGGCTATAATATG 
                 
                 
                     
                 
                 
                   GGTATTAGCGCAGATCGCTTTAACGAGGATACCAACTATATTGGCACCACCTATGGTACAACCCATGATCTGACC 
                 
                 
                     
                 
                 
                   ACCGATTTTGAAATTATTCAGCGCCAAGAGAAATACCGCAATTATTGTCAGCTGAAAACCCCGTATAACATCTTT 
                 
                 
                     
                 
                 
                   CATAAAAGCGGTCTGATGAGCACCGAAACCAGCAAACCGACCTTCCATGATTATCGCGATTGGGTTTATAGCAGC 
                 
                 
                     
                 
                 
                   GCATGGTATTTTCAGAACTATGAAAATCTGAACCTGCGCAAACATACCAAAACCAACTGGTATTTTATCCCGAAA 
                 
                 
                     
                 
                 
                   GATGAAGGTTGGGACGAAGAT 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of BoNT with a Native A1 Loop) 
                 
                 
                   SEQ ID NO: 46 
                     
                 
                 
                   MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNTNDLNIPSEPIMEADA 
                     
                 
                 
                     
                 
                 
                   IYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIPLPLVSNGALTLSDNETIAYQENNNIVSNLQ 
                 
                 
                     
                 
                 
                   ANLVIYGPGPDIANNATYGLYSTPISNGEGTLSEVSFSPFYLKPFDESYGNYRSLVNIVNKFVKREFAPDPASTL 
                 
                 
                     
                 
                 
                   MHELVHVTHNLYGISNRNFYYNFDTGKIETSRQQNSLIFEELLTFGGIDSKAISSLIIKKIIETAKNNYTTLISE 
                 
                 
                     
                 
                 
                   RLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLNTILFVLNESNLAQRFSILVRKHYLKERPIDPIYVN 
                 
                 
                     
                 
                 
                   ILDDNSYSTLEGFNISSQGSNDFQGQLLESSYFEKIESNALRAFIKICPRNGLLYNAIYRNSKNLEVLFQGPHHH 
                 
                 
                     
                 
                 
                   HHHHHHHLEVLFQGPYLNNIDLEDKKTTSKTNVSYPCSLLNGCIEVENKDLFLISNKDSLNDINLSEEKIKPETT 
                 
                 
                     
                 
                 
                   VFFKDKLPPQDITLSNYDFTEANSIPSISQQNILERNEELYEPIRNSLFEIKTIYVDKLTTFHFLEAQNIDESID 
                 
                 
                     
                 
                 
                   SSKIRVELTDSVDEALSNPNKVYSPFKNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDVIDKSSDTLA 
                 
                 
                     
                 
                 
                   IVPYIGPLLNIGNDIRHGDFVGAIELAGITALLEYVPEFTIPILVGLEVIGGELAREQVEAIVNNALDKRDQKWA 
                 
                 
                     
                 
                 
                   EVYNITKAQWWGTIHLQINTRLAHTYKALSRQANAIKMNMEFQLANYKGNIDDKAKIKNAISETEILLNKSVEQA 
                 
                 
                     
                 
                 
                   MKNTEKFMIKLSNSYLTKEMIPKVQDNLKNEDLETKKTLDKFIKEKEDILGTNLSSSLRRKVSIRLNKNIAFDIN 
                 
                 
                     
                 
                 
                   DIPFSEFDDLINQYKNEIEDYEVLNLGAEDGKIKDLSGTTSDINIGSDIELADGRENKAIKIKGSENSTIKIAMN 
                 
                 
                     
                 
                 
                   KYLRFSATDNFSISFWIKHPKPTNLLNNGIEYTLVENFNQRGWKISIQDSKLIWYLRDHNNSIKIVTPDYIAFNG 
                 
                 
                     
                 
                 
                   WNLITITNNRSKGSIVYVNGSKIEEKDISSIWNTEVDDPIIFRLKNNRDTQAFTLLDQFSIYRKELNQNEVVKLY 
                 
                 
                     
                 
                 
                   NYYFNSNYIRDIWGNPLQYNKKYYLQTQDKPGKGLIREYWSSFGYDYVILSDSKTITFPNNIRYGALYNGSKVLI 
                 
                 
                     
                 
                 
                   KNSKKLDGLVRNKDFIQLEIDGYNMGISADRFNEDTNYIGTTYGTTHDLTTDFEIIQRQEKYRNYCQLKTPYNIF 
                 
                 
                     
                 
                 
                   HKSGLMSTETSKPTFHDYRDWVYSSAWYFQNYENLNLRKHTKTNWYFIPKDEGWDED 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of Trypsin) 
                 
                 
                   SEQ ID NO: 47 
                     
                 
                 
                   MHPLLILAFVGAAVAFPSDDDDKIVGGYTCAENSVPYQVSLNAGYHFCGGSLINDQWVVS 
                     
                 
                 
                     
                 
                 
                   AAHCYQYHIQVRLGEYNIDVLEGGEQFIDASKIIRHPKYSSWTLDNDILLIKLSTPAVIN 
                 
                 
                     
                 
                 
                   ARVSTLALPSACASGSTECLISGWGNTLSSGVNYPDLLQCLEAPLLSHADCEASYPGEIT 
                 
                 
                     
                 
                 
                   NNMICAGFLEGGKDSCQGDSGGPVACNGQLQGIVSWGYGCAQKGKPGVYTKVCNYVDWIQ 
                 
                 
                     
                 
                 
                   ETIAANS 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of Lys-C) 
                 
                 
                   SEQ ID NO: 48 
                     
                 
                 
                   G V S G S C N I D V V C P E G N G H R D V I R S V A A Y S K Q G T M W C T G 
                     
                 
                 
                     
                 
                 
                   S L V N N S A N D K K M Y F L T A N H C G M T T A A I A S S M V V Y W N Y Q 
                 
                 
                     
                 
                 
                   N S T C R A P G S S S S G A N G D G S L A Q S Q T G A V V R A T N A A S D F 
                 
                 
                     
                 
                 
                   T L L E L N T A A N P A Y N L F W A G W D R R D Q N F A G A T A I H H P N V 
                 
                 
                     
                 
                 
                   A E K R I S H S T V A T E I S G Y N G A T G T S H L H V F W Q A S G G V T E 
                 
                 
                     
                 
                 
                   P G S S G S P I Y S P E K R V L G Q L H 211 G G P S S C S A T G A D R S D Y 
                 
                 
                     
                 
                 
                   Y G R V F T S W T G G G T S A T R L S D W L D A A G T G A Q F I D G L D S T 
                 
                 
                     
                 
                 
                   G T P P V 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of Enterokinase Light Chain) 
                 
                 
                   SEQ ID NO: 49 
                     
                 
                 
                   IVGGSDSREGAWPWVVALYFDDQQVCGASLVSRDWLVSAAHCVYGRNMEPSKWKAVLGLH 
                     
                 
                 
                     
                 
                 
                   MASNLTSPQIETRLIDQIVINRHYNKRRKNNDIAMMHLEMKVNYTDYIQPICLPEENQVF 
                 
                 
                     
                 
                 
                   PPGRICSIAGWGALIYQGSTADVLQEADVPLLSNEKCQQQMPEYNITENMVCAGYDAGGV 
                 
                 
                     
                 
                 
                   DSCQGDSGGPLMCQENNRWLLAGVTSFGYQCALPNRPGVYARVPRFTEWIQSFLH 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of Factor Xa Heavy Chain) 
                 
                 
                   SEQ ID NO: 50 
                     
                 
                 
                   IVGGRDCAEGECPWQALLVNEENEGFCGGTILNEFYVLTAAHCLHQAKRFTVRVGDRNTEQEEGNEMAHEVEMTV 
                     
                 
                 
                     
                 
                 
                   KHSRFVKETYDFDIAVLRLKTPIRFRRNVAPACLPEKDWAEATLMTQKTGIVSGFGRTHEKGRLSSTLKMLEVPY 
                 
                 
                     
                 
                 
                   VDRSTCKLSSSFTITPNMFCAGYDTQPEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKFGVYTKVSNFL 
                 
                 
                     
                 
                 
                   KWIDKIMKARAGAAGSRGHSEAPATWTVPPPLPL 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of Factor Xa Light Chain) 
                 
                 
                   SEQ ID NO: 51 
                     
                 
                 
                   ANSFLEEVKQGNLERECLEEACSLEEAREVFEDAEQTDEFWSKYKDGDQCEGHPCLNQGHCKDGIGDYTCTCAEG 
                     
                 
                 
                     
                 
                 
                   FEGKNCEFSTREICSLDNGGCDQFCREERSEVRCSCAHGYVLGDDSKSCVSTERFPCGKFTQGRS 
                 
                 
                     
                 
                 
                   (Polypeptide Sequence of Anthrax Toxin Protective Antigen - NCBI Ref Seq: 
                 
                 
                   NP_052806) 
                 
                 
                   SEQ ID NO: 52 
                     
                 
              
             
             
                 
                 
                 
              
                 
                   1 
                   mkkrkvlipl malstilvss tgnlevigae vkqenrllne sesssqgllg yyfsdlnfqa 
                     
                 
                 
                     
                 
                 
                   61 
                   pmvvtssttg dlsipssele nipsenqyfq saiwsgfikv kksdeytfat sadnhvtmwv 
                 
                 
                     
                 
                 
                   121 
                   ddqevinkas nsnkirlekg rlyqikiqyq renptekgld fklywtdsqn kkevissdnl 
                 
                 
                     
                 
                 
                   181 
                   qlpelkqkss nsrkkrstsa gptvpdrdnd gipdsleveg ytvdvknkrt flspwisnih 
                 
                 
                     
                 
                 
                   241 
                   ekkgltkyks spekwstasd pysdfekvtg ridknvspea rhplvaaypi vhvdmeniil 
                 
                 
                     
                 
                 
                   301 
                   sknedqstqn tdsqtrtisk ntstsrthts evhgnaevha sffdiggsys agfsnsnsst 
                 
                 
                     
                 
                 
                   361 
                   vaidhslsla gertwaetmg lntadtarin aniryvntgt apiynvlptt slvlgknqtl 
                 
                 
                     
                 
                 
                   421 
                   atikakenql sqilapnnyy psknlapial naqddfsstp itmnynqfle lektkqlrld 
                 
                 
                     
                 
                 
                   481 
                   tdqvygniat ynfengrvrv dtgsnwsevl pqiqettari ifngkdlnlv erriaavnps 
                 
                 
                     
                 
                 
                   541 
                   dplettkpdm tlkealkiaf gfnepngnlq yqgkditefd fnfdqqtsqn iknqlaelna 
                 
                 
                     
                 
                 
                   601 
                   tniytvldki klnakmnili rdkrfhydrn niavgadesv vkeahrevin ssteglllni 
                 
                 
                     
                 
                 
                   661 
                   dkdirkilsg yiveiedteg lkevindryd mlnisslrqd gktfidfkky ndklplyisn 
                 
                 
                     
                 
                 
                   721 
                   pnykvnvyav tkentiinps engdtstngi kkilifskkg yeig 
                 
                 
                     
                 
              
             
             
                 
                 
              
                 
                   (LH N /A with a C1 Activation Loop) 
                     
                 
                 
                   SEQ ID NO: 53 
                     
                 
                 
                   MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN 
                     
                 
                 
                     
                 
                 
                   PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG 
                 
                 
                     
                 
                 
                   STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY 
                 
                 
                     
                 
                 
                   GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN 
                 
                 
                     
                 
                 
                   RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA 
                 
                 
                     
                 
                 
                   KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV 
                 
                 
                     
                 
                 
                   LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT 
                 
                 
                     
                 
                 
                   GLFEFYKLLCHKA  SLYNKTLDCIKVNNWDLFFSPSEDNFTNDLNKGEE 
                 
                 
                     
                 
                 
                   ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG 
                 
                 
                     
                 
                 
                   KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA 
                 
                 
                     
                 
                 
                   AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG 
                 
                 
                     
                 
                 
                   AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK 
                 
                 
                     
                 
                 
                   VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA 
                 
                 
                     
                 
                 
                   MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK 
                 
                 
                     
                 
                 
                   VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIK 
                 
                 
                     
                 
                 
                   (LH N /B with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 54 
                     
                 
                 
                   MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTEGYKPEDFN 
                     
                 
                 
                     
                 
                 
                   KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG 
                 
                 
                     
                 
                 
                   DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH 
                 
                 
                     
                 
                 
                   FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY 
                 
                 
                     
                 
                 
                   GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV 
                 
                 
                     
                 
                 
                   DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN 
                 
                 
                     
                 
                 
                   IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA 
                 
                 
                     
                 
                 
                   YEEISKEHLAVYKIQMCHKA  SLYNKTLDCIDVDNEDLFFIADKNSFSDDLSKNE 
                 
                 
                     
                 
                 
                   RIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIF 
                 
                 
                     
                 
                 
                   TDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFA 
                 
                 
                     
                 
                 
                   GWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASIL 
                 
                 
                     
                 
                 
                   LEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQ 
                 
                 
                     
                 
                 
                   FYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNI 
                 
                 
                     
                 
                 
                   NNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKY 
                 
                 
                     
                 
                 
                   LKTIMPFDLSIYTNDTILIEMFNKYNS 
                 
                 
                     
                 
                 
                   (LH N /D with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 55 
                     
                 
                 
                   MTWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSK 
                     
                 
                 
                     
                 
                 
                   PPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDS 
                 
                 
                     
                 
                 
                   STPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSN 
                 
                 
                     
                 
                 
                   PSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYG 
                 
                 
                     
                 
                 
                   INIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDI 
                 
                 
                     
                 
                 
                   AKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSE 
                 
                 
                     
                 
                 
                   VVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPA 
                 
                 
                     
                 
                 
                   LQKLSSESVVDLFTKVCHKA  SLYNKTLDCIKVKNNRLPYVADKDSISQEIFENKIITDE 
                 
                 
                     
                 
                 
                   TNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYL 
                 
                 
                     
                 
                 
                   NSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANE 
                 
                 
                     
                 
                 
                   VVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNENQAFATAGVAFLLEGFP 
                 
                 
                     
                 
                 
                   EFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHIN 
                 
                 
                     
                 
                 
                   YQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIR 
                 
                 
                     
                 
                 
                   ECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTM 
                 
                 
                     
                 
                 
                   PFNIFSYTNNSLLKDIINEYFN 
                 
                 
                     
                 
                 
                   (LH N /E with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 56 
                     
                 
                 
                   MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGTTPQDFHPPTS 
                     
                 
                 
                     
                 
                 
                   LKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSGGILLEELSKANPYLGNDNTP 
                 
                 
                     
                 
                 
                   DNQFHIGDASAVEIKFSNGSQDILLPNVIIMGAEPDLFETNSSNISLRNNYMPSNHRFGS 
                 
                 
                     
                 
                 
                   IAIVTESPEYSFRFNDNCMNEFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPL 
                 
                 
                     
                 
                 
                   ITNIRGTNIEEFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNPLLNPYK 
                 
                 
                     
                 
                 
                   DVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLRTKFQVKCRQTYIGQYKYFKL 
                 
                 
                     
                 
                 
                   SNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPITGRGLVKKIIRFCHKA   
                 
                 
                     
                 
                 
                   SLYNKTLDCIEINNGELFFVASENSYNDDNINTPKEIDDTVTSNNNYENDLDQVILNFNS 
                 
                 
                     
                 
                 
                   ESAPGLSDEKLNLTIQNDAYIPKYDSNGTSDIEQHDVNELNVFFYLDAQKVPEGENNVNL 
                 
                 
                     
                 
                 
                   TSSIDTALLEQPKIYTFFSSEFINNVNKPVQAALFVSWIQQVLVDFTTEANQKSTVDKIA 
                 
                 
                     
                 
                 
                   DISIVVPYIGLALNIGNEAQKGNFKDALELLGAGILLEFEPELLIPTILVFTIKSFLGSS 
                 
                 
                     
                 
                 
                   DNKNKVIKAINNALKERDEKWKEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNAIKT 
                 
                 
                     
                 
                 
                   IIESKYNSYTLEEKNELTNKYDIKQIENELNQKVSIAMNNIDRFLTESSISYLMKIINEV 
                 
                 
                     
                 
                 
                   KINKLREYDENVKTYLLNYIIQHGSILGESQQELNSMVTDTLNNSIPFKLSSYTDDKILI 
                 
                 
                     
                 
                 
                   SYFNKFFK 
                 
                 
                     
                 
                 
                   (LH N /F with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 57 
                     
                 
                 
                   MPVVINSFNYNDPVNDDTILYMQIPYEEKSKKYYKAFEIMRNVWIIPERNTIGTDPSDFD 
                     
                 
                 
                     
                 
                 
                   PPASLENGSSAYYDPNYLTTDAEKDRYLKTTIKLFKRINSNPAGEVLLQEISYAKPYLGN 
                 
                 
                     
                 
                 
                   EHTPINEFHPVTRTTSVNIKSSTNVKSSIILNLLVLGAGPDIFENSSYPVRKLMDSGGVY 
                 
                 
                     
                 
                 
                   DPSNDGFGSINIVTFSPEYEYTFNDISGGYNSSTESFIADPAISLAHELIHALHGLYGAR 
                 
                 
                     
                 
                 
                   GVTYKETIKVKQAPLMIAEKPIRLEEFLTFGGQDLNIITSAMKEKIYNNLLANYEKIATR 
                 
                 
                     
                 
                 
                   LSRVNSAPPEYDINEYKDYFQWKYGLDKNADGSYTVNENKFNEIYKKLYSFTEIDLANKF 
                 
                 
                     
                 
                 
                   KVKCRNTYFIKYGFLKVPNLLDDDIYTVSEGFNIGNLAVNNRGQNIKLNPKIIDSIPDKG 
                 
                 
                     
                 
                 
                   LVEKIVKFCHKA  SLYNKTLDCIRVNNRELFFVASESSYNENDINTPKEIDDTTNLN 
                 
                 
                     
                 
                 
                   NNYRNNLDEVILDYNSETIPQISNQTLNTLVQDDSYVPRYDSNGTSEIEEHNVVDLNVFF 
                 
                 
                     
                 
                 
                   YLHAQKVPEGETNISLTSSIDTALSEESQVYTFFSSEFINTINKPVHAALFISWINQVIR 
                 
                 
                     
                 
                 
                   DFTTEATQKSTFDKIADISLVVPYVGLALNIGNEVQKENFKEAFELLGAGILLEFVPELL 
                 
                 
                     
                 
                 
                   IPTILVFTIKSFIGSSENKNKIIKAINNSLMERETKWKEIYSWIVSNWLTRINTQFNKRK 
                 
                 
                     
                 
                 
                   EQMYQALQNQVDAIKTVIEYKYNNYTSDERNRLESEYNINNIREELNKKVSLAMENIERF 
                 
                 
                     
                 
                 
                   ITESSIFYLMKLINEAKVSKLREYDEGVKEYLLDYISEHRSILGNSVQELNDLVTSTLNN 
                 
                 
                     
                 
                 
                   SIPFELSSYTNDKILILYFNKLYK 
                 
                 
                     
                 
                 
                   (LH N /G with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 58 
                     
                 
                 
                   MPVNIKXFNYNDPINNDDIIMMEPFNDPGPGTYYKAFRIIDRIWIVPERFTYGFQPDQFN 
                     
                 
                 
                     
                 
                 
                   ASTGVFSKDVYEYYDPTYLKTDAEKDKFLKTMIKLFNRINSKPSGQRLLDMIVDAIPYLG 
                 
                 
                     
                 
                 
                   NASTPPDKFAANVANVSINKKIIQPGAEDQIKGLMTNLIIFGPGPVLSDNFTDSMIMNGH 
                 
                 
                     
                 
                 
                   SPISEGFGARMMIRFCPSCLNVFNNVQENKDTSIFSRRAYFADPALTLMHELIHVLHGLY 
                 
                 
                     
                 
                 
                   GIKISNLPITPNTKEFFMQHSDPVQAEELYTFGGHDPSVISPSTDMNIYNKALQNFQDIA 
                 
                 
                     
                 
                 
                   NRLNIVSSAQGSGIDISLYKQIYKNKYDEVEDPNGKYSVDKDKFDKLYKALMFGFTETNL 
                 
                 
                     
                 
                 
                   AGEYGIKTRYSYFSEYLPPIKTEKLLDNTIYTQNEGFNIASKNLKTEFNGQNKAVNKEAY 
                 
                 
                     
                 
                 
                   EEISLEHLVIYRIAMCHKA  SLYNKTLDCIIVNNEDLFFIANKDSFSKDLAKAETIAYN 
                 
                 
                     
                 
                 
                   TQNNTIENNFSIDQLILDNDLSSGIDLPNENTEPFTNFDDIDIPVYIKQSALKKIFVDGD 
                 
                 
                     
                 
                 
                   SLFEYLHAQTFPSNIENLQLTNSLNDALRNNNKVYTFFSTNLVEKANTVVGASLFVNWVK 
                 
                 
                     
                 
                 
                   GVIDDFTSESTQKSTIDKVSDVSIIIPYIGPALNVGNETAKENFKNAFEIGGAAILMEFI 
                 
                 
                     
                 
                 
                   PELIVPIVGFFTLESYVGNKGHIIMTISNALKKRDQKWTDMYGLIVSQWLSTVNTQFYTI 
                 
                 
                     
                 
                 
                   KERMYNALNNQSQAIEKIIEDQYNRYSEEDKMNINIDFNDIDFKLNQSINLAINNIDDFI 
                 
                 
                     
                 
                 
                   NQCSISYLMNRMIPLAVKKLKDFDDNLKRDLLEYIDTNELYLLDEVNILKSKVNRHLKDS 
                 
                 
                     
                 
                 
                   IPFDLSLYTKDTILIQVFNNYIS 
                 
                 
                     
                 
                 
                   (LH N /TeNT with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 59 
                     
                 
                 
                   MPITINNFRYSDPVNNDTIIMMEPPYCKGLDIYYKAFKITDRIWIVPERYEFGTKPEDFN 
                     
                 
                 
                     
                 
                 
                   PPSSLIEGASEYYDPNYLRTDSDKDRFLQTMVKLFNRIKNNVAGEALLDKIINAIPYLGN 
                 
                 
                     
                 
                 
                   SYSLLDKFDTNSNSVSFNLLEQDPSGATTKSAMLTNLIIFGPGPVLNKNEVRGIVLRVDN 
                 
                 
                     
                 
                 
                   KNYFPCRDGFGSIMQMAFCPEYVPTFDNVIENITSLTIGKSKYFQDPALLLMHELIHVLH 
                 
                 
                     
                 
                 
                   GLYGMQVSSHEIIPSKQEIYMQHTYPISAFELFTFGGQDANLISIDIKNDLYEKTLNDYK 
                 
                 
                     
                 
                 
                   AIANKLSQVTSCNDPNIDIDSYKQIYQQKYQFDKDSNGQYIVNEDKFQILYNSIMYGFTE 
                 
                 
                     
                 
                 
                   IELGKKFNIKTRLSYFSMNHDPVKIPNLLDDTIYNDTEGFNIESKDLKSEYKGQNMRVNT 
                 
                 
                     
                 
                 
                   NAFRNVDGSGLVSKLIGLCHKA  SLYNKTLDCIKIKNEDLTFIAE 
                 
                 
                     
                 
                 
                   KNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAP 
                 
                 
                     
                 
                 
                   EYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVI 
                 
                 
                     
                 
                 
                   SKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGN 
                 
                 
                     
                 
                 
                   FIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYK 
                 
                 
                     
                 
                 
                   LVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKN 
                 
                 
                     
                 
                 
                   KLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIG 
                 
                 
                     
                 
                 
                   ITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDV 
                 
                 
                     
                 
                 
                   (LH N /X with a C1 Activation Loop) 
                 
                 
                   SEQ ID NO: 60 
                     
                 
                 
                   MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNT 
                     
                 
                 
                     
                 
                 
                   NDLNIPSEPIMEADAIYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIP 
                 
                 
                     
                 
                 
                   LPLVSNGALTLSDNETIAYQENNNIVSNLQANLVIYGPGPDIANNATYGLYSTPISNGEG 
                 
                 
                     
                 
                 
                   TLSEVSFSPFYLKPFDESYGNYRSLVNIVNKFVKREFAPDPASTLMHELVHVTHNLYGIS 
                 
                 
                     
                 
                 
                   NRNFYYNFDTGKIETSRQQNSLIFEELLTFGGIDSKAISSLIIKKIIETAKNNYTTLISE 
                 
                 
                     
                 
                 
                   RLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLNTILFVLNESNLAQRFSILVR 
                 
                 
                     
                 
                 
                   KHYLKERPIDPIYVNILDDNSYSTLEGFNISSQGSNDFQGQLLESSYFEKIESNALRAFI 
                 
                 
                     
                 
                 
                   KICHKA  SLYNKTLDCIEVENKDLFLISN 
                 
                 
                     
                 
                 
                   KDSLNDINLSEEKIKPETTVFFKDKLPPQDITLSNYDFTEANSIPSISQQNILERNEELY 
                 
                 
                     
                 
                 
                   EPIRNSLFEIKTIYVDKLTTFHFLEAQNIDESIDSSKIRVELTDSVDEALSNPNKVYSPF 
                 
                 
                     
                 
                 
                   KNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDVIDKSSDTLAIVPYIGPLLNI 
                 
                 
                     
                 
                 
                   GNDIRHGDFVGAIELAGITALLEYVPEFTIPILVGLEVIGGELAREQVEAIVNNALDKRD 
                 
                 
                     
                 
                 
                   QKWAEVYNITKAQWWGTIHLQINTRLAHTYKALSRQANAIKMNMEFQLANYKGNIDDKAK 
                 
                 
                     
                 
                 
                   IKNAISETEILLNKSVEQAMKNTEKFMIKLSNSYLTKEMIPKVQDNLKNFDLETKKTLDK 
                 
                 
                     
                 
                 
                   FIKEKEDILGTNLSSSLRRKVSIRLNKNIAFDINDIPFSEFDDLINQYKNEIEDYEVLNL 
                 
                 
                     
                 
                 
                   GAEDGKIKDLSGTTSDINIGSDIE 
                 
              
             
           
         
       
     
    
    
     EXAMPLES 
     Materials &amp; Methods 
     Materials
         5 ml HiTrap Butyl HP (GE #: 28411005)   5 ml HiTrap Q HP (GE #: 17-1154-01)   5 ml HiTrap Phenyl HP column (GE #17-5195-01)   CHT Type II column (Biorad #7324756)   TrypZean (Sigma #T3568)   Lys-C(Sigma #000000011047825001)   Enterokinase, light chain (NEB #P8070)   Factor Xa (NEB #P8010)   ACQUITY UPLC Protein BEH C4 Column (Waters #186004495)       

     Protein Purification 
       E. coli  BL21 (DE3) or NiCo (DE3) (NEB) were utilized for protein expression. In general, bacteria were cultured at 37° C. until induction, temperature was dropped to 16° C. and protein expression was induced with 1 mM IPTG overnight. 
     BoNT/AC with a C1 Loop (SEQ ID NO: 13) 
     Bacterial pellets were disrupted in lysis buffer (50 mM Tris-HCl pH=8) by sonication and clarified by centrifugation. Ammonium sulphate concentration was adjusted to 1.3M and target protein was captured using Butyl HP resin (GE). Fractions containing target protein were desalted and loaded onto Q HP resin (GE). Purified protein was activated overnight at 4° C. with 6 μg/1 mg of BoNT Factor Xa (NEB), followed by polishing using Phenyl HP resin (GE). 
     BoNT/E with a C1 Loop (SEQ ID NO: 11) 
     Bacterial pellets were disrupted in lysis buffer (100 mM sodium phosphate pH=7.8; 100 mM NaCl) by sonication and clarified by centrifugation. Ammonium sulphate concentration was adjusted to 1.25 M and target protein was captured using Butyl HP resin (GE). Fractions containing target protein were desalted and loaded onto Q HP resin (GE). Purified protein was activated overnight at 4° C. with either 5 μg/1 mg of BoNT Factor Xa (NEB) or 80 U/ml of Enterokinase (NEB), followed by polishing using CHT Type II resin (Biorad). 
     BoNT/X (SEQ ID NO: 5) 
     Bacterial pellets were disrupted in lysis buffer (50 mM Tris-HCl pH=8, 500 mM NaCl) by sonication and clarified by centrifugation. Target protein was captured using HisTrap HP column (GE). Fractions containing target protein were desalted and loaded onto Q HP resin (GE). Purified protein was activated overnight at 4° C. with either 5 μg/1 mg of BoNT Factor Xa (NEB) or 80 U/1 mg of BoNT of Enterokinase (NEB), followed by polishing using 1 ml HisTrap column (GE). 
     LC/MS 
     Samples were buffer exchanged into 50 mM ammonium bicarbonate prior to analysis. Samples were either intact protein or reduced by incubation with 10 mM DTT for 30 minutes at 37° C. Samples were tested using Waters Acquity H-Class UPLC system combined with Waters Xevo G2-XS QToF mass spectrometer.
         Mobile phase A 0.1% formic acid in water   Mobile phase B 0.1% formic acid in acetonitrile   Column: ACQUITY UPLC Protein BEH C4 (Waters)       

     Example 1 
     The BoNT/C1 Activation Loop can be Cleaved by Multiple Proteases 
     Inactive BoNT/C1 (0) (SEQ ID NO: 15) was incubated with a set of proteases: trypsin, Lys-C, enterokinase and Factor Xa. All proteases showed cleavage within the activation loop. BoNT/C1 (0) (SEQ ID NO: 15) was digested with enterokinase (EK) or factor Xa (FXa) overnight at 4° C. and 25° C. In addition, BoNT/C1 (0) was trypsin digested over a 16 hr timecourse at 20° C. ( FIGS. 2  A, B). All three proteases can cleave the BoNT/C1 activation loop and create a di-chain molecule when compared to protease untreated control. However, additional cleavage products were visible after tryptic and Lys-C digest. 
     Example 2 
     Characterisation and Improvement of BoNT/X Proteolytic Activation 
     Partially purified wild-type BoNT/X-10HT (SEQ ID NO: 34) was incubated overnight at 4° C. with increasing amounts of trypsin (TrypZean) and Lys-C, as well as factor Xa (FXa) and enterokinase (EK). 
       FIG. 3  shows that wild-type BoNT/X was completely degraded by both Lys-C ( FIG. 3A ) and trypsin ( FIG. 3B , lanes 12-13 and 15-17). Notably, FXa and EK were unable to cleave the protein into a di-chain form ( FIG. 3B , lanes 18 and 19, respectively). 
     In an attempt to improve activation of BoNT/X, the BoNT/X activation loop was replaced by the BoNT/C1 activation loop (SEQ ID NO: 2) creating engineered BoNT protein SEQ ID NO: 5. The engineered BoNT was purified using several chromatographic steps and treated with enterokinase (EK) or factor Xa (FXa) to verify that the presence of BoNT/C loop allowed for production of a di-chain molecule. Surprisingly,  FIG. 4  shows that EK and FXa specifically cleave engineered BoNT/X into the di-chain form. 
     Example 3 
     Characterisation and Improvement of BoNT/E Proteolytic Activation 
     Wild-type BoNT/E was cleaved with Lys-C and trypsin (TryZean).  FIG. 5A  shows that Lys-C inaccurately cleaves/degrades BoNT/E. Treatment with trypsin resulted in truncation of BoNT/E meaning an additional purification step was required to separate the full-length protein from the truncation product ( FIG. 5B ). 
     In an attempt to improve activation of BoNT/E, the BoNT/E activation loop was replaced by the BoNT/C1 activation loop (SEQ ID NO: 2) creating engineered BoNT protein SEQ ID NO: 11. The engineered BoNT was purified using several chromatographic steps and treated with enterokinase (EK) or factor Xa (FXa) to verify that the presence of BoNT/C loop allowed for production of a di-chain molecule. Surprisingly,  FIG. 6  shows that EK and FXa specifically cleave engineered BoNT/E into the di-chain form. 
     Example 4 
     Proteolytic Activation of a BoNT/A1C1 Chimera 
     The BoNT/C loop was introduced into a BoNT/A1C1 chimera (LH N /A1 with a C1 H C  domain) to facilitate proteolytic protein activation. The BoNT/A1 activation loop of BoNT/A1C1 was replaced with a BoNT/C1 loop creating engineered BoNT protein SEQ ID NO: 13. The engineered BoNT was purified using several chromatographic steps and treated with factor Xa (FXa) to verify that the presence of BoNT/C loop allowed for production of a di-chain molecule.  FIG. 7A  shows that FXa specifically cleaves engineered BoNT/A1C1 into the di-chain form. For comparison purposes, wild-type Met BoNT/A1 (commercially available from MetabiologicsA1080116) containing the A1 activation loop was incubated with FXa and EK.  FIG. 7B  shows that FXa does not cleave the A1 activation loop, while EK cleaves with only minimal activity, and both FXa and EK results in formation of additional improper cleavage products (degradation products). 
     Example 5 
     BoNTs Containing the C1 Loop Retain SNARE Cleavage Activity 
     Rat primary cortical neurons were treated for 24 h with BoNT/A1C1 (SEQ ID NO: 13) of Example 4 containing the BoNT/C1 activation loop and purified recombinant BoNT/C1 (SEQ ID NO: 17). SNARE-dependent glutamate release from the cells stimulated by potassium chloride was measured after incubation ( FIG. 8 ). These data confirm activity of clostridial neurotoxins modified to include the BoNT/C1 activation loop. 
     Example 6 
     Factor Xa and Enterokinase Cleave BoNT/C Activation Loop at the Same Site IDGR↓SL 
     Purified BoNT/E containing the BoNT/C1 loop (SEQ ID NO: 11) was activated by either enterokinase or factor Xa proteases and was incubated with 10 mM DTT to reduce disulphide bridges and separate light and heavy chain. Liquid chromatography-mass spectrometry analysis of intact protein mass was performed on reduced and non-reduced engineered BoNT/E (SEQ ID NO: 11) samples to map the cleavage sites of both proteases. Both proteases cleaved BoNT/E to produce light and heavy chain of the same size indicating that both enterokinase and factor Xa cleave at the same site (Table 1). 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Comparison of predicted and measured masses of engineered 
               
               
                 BoNT/E (SEQ ID NO: 11)after cleavage at IDGR↓SL site 
               
               
                 within the C-loop. Heavy chain mass indicates cleavage 
               
               
                 at the predicted site by both enterokinase and factor Xa. 
               
            
           
           
               
               
               
               
            
               
                   
                 predicted 
                 observed mass 
                 observed mass 
               
               
                   
                 theoretical 
                 after EK cleavage 
                 after FXa cleavage 
               
               
                   
                 mass [Da] 
                 [Da] 
                 [Da] 
               
               
                   
                   
               
            
           
           
               
               
               
               
            
               
                 intact 
                 143952 
                 143853 (FIG. 9)  
                 143850 (FIG. 11)  
               
               
                 molecule 
               
               
                 light chain 
                 47633 
                 47518 (FIG. 10) 
                 47518 (FIG. 12) 
               
               
                 heavy chain 
                 96337 
                 96338 (FIG. 10) 
                 96335 (FIG. 12) 
               
               
                   
               
            
           
         
       
     
     Comparative Example 7 
     Insertion of a Protease Recognition Site into an Endogenous Loop 
     The BoNT/C1 activation loop is the only BoNT activation loop that contains a naturally occurring cleavage site for site specific proteases FXa (and surprisingly EK) (see  FIG. 1 ). All other loops are cleaved by non-specific proteases such as trypsin or Lys-C. Cleavage by Lys-C and trypsin often leads to undesired protein truncation as the cleavage site is determined by protease accessibility rather than a specific recognition sequence. 
     Natural activation loops from different serotypes evolved to allow protease accessibility and process toxin into a di-chain form by  Clostridium . Without wishing to be bound by theory, it is believed that mutating these loops to create a protease recognition site can lead to conformational changes, which could negatively affect cleavage efficiency. 
     To test this hypothesis, a polypeptide having the BoNT/A1 light chain and translocation domain (LH N /A1) was modified to include an EK protease recognition sequence DDDDK (SEQ ID NO: 44). The efficiency of proteolytic cleavage of modified LH N /A1 with EK was assessed and compared with cleavage of the wild-type A1 activation loop with Lys-C (note owing to an absence of EK recognition sites in the wild-type loop a direct comparison using EK is not possible).  FIG. 13  shows that cleavage of the modified loop is much less efficient than the wild-type loop. 
     Example 8 
     Proteolytic Activation of a BoNT/XA Chimera 
     A BoNT/XA chimera containing the light chain and translocation domain of BoNT/X, the binding domain of BoNT/A1, and the BoNT/C1 activation loop was manufactured (SEQ ID NO: 7).  FIG. 14  shows that the di-chain form of the engineered BoNT/XA chimera was produced following activation with FXa. 
     Example 9 
     Proteolytic Activation of a BoNT/XB Chimera 
     A BoNT/XB chimera containing the light chain and translocation domain of BoNT/X, the binding domain of BoNT/B, and the BoNT/C1 activation loop was manufactured (SEQ ID NO: 9).  FIG. 15  shows that the di-chain form of the engineered BoNT/XB chimera was produced following activation with FXa. 
     All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.